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Conception rationnelle, synthèse, modélisation moléculaire et évaluation de dérivés -
carbolines et 5H-indéno[1,2-c]pyridazin-5-ones comme inhibiteurs potentiels de la MAO 
et d’IDO 
 
 
Par Jérémy Reniers 
 
 
Résumé:  
 
La monoamine oxydase A (MAO-A) et –B (MAO-B) sont des cibles intéressantes 
pour une large gamme de thérapies contre des pathologies telles que la dépression, l’anxiété et 
les maladies de Parkinson et d’Alzheimer. La plupart des inhibiteurs actuels mènent à des 
effets secondaires par un manque d’affinité et de sélectivité envers une des isoformes. 
Récemment, les structures cristallographiques de hMAO-A et –B en complexe avec des 
inhibiteurs ont ouvert le chemin vers la découverte de nouveaux inhibiteurs plus sélectifs et 
plus puissants. En conséquence, l’objectif principal de ce travail, fut la conception de 
nouveaux inhibiteurs plus puissants, réversibles et sélectifs de MAO-A ou –B à partir des 
motifs β-carbolines et 5H-indéno[1,2-c]pyridazin-5-ones respectivement, en suivant une 
stratégie classique comprenant une approche expérimentale (synthèse et évaluation 
biologique) et théorique (modélisation moléculaire). Les pouvoirs d’inhibition sur la MAO 
ont montré que la substitution du groupe méthoxy de l’harmine par des groupes plus 
lipophiles augmente l’inhibition de MAO-A. Des études sur les 5H-indéno[1,2-c]pyridazin-5-
ones substituées à la fois aux positions 3 et 8 par des groupes lipophiles ont montré que la 
substitution en position 3 influence significativement les propriétés d’inhibition de la MAO-
B.   
De plus, l’implication à travers une même voie métabolique et la similarité dans les propriétés 
structurales de la MAO avec l’indoléamine 2,3-dioxygénase (IDO) et la lysine spécifique 
déméthylase 1 (LSD1) respectivement, nous ont amené à l’investigation des -carbolines et 
5H-indéno[1,2-c]pyridazin-5-ones comme inhibiteurs potentiels d’IDO et de LSD1. 
Cependant, les deux series n’inhibent pas ces deux systèmes enzymatiques et sont donc 
sélectives de MAO.  
Finalement, en partant de la même stratégie utilisée pour la MAO, nous nous sommes aussi 
intéressés à la synthèse de deux nouvelles -carbolines substitutées en position 3 par des 
groupements aminés et directement dérivées du 3-butyl--carboline, un inhibiteur connu 
d’IDO. Ces deux composés présentent en effet une charge positive à pH physiologique 
laquelle pourrait établir une interaction coulombienne supplémentaire avec le 7-propionate de 
l’hème comparé au 3-butyl--carboline. Cependant, les premiers résultats tendent à démontrer 
que l’introduction d’une charge positive abolit l’inhibition d’IDO. 
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By Jérémy Reniers 
 
 
Abstract:  
 
Monoamine oxidase A (MAO-A) and –B (MAO-B) are attractive targets for a broad 
range of treatments against pathologies including depression, anxiety disorders, Parkinson’s 
and Alzheimer’s diseases. Most current MAO inhibitors lead to side effects by a lack of 
affinity and selectivity towards one of the isoforms. Recently, the crystal structures of hMAO-
A and –B in complex with inhibitors opened the way towards the discovery of new, more 
selective and potent inhibitors. Thus, the main objective of this work, was the design of new, 
more potent, reversible and selective MAO-A or –B inhibitors derived from β-carboline and 
5H-indeno[1,2-c]pyridazin-5-one scaffolds respectively, following a classical strategy 
including experimental (synthesis and biological evaluation) and theoretical (molecular 
modeling) approaches. The MAO inhibitory potencies showed that the replacement of the 
methoxy group of harmine by more lipophilic groups increases the inhibition for MAO-A. 
Studies on 5H-indeno[1,2-c]pyridazin-5-one scaffold bearing lipophilic groups in the 3 and 8-
positions showed that the substitution in the 3-position dramatically influences the MAO-B-
inhibiting properties.   
Furthermore, the involvement through a same metabolic pathway and the similarity in the 
structural properties of MAO with indoleamine 2,3-dioxygenase (IDO) and lysine specific 
demethylase 1 (LSD1) respectively, led us to the investigation of the -carboline and 5H-
indeno[1,2-c]pyridazin-5-one derivatives as potential IDO and LSD1 inhibitors. However, the 
two series show no inhibition of those two enzymes and are thus selective of MAO.  
Finally, starting from the same strategy used for MAO, we are also interested in the synthesis 
of two new 3-substituted--carboline derivatives with amino groups and directly derived from 
3-butyl--carboline, a known IDO inhibitor. Indeed, these two compounds display a positive 
charge at physiological pH which might establish an additional coulomb interaction with 7-
propionate of the heme compared to 3-butyl--carboline. Howerver, first results tend to 
demonstrate that the introduction of a positive charge abolishes the inhibition of IDO. 
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The discovery in the 1950s of the antidepressant properties of monoamine oxidase inhibitors 
(MAOIs) was the major finding that led to the monoamine theory of depression [1]. Earlier 
MAOIs introduced into clinical practice for the treatment of depression were abandoned due 
to adverse side effects, such as hepatotoxicity, orthostatic hypotension and the so called 
‗cheese effect‘ characterized by hypertensive crises. These side effects were hypothesized to 
be related to non-selective and irreversible monoamine oxidase inhibition.  
Since the 1950s, monoamine oxidase A (MAO-A) and –B (MAO-B) have been extensively 
studied with approximately 20000 published papers listed in databases such as PubMed [2]. 
This long-term interest stems from their roles in the oxidative catabolism of important amine 
neurotransmitters. The identification of two isoforms (MAO-A and –B) and the recent 
determination of the crystal structures of hMAO-A [3] and –B [4] have led to renewed interest 
in the rational design of potent, specific inhibitors with therapeutic potential and no 
undesirable side effects. 
Nowadays, the therapeutic interest of MAOIs falls into two major categories. Selective MAO-
A inhibitors are used as anti-depressant and anti-anxiety drugs whereas selective MAO-B 
inhibitors are used alone or in combination in the therapy of Alzheimer‘s and Parkinson‘s 
diseases [5]. 
 
 
1. MONOAMINE OXIDASE (MAO) 
 
1.1 Biological actions of MAO 
 
MAO is a flavoenzyme with the flavin adenine dinucleotide (FAD) covalently bound to a 
cysteine residue by an 8α-(S-cysteinyl)-flavin linkage. The enzyme is anchored to the 
mitochondrial outer membrane of neuronal, glial and several other cell types. It catalyzes the 
oxidative deamination of biogenic and xenobiotic amines to the corresponding aldehyde and 
ammonia in the periphery as well as in the central nervous system (CNS) (Scheme 1.I) [6-7]. 
MAO is involved in the biodegradation of aromatic monoamines, including classical 
neurotransmitters, such as serotonin (5-HT), adrenaline and dopamine, and appears to play a 
central role in several psychiatric and neurological disorders.  
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MAO first transforms the amino substrate into imine derivative which is hydrolysed 
spontaneously to yield the corresponding aldehyde and ammonia. Reoxidation of the cofactor 
by molecular oxygen produces hydrogen peroxide (H2O2). 
 
 
 
Scheme 1.I. Oxidative deamination pathway of monoamines by MAO [7]. 
 
 
1.2 MAO subtypes 
 
In mammals, MAO exists in two isoforms, MAO-A and –B. They are encoded by separate 
genes. MAO-B shares 70% of the amino acid sequence of MAO-A and, in particular, the 
active center of both enzymes is very similar (RMSD = 0.40 Å) [8]. However, they differ with 
respect to distribution in body‘s tissues, and substrate/inhibitor specificity.  
 
 
1.2.1 MAO distribution and localization 
 
MAO-A and –B are tightly associated with the mitochondrial outer membrane. MAO is 
present in most tissues, but the proportions of the two isoenzymes vary from tissue to tissue. 
Although in humans they are both expressed in most peripheral tissues and organs, MAO-A is 
prevalent in fibroblasts and placental tissue [9], while MAO-B is the only isoform in platelets 
and lymphocytes. In the human brain, there are regional differences in MAO activity: the 
basal ganglia (striatum) and hypothalamus show the highest levels activity, whereas low 
levels of activity are observed in the cerebellum and neocortex [10]. The two isoenzymes are 
not evenly distributed in the human brain, and the main form in the basal ganglia is MAO-B. 
Immunohistochemical and autoradiographic studies have established that, in the brain, MAO-
A is predominantly localized in catecholaminergic neurons, whereas MAO-B is mainly 
expressed in serotonergic and histaminergic neurons, as well as in astrocytes [9]. This finding, 
albeit well documented by several laboratories, is in apparent contrast with the 
pharmacological evidence that serotonin levels are enhanced only following MAO-A, but not 
MAO-B, inhibition. The reasons of this mismatch, however, are still mostly elusive. 
H2O
H2O2                           MAO-FAD                           R'CH2-NHR''
O2                                MAO-FADH2                      R'HC=NR''                                  R'CHO + H2NR''
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MAO-A levels have also been found to dramatically increase (~9-fold) in the heart of aged 
rats, thereby suggesting the probability of age-dependent increases in MAO-A levels in 
humans [2].  
 
 
1.2.2 MAO substrates 
 
The main substrates of the MAO-A and –B isoforms are aromatic monoamines, including the 
classical neurotransmitters (i.e., 5-HT, dopamine, noradrenaline and adrenaline). Several 
studies showed that no definite subdivision into substrates highly specific for one or the other 
isoforms of MAO can be made, and that most natural substrates can be metabolized by both 
MAO-A and –B [7]. The deamination of the substrates by MAO-A and/or –B in living 
organisms depends on several factors. These include the kinetic constants (Km and kcat), 
characteristic for each enzyme form in relation to its various substrates, the ratio between the 
amount of MAO-A and –B in the tissues and the specific localization of the two enzymes in 
the different cells. MAO-A preferentially catalyzes the deamination of serotonin (5HT), 
adrenaline, and noradrenaline [9]. Noradrenaline is considered to be mainly a substrate for 
MAO-A while it also appears to be metabolized by MAO-B, particularly in tissues expressing 
high amounts of this isoform [11]. MAO-B preferentially catalyzes the deamination of β-
phenylethylamine and benzylamine. In vitro, dopamine and other monoamines (such as 
tryptamine and tyramine) are deaminated by both isoforms, but dopamine in vivo is 
preferentially metabolized by MAO-B [9]. Apart from the substrates already mentioned, 
MAO-A and –B are able to oxidize a large variety of primary, secondary and tertiary amines 
[12]. As a general rule primary and secondary amine derivatives are usually deaminated by 
both forms while tertiary amines seem to be selective MAO-B substrates [13]. This ability to 
oxidize tertiary amines is thus thought to be a selective feature of MAO-B. 
 
 
1.2.3 Three-dimensional structures  
 
The three dimensional structures of hMAO-A [3] and hMAO-B [4] have been determined and 
are shown in figure 1.I.  
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Figure 1.I. Three-dimensional structures of hMAO-A (left) [3] and hMAO-B (right) [4]. The 
FAD cofactor is in yellow. The active site cavity in each enzyme molecule is drawn as a gray 
surface. The cavity-shaping loop (residues 210-216 and 201-207 in hMAO-A and –B 
respectively) is highlighted in cyan. The entrance loop (residues 108-118 and 99-110 in 
hMAO-A and –B respectively) is highlighted in blue [2].  
 
The X-ray structure of hMAO-B has been determined in complex with a range of inhibitors to 
a resolution of 1.60 Ǻ for the best structure (safinamide (1.I), 2V5Z.pdb [4], Figure 2.I). 
Currently, only two X-ray structures of hMAO-A are available in the data bank. Human 
MAO-A was first co-crystallized with an irreversible inhibitor (clorgyline (2.I), 2BXS.pdb 
[14], Figure 2.I) to a resolution of 3.15 Ǻ. Recently, Son et al have determined the X-ray 
structure of hMAO-A in complex with a reversible potent inhibitor (harmine (3.I), 2Z5X.pdb 
[3], Figure 2.I) with a better resolution (2.20 Ǻ). The resolution of both structures has 
provided new insights into the differences that exist between the two human isozymes. 
MAO-A and –B have structures with similar folds and with a high degree of identity in their 
respective Cα coordinates [2]. These structures show that the membrane binding motifs of the 
enzymes are located in the 35-40 C-terminal residues (Figures 1.I and 3.I). In hMAO-B, this 
transmembrane region folds into an α-helix protruding perpendicularly from the main 
globular body of the protein, although the last 20 residues of this motif are too disordered to 
provide definitive electron density [15] (Figure 1.I, right). The C-terminal part of hMAO-A 
C-terminal 
C-terminal 
Cavity-shaping 
 loop 
Cavity-shaping 
 loop 
Entrance loop 
Entrance loop 
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displays an electron density sufficiently defined to provide a complete view of the 
transmembrane α-helix [3] (Figure 1.I, left).  
 
N
H
O
O
F
O
N
O
NH2
N
H
NO
Cl Cl
O N
NH2
 
 
Figure 2.I. Chemical structures of safinamide (1.I), clorgyline (2.I), harmine (3.I), isatin (4.I) 
and tranylcypromine (5.I).  
 
The protein structures around the active site covalent FAD coenzymes are quite similar 
among the two isoforms. The position of the FAD cofactor with respect to the overall 
structure is highly conserved, and the substrate-binding sites consist of elongated cavities 
(Figure 1.I) whose features will be thoroughly discussed in the next section. In both enzymes, 
the flavin rings exist in ―bent‖ rather than the more common planar conformations about the 
N(5)-N(10) axis (Figure 3.I, right), demonstrating strain at the coenzyme binding sites that 
may have catalytic relevance (discussed in the section 1.3).  
The largest differences in structures among the two isoforms are the respective natures of 
their oligomeric states (Figure 1.I) [2]; hMAO-B is a dimer, while hMAO-A is a monomer. A 
survey of the literature shows membrane proteins are generally oligomeric in the membrane, 
with dimerization being most common [18]. Recently published data show that hMAO-A and 
–B enzymes are dimeric in their membrane-bound forms (Figure 3.I, left) [19]. In the 
detergent-solubilized, purified preparations, hMAO-B is found to remain 100% dimeric, 
whereas hMAO-A exists only fractionally (50%) in its dimeric form. Dissociation of 
oligomeric structures of membrane proteins in detergent micelles is found to be the case for 
MAO-A but not for MAO-B. The hMAO-A monomer species is more likely to crystallize 
than its dimeric form.  
 
 
 
 
PF 9601N (21) 
1.I    2.I              3.I 
4.I    5.I    
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Figure 3.I. (Left) Binding mode of hMAO-B (dimeric form) to the outer mitochondrial 
membrane [16]. (Right) Relative conformations of the isoalloxazine rings in hMAO-B 
(1OJA.pdb [17]) and hMAO-A (2Z5X.pdb [3]).  
 
 
1.2.4 Structure of active site cavities in hMAO-A and –B [2] 
 
The structural elucidation of hMAO-A and –B revealed that substrate binding and oxidation 
occurs in elongated cavities extending from the flavin site at the core of the enzyme to the 
surface of the protein on the opposite side of the FAD adenosine ring (Figures 1.I and 4.I). A 
comparison of the active sites of hMAO-A and –B is shown in figure 4.I. Although in both 
enzymes the cavities are generally hydrophobic, details of the active site architectures 
demonstrate differences in their respective structural properties that account for their distinct 
substrate and inhibitor specificities. The recently reported 2.20 Ǻ crystal structure of hMAO-
A in complex with harmine [3] allows a more detailed comparison of the active sites between 
the two human enzymes. The volume of the hMAO-A cavity is ~550 Å
3 
[20], whereas that of 
the two combined cavities of hMAO-B is ~700 Ǻ3 [21]. The MAO-B cavity is bipartite and is 
comprised of two separate spaces, the substrate cavity (~400 Ǻ3) and the entrance cavity 
(~300 Ǻ3). Therefore, MAO-A has a single cavity that exhibits a rounder shape and is larger 
in volume than the substrate cavity of MAO-B. Analysis of residue side chains in either active 
site shows the substrate to have less freedom for rotation in the MAO-B site than in MAO-A. 
Whether the active site of MAO-B is a large single cavity or a bipartite cavity is an example 
of catalytic site plasticity determined by the conformation of Ile199 (Figure 4.I).  
 
PF 9601N (21) 
N(10) 
N(5) 
hMAO-B hMAO-A 
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Figure 4.I. Active site cavity and inhibitor binding of harmine (3.I) in hMAO-A (top, 
2Z5X.pdb) and safinamide (1.I) in hMAO-B (bottom, 2V5Z.pdb) respectively. The water 
molecules are displayed as red spheres.  
 
The side chain of this ―gating‖ residue may, depending on the nature of the bound ligand, 
adopt two different conformations (―closed‖ and ―open‖) [17]. The cavity can host either 
small inhibitors (Ile199 into the closed conformation), such as isatin (4.I) and 
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tranylcypromine (5.I), or cavity-filling ligands (Ile199 into the open conformation) such as 
safinamide (1.I, Figure 2). In the former case, the active site is restricted to a small cavity 
separated from an entrance cavity space that opens to the exterior like a funnel, whereas in the 
latter, the cavity shape is a compact ellipsoid. It is important to note that in all these MAO-B-
inhibitor complexes, the position of the active site residues, apart from gating residue Ile199, 
is highly conserved. From a pharmacological viewpoint, this inhibitory versatility has 
important implications. Small compounds such as isatin and tranylcypromine, which can be 
hosted in a limited pocket, show similar binding affinities for both MAO-A and –B, whereas 
cavity-filling ligands are highly specific MAO-B inhibitors. The corresponding residue in 
hMAO-A is Phe208, but it does not function as a gating residue (Figure 4.I). Another 
difference between MAO-A and –B structures also involves the active site cavity structures. 
The Tyr326 side chain in MAO-B, although not directly involved in the partition of the two 
cavities, does produce a restriction that is less pronounced in hMAO-A where Ile335 occupies 
that position. Conserved active site residues in both enzymes include the aromatic cage 
(formed by Tyr407, Tyr444 and FAD in hMAO-A; Tyr398, Tyr435 and FAD in hMAO-B, 
Figure 4.I) which is important for recognition and direction of the amine group of the 
substrate. Positioning of the amine between these residues and the flavin is important for 
catalysis. Another conserved active site residue includes a Lys residue hydrogen bonded via a 
water molecule to the N(5) position of the flavin (Lys305 in MAO-A and Lys296 in MAO-B). 
Other non-conserved residues in the active sites include Ile180 and Asn181 in MAO-A 
(Leu171 and Cys172 in MAO-B, respectively), which, however, do not significantly affect 
the shapes of the cavities. Therefore, the MAO-A Phe208-Ile335 and MAO-B Ile199-Tyr326 
pairs appear to be major determinants in dictating the differential substrate and inhibitor 
specificities of the two enzymes.  
An intriguing issue in MAO enzymology is to understand where and how the substrates (or 
inhibitors) are admitted to the active sites. In hMAO-B, the cavity is extended and substrate 
binding is likely to occur in the proximity of the outer mitochondrial membrane surface 
region with the entrance loop (residues 99-110) involved in the access (colored blue in figure 
1.I). In hMAO-A, the active site cavity is more compact. However, Son et al. [3] have 
recently demonstrated by site-directed mutagenesis that the conserved Gly110 is important for 
ensuring flexibility of the entrance loop (residues 108-118) required to provide access for the 
substrate. Therefore, the structural data suggest that MAO-A and –B ligands follow similar 
pathways in binding.  
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Aside from obvious differences in the amino acid residues in the active sites, perhaps the 
largest difference occurs in the conformation of a 6-residue loop (residues 210–216 in hMAO-
A and residues 201-207 in hMAO-B, Figure 1.I) which is referred to as the ‗‗cavity-shaping 
loop‘‘ [20]. The conformation of this loop has a significant effect on the shape and volume of 
the substrate binding cavity and probably contributes substantively to the different 
specificities of the two enzymes.  
 
 
1.3 Mechanistic studies on MAO catalysis [2]  
 
MAO-A and –B catalyze the oxidative deamination of amine neurotransmitters using O2 as 
the electron acceptor. The catalytic mechanism of MAO catalysis consists of a reductive half 
reaction where the Cα–H bond of the amine is cleaved with the transfer of two reducing 
equivalents to the flavin to form, respectively the imine and flavin hydroquinone (E.FADred) 
as shown in the reaction pathway in scheme 2.I [22]. There are two general catalytic reaction 
pathways (scheme 2.I). For most substrates, both MAO-A and –B follow the lower loop of the 
pathway in which oxygen reacts with the enzyme product complex (E.FADred -- Imine) before 
product has dissociated. There is general consensus that the deprotonated (rather than the 
protonated) amine moiety on the substrate binds to the active site of the enzymes and is 
oxidized to the protonated imine (found with both MAO-B and –A) with the FAD cofactor 
being reduced to its hydroquinone form (E.FADred). To complete the catalytic cycle, the 
reduced FAD cofactor reacts with O2 to generate oxidized flavin (E.FADox) and H2O2. The 
dissociated protonated imine is released from the enzyme and undergoes a non-catalyzed 
hydrolysis to form NH4
+
 and the corresponding aldehyde.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.I. General reaction scheme for MAO catalysis [22]. 
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The exact chemical mechanism of this oxidative deamination is, however, still subject to 
controversy. Currently, two mechanisms are proposed for the reductive half-reaction of MAO 
catalysis (Scheme 3.I) [22];  
 
- Polar nucleophilic mechanism (Scheme 3.I, top) 
- Single electron transfer mechanism (SET) (Scheme 3.I, bottom) 
 
The stereochemistry of the hydrogen transfer step is well-documented to be the pro-R H of the 
substrate for both MAO-A and –B [23]. Furthermore, the re face of the covalent FAD forms 
the amine binding site. 
Current mechanistic data do support that both enzymes function by a proton abstraction 
mechanism with the polar nucleophilic mechanism proposed by Miller and Edmondson for 
hMAO-A catalysis (Scheme 3.I) [24]. To accomplish this difficult proton abstraction [the pKa 
for a benzyl hydrogen is ∼25 [25]], no basic amino acid residues are in the catalytic site, and 
therefore, the flavin must be activated to become a strong base. This could be accomplished 
by C(4a) addition of the amine followed by or in conjunction with abstraction of the R-CH 
group by the resulting basic N(5), which is estimated to exhibit a pKa of ∼25 from NMR 
studies of reduced flavin models [26]. The reaction mechanism for this proposed reaction is 
shown in scheme 3.I (top). Since deprotonated amines do not appear to exhibit the 
nucleophilicity to readily add to the flavin C(4a) position in model systems and no direct 
evidence for a stable amine-flavin adduct has been found, one must examine factors in the 
enzyme that would facilitate this type of reaction. Structural data show the isoalloxazine ring 
of the flavin to exist in a conformation ∼30° bent from planarity in the oxidized form of the 
enzyme. This bending has been shown by NMR studies of other flavoenzymes to result in 
C(4a) being more electrophilic and N(5) being more nucleophilic [27]. 
A survey of the literature reveals that the SET mechanism for MAO catalysis originally 
proposed by Lu and co-workers [28] is also favored by a number of investigators (Scheme 3.I, 
bottom) [22]. This mechanism is based on the rationale that one-electron oxidation of the 
substrate amine nitrogen results in labilization of the α-CH bond to allow abstraction by a 
basic residue normally associated with proteins. In spite of considerable experimental effort, 
no direct evidence has been found for any radical intermediate during substrate oxidation.  
Recent theoretical calculations on MAO catalysis have demonstrated the plausibility of the 
polar nucleophilic mechanism for MAO catalysis [22, 29]. Despite intense research in many 
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laboratories the mechanism of substrate oxidation in MAO remains to be clarified, with 
several alternatives having been proposed including a concerted nucleophilic mechanism and 
a SET mechanism [30].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
Scheme 3.I. Proposed polar nucleophilic (top) and SET (bottom) mechanisms for the 
reductive half-reaction of MAO catalysis [22]. 
 
N(5) 
C(4a) 
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1.4 Therapeutic uses of MAO-A and –B inhibitors 
 
A wide range of MAOIs including reversible and irreversible inhibitors of MAO-A, MAO-B, 
or both is reported in table 1.I [9-10]. These are proving to have therapeutic value in several 
diverse conditions, including affective disorders, neurodegenerative diseases, stroke and 
ageing. The therapeutic use of MAOIs in these conditions is discussed below. 
 
Table 1.I. Known MAOIs and their main current or potential therapeutic uses [9-10]. 
 
Group Class Compound MAO 
selectivity 
Inhibition 
type 
Application 
Non-selective Hydrazines Isocarboxazid A and B Irreversible Antidepressant 
  Phenelzine A and B Irreversible Antidepressant 
  Nialamide A and B Irreversible Antidepressant 
  Isoniazid A and B Irreversible Antidepressant 
  Iproniazid A and B Irreversible Antidepressant 
  Iproclozide A and B Irreversible Antidepressant 
 Amphetamine derivates Tranylcypromine A and B Irreversible Antidepressant 
Selective- 
irreversible 
Propargylamines Clorgyline A Irreversible Antidepressant 
 l-Deprenyl 
(Selegiline) 
B Irreversible Antiparkinson 
  Rasagiline B Irreversible Antiparkinson 
  2-HMP  
(and other 
 aliphatic 
propargylamines) 
B Irreversible Antiparkinson 
  PF 9601N B Irreversible Antiparkinson 
Selective- 
reversible 
(RIMAS) 
Piperidylbenzofurans Brofaromine A Reversible Antidepressant 
Morpholinobenzamides Moclobemide A Reversible Antidepressant 
Oxazolidinones Toloxatone A Reversible Antidepressant 
  Befloxatone A Reversible Antidepressant 
  Cimoxatone A Reversible Antidepressant 
Selective- 
reversible 
(MAO-B) 
Aminoethylpicolinamide Lazabemide B Reversible Antiparkinson 
Benzylaminopropanamide Safinamide B Reversible Antiparkinson 
Mixed MAO-
cholinesterase 
inhibitors 
Propylamines Ladostigil A and B 
(brain 
selective) 
Irreversible Antidepressant, 
antiparkinson 
and 
anti-Alzheimer 
Other  M30 A and B 
(brain 
selective) 
Irreversible Antidepressant, 
antiparkinson 
and 
anti-Alzheimer 
2-HMP, N-(2-heptyl)-N-methylpropargylamine 
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1.4.1 Depression and anxiety disorders   
 
MAOIs have been used for decades in the treatment of depression [31-32]. The antidepressant 
properties of MAOIs result from selective MAO-A inhibition in the CNS, which leads to 
increased brain levels of dopamine, noradrenaline and serotonin [10]. The development of 
MAOIs started with the serendipitous finding of antidepressant effects in patients treated with 
iproniazid (6.I), a hydrazine-based antitubercular agent structurally similar to isoniazid (7.I) 
(Figure 5.I, Table 1.I) [9]. Originally proposed as a tuberculostatic agent, iproniazid (6.I) was 
the first modern antidepressant and was introduced into the market under the trade name 
Marsilid
®
 [33]. This discovery, together with the demonstration that iproniazid (6.I) was a 
potent MAOI, led to the design and production of other MAOIs, such as phenelzine (8.I) 
(Figure 5.I, Table 1.I) [9]. Following the ascertainment that hydrazine-based MAOIs caused 
liver toxicity, however, novel chemical categories of drugs were established (Table 1.I). 
Another undesirable side effect of MAO non-selective inhibitors, was the so-called ―cheese 
reaction‖, consisting in severe, potentially lethal hypertensive crises with cerebral 
hemorrhages, following the consumption of cheese, wine and other fermented foods, typically 
rich in tyramine and sympathomimetic amines. Due to the lack of intestinal metabolism by 
MAO-B, these compounds are absorbed and enter circulation, to induce increased 
noradrenaline release in the medulla, which in turn activates the sympathetic system and, in 
the absence of MAO-A-mediated metabolism, causes the sudden increment in blood pressure. 
The quest for MAOIs devoid of untoward effects prompted research to characterize selective 
MAO-A and –B inhibitors [9]. Some of the non-selective irreversible inhibitors discussed 
above, including phenelzine (8.I) and tranylcypromine (5.I), are still in clinical use along with 
the reversible MAOIs moclobemide (9.I, Moclamine
®
), befloxatone (10.I) and toloxatone 
(11.I, Humoryl
®
) (Figure 5.I, Table 1.I) [10]. The reversible MAO-A inhibitors (RIMAs) 
have been reported to be particularly effective in the treatment of depression in elderly 
patients [34]. MAO-A and non-selective MAOIs seem to be particularly valuable in the 
treatment of phobic anxiety and atypical depressions, such as those involving hysterical traits, 
hypersomnia, bulimia, tiredness and impression of rejection, for which they are superior to 
amine-uptake inhibitors [32].  
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Figure 5.I. Chemical structures of iproniazid (6.I), isoniazid (7.I), phenelzine (8.I), 
moclobemide (9.I), befloxatone (10.I), toloxatone (11.I), l-deprenyl (12.I), rasagiline (13.I), 
lazabemide (14.I), physostigmine (15.I), ladostigil (16.I), M30 (17.I), CGP 3466 (18.I) and 
fluoxetine (19.I). 
 
 
1.4.2 Parkinson’s disease  
 
The Parkinson‘s disease (PD) is associated to a neuronal death of the dopaminergic neurons in 
the substance nigra of the brain [7]. The exact origin of this neuronal death is not yet clearly 
understood. This neuronal death of the dopaminergic neurons results in a large loss of 
dopamine (DA) in the brain and throws off the normal dopamine/acetylcholine balance, since 
the acetylcholine level remains normal. The result of this imbalance is a lack of coordination 
of the movement that often appears as tremor, stiff muscles and joints, and/or difficulty 
moving. Currently, there is no way to stop the loss of nerve cells that produce dopamine or to 
restore those that have already been lost. 
The rationale behind the usage of MAO-B inhibitors in PD was originally based on the 
concept that DA is preferentially deaminated by this isoenzyme in the human nigrostriatal 
dopaminergic system [9]. The inhibition of this enzyme would result in an increased level of 
PF 9601N (21) 
6.I               7.I     8.I      9.I 
10.I               11.I     12.I      13.I 
14.I               15.I     16.I      17.I 
18.I                  19.I 
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dopamine and therefore conduct to a prolongation of the availability of the dopamine in 
residual neurons in the substantia nigra [35]. Furthermore, MAO-B is also believed to 
contribute to the development or progression of the disease [7]. Because the dopamine 
turnover is elevated in the parkinsonian brain, it follows that the surviving dopaminergic 
neurons are exposed to an increased flux of hydrogen peroxide (H2O2) derived as a 
consequence of MAO-B activity and which contributes to the formation of other ROS 
(reactive oxygen species) and can trigger mitochondrial damage and neuronal death. Finally, 
the MAO-B is also responsible of the metabolism of some endogeneous (tetrahydroquinoline) 
[36] and exogenous compounds (MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) 
which are transformed into toxic substances [37]. All such data provide a rationale for the use 
of MAO-B inhibitors in the treatment of PD.  
The use of MAOIs as dopamine-sparing agents or as adjuncts to L-DOPA was considered as a 
treatment for PD, but such an approach with non-selective inhibitors was abandoned because 
of the cheese reaction [10]. As levels of MAO-B are increased in the brain of people with PD 
as a consequence of gliosis, because the human basal ganglia has higher MAO-B than MAO-
A activity, and because dopamine is equally well metabolized by both isoenzymes in humans, 
the selective MAO-B inhibitor l-deprenyl (12.I, Eldepryl® and Jumex®, Figure 5.I, Table 1.I) 
was first investigated as an adjuvant to L-DOPA. l-Deprenyl (12.I) is effective both as an 
adjuvant to L-DOPA and as monotherapy. Although l-deprenyl (12.I) seems to slow disease 
progression during the first year of treatment, no significant effect on the course of the disease 
was found after that time [10]. Inhibitors that have been demonstrated to be of clinical value 
include the mechanism based inactivators, l-deprenyl (12.I) and rasagiline (13.I, Figure 5.I, 
Table 1.I), and reversible inhibitors such as lazabemide (14.I) and safinamide (1.I, Figure 5.I, 
Table 1.I) [38]. The efficacy of rasagiline (13.I) in early-stage and late-stage PD has 
previously been demonstrated in phase III clinical trials [39]. Safinamide (1.I) is currently in 
phase III clinical trials for the treatment of PD and displays a novel mode of action as a 
dopamine modulator (comprising both selective and reversible MAO-B inhibition and also 
blockade of dopamine reuptake) [4, 40]. From a safety point of view, reversible inhibitors 
may be therapeutically more desirable than inactivators since MAO-B activity can be 
regained relatively quickly following withdrawal of the reversible inhibitor. In contrast, return 
of enzyme activity following treatment with inactivators requires de novo synthesis of the 
MAO-B protein which may require several weeks [38]. For this reason, several studies are 
currently underway to develop reversible inhibitors of MAO-B.  
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1.4.3 Alzheimer’s disease  
 
The origin of the Alzheimer‘s disease (AD) is not yet clearly understood. It is, however, 
suggested that the -amyloid and the tau proteins and genetic factors might play a role in this 
disease [7, 41]. MAO-B activity has been shown to increase with age and is particularly high 
around the senile plaques in AD patients [42-43]. The production of the hydroxyl radical from 
hydrogen peroxide, produced by the MAO-B activity, might also play a role in the 
development or progression of the disease. It was shown that the hydroxyl radical favor the 
transformation of the soluble -amyloid protein into neurotoxic agregated -amyloid proteins 
[7].  
Age-related increases in MAO-B activity, as well as the neuroprotective effects of its 
inhibitors, have been considered as rational bases to use selective MAO-B inhibitors in the 
therapy of AD [9]. Clinical trails with l-deprenyl (12.I) in patients with AD have not given 
conclusive results, although MAO-B activity is increased in the brain of such patients and 
might contribute to oxidative stress in this disorder. Currently, acetylcholinesterase inhibitors 
are the only drugs approved for the treatment of cognitive dysfunction in AD [10]. Thus, it 
has been proposed that combined treatment with a MAO-B inhibitor plus one of the approved 
cholinesterase inhibitors, such as physostigmine (15.I, Figure 5.I), could be beneficial for the 
treatment of AD. A related approach is to combine these two enzyme inhibitory functions in 
the same molecule. The drug ladostigil (16.I, Figure 5.I, Table 1.I) combines the 
pharmacophore of rasagiline (13.I) with a carbamate cholinesterase inhibitory moiety into a 
single molecule. Its pharmacological activities include neuroprotection, butyrylcholinesterase 
and acetylcholinesterase inhibition, and brain-selective MAO-A/B inhibition. It appears to be 
effective in enhancing cognition in old primates, as well as having antidepressant and 
anxiolytic activity, and is now in clinical trials for AD [10]. M30 (17.I, Figure 5.I, Table 1.I) 
is a brain selective agent characterized by the presence of both propargyl anti-MAO and iron 
chelating moieties; it might serve as drug for neurodegenerative disorders, such as PD and 
AD, in which oxidative stress and iron alteration are implicated [44]. 
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1.4.4 Other neurodegenerative diseases 
 
Neurodegenerative diseases such as Huntington‘s disease and amyotrophic lateral sclerosis 
(ALS) share many of the pathological features of PD and AD, such as oxidative stress, iron 
accumulation, excitotoxicity, inflammatory processes and the misfolding of toxic proteins that 
cannot be degraded after ubiquitination [10]. l-Deprenyl (12.I) treatment has not been 
successful in the treatment of ALS. However, rasagiline (13.I) and CGP 3466 (18.I, Figure 
5.I) have been reported to be effective in mouse models of ALS [10]. A single-patient study 
has reported beneficial effects of l-deprenyl (12.I), in combination with the 5-HT reuptake 
inhibitor fluoxetine (19.1, Prozac
®
, Figure 5.I), in Huntington‘s disease [45]. In spite of some 
promising results in animal models, however, clinical results have not been encouraging so far 
[9]. 
 
 
1.4.5 Cerebral ischaemia 
 
l-Deprenyl (12.I) decreases the peripheral tissue damage that results from cardiac failure and 
that arising in the brain from cerebral ischaemia in animal models [10]. This protective effect 
has been attributed to a decrease in hydrogen peroxide generated by MAO during ischaemia-
reperfusion. The results of a Phase II trial with a limited number of participants have 
confirmed that l-deprenyl (12.I) can enhance recovery after cerebral infarction [46]. 
 
 
1.4.6 Ageing 
 
The process of ageing seems to involve changes in the levels of MAO activity. In human skin 
fibroblasts cultured from males of between 1 and 60 years of age, the specific activity of 
MAO-A, assessed during proliferative growth, increased 5 to 10 fold with the age of the 
donor, whereas the increase in MAO-B activity was less than 3 fold [10].  
Increases in human brain MAO-B activity with age have been attributed to glial cell 
proliferation, whereas for MAO-A activity, both increases and no change have been reported 
with advancing age [10]. Knoll was first to report that l-deprenyl (12.I) enhanced the sexual 
activity and extended the lifespan of rats [47]. This might result from increased antioxidant 
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capacity and the mobilization of several hormonal factors. The actions of l-deprenyl (12.I) 
might increase neuronal survival fitness (‗neurofitness‘) by preventing, or perhaps to some 
extent reversing, the decline in resistance that is normally associated with cellular ageing. 
More recent work has shown that l-deprenyl (12.I) can also enhance the learning ability of 
aged rats [48].  
MAO-A levels have also been found to dramatically increase (~9 fold) in the heart of aged 
rats, thereby suggesting the probability of age-dependent increases in MAO-A levels in 
humans [2, 49]. The consequence of this large increase in the level of MAO-A in the heart is 
suggested to involve increased apoptosis and necrosis of cardiac cells due to increased levels 
of reactive oxygen species from the H2O2 produced. As suggested from the work of Parini and 
co-workers [50], the identification of the involvement of MAO-A in cardiac cellular 
degeneration thus presents a potential drug target for the development of cardioprotective 
agents for an aging population. Initial attempts have been published [51]; however, this area 
of MAO research is still in its infancy. 
 
 
1.4.7 Smoking cessation  
 
MAO-B inhibitors are devoid of antidepressant activity and do not promote the cheese 
reaction unless administered at concentrations high enough to inhibit MAO-A [10]. However, 
l-deprenyl (12.I) and lazabemide (14.I) have both been reported to aid smoking cessation and 
continued abstinence [52-53]. The MAO-A inhibitor moclobemide has been shown to have 
similar effects, and this might relate to increased levels of 5-HT in the brain [54]. Because 
MAO-A and –B are inhibited in cigarette smokers [55], this effect might simply be related to 
the continuation of a level of MAO inhibition to which smokers have become habituated [10]. 
 
 
1.5 Concluding remarks 
 
So, the development of MAOIs is important not only from the standpoint of symptomatic 
treatment (e.g., by increasing the biological half-life of monoamine neurotransmitters), but 
also with regard to the neuroprotective effects (e.g., prevention or delay of neurodegeneration 
itself) [56]. All of these aspects have led to an intensive search for novel MAOIs and this 
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effort has increased considerably in recent years. Due to their selective and reversible 
inhibition of MAO, this new generation of MAOIs displays a safer profile compared to the 
former irreversible MAOIs, particularly with regard to the cheese-effect, and drug 
interactions. The next point discusses about diverse series which have also been extensively 
used as scaffolds in medicinal chemistry programs searching for novel MAO-A and –B 
inhibitors. 
 
 
1.6 MAO-A and –B inhibitors  
 
1.6.1 Indole derivatives 
 
Studies have shown that the indole derivatives may be used for the design of potent anti-MAO 
agents [57-62]. Previous studies on indolylmethylamine derivatives bearing substituents in the 
1 and 5-positions of the indole ring acted as irreversible and selective MAOIs in rat liver 
mitochondrial [60]. For example, the irreversible MAO-B inhibitor PF9601N (20a.I, Ki 
rMAO-B = 0.75 nM with a selectivity index (SI) >1000 toward rMAO-B, Figure 6.I) shows 
antioxidant/neuroprotective properties in an experimental model of PD [61] whereas 20b.I is 
a potent MAO-A inhibitor (Ki rMAO-A = 0.8 nM with a SI of 5 toward rMAO-A, Figure 6.I).  
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Figure 6.I. Chemical structures of indole derivatives (20a-f.I).  
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The small molecule isatin (4.I, Figure 2.I) is a natural reversible inhibitor of both hMAO-A 
and –B (Ki = 15 and 3 µM respectively) [63]. The crystal structure of hMAO-B in complex 
with isatin has been solved (1OJA.pdb) [17]. The isatin binds within the substrate cavity 
leaving the entrance cavity of MAO-B unoccupied and so explains the weak affinity of isatin 
on hMAO-B. In an attempt to identify inhibitors with enhanced potencies and specificities for 
MAO-B, investigations of additional C5- and C6-substituted isatin analogues with 
hydrophobic groups toward hMAO-A and –B have revealed that the C5-substituted isatins 
exhibited higher binding affinities to MAO-B than the corresponding C6-substituted 
analogues [64]. The most potent and selective MAO-B inhibitor, 5-(4-phenylbutyl)isatin 
(20c.I, Figure 6.I), exhibited a Ki value of 0.28 nM and a SI of 2030 toward hMAO-B, 
approximately 18500-fold more potent than isatin. Molecular docking studies with MAO-B 
indicate that the increased binding affinity exhibited by 20c.I analogue, in comparison to 
isatin, is best explained by the ability of the lateral chain to bridge both the entrance and 
substrate cavities of the enzyme. 
Recently, La Regina et al have identified new reversible MAOIs with indole scaffold [61]. 
Several compounds were potent MAO-A or –B inhibitors, and displayed Ki values in the 
nanomolar concentration range. In particular, 20d.I (Ki bovine MAO-A (Ki boMAO-A) = 
0.92 nM, SI of 68478 toward MAO-A, Figure 6.I) was exceptionally potent and selective as 
MAO-A inhibitor. Introduction of a methyl group in the 1-position of the indole provided a 
compound endowed with higher MAO-B inhibitory activity but low selectivity (Ki boMAO-B 
= 1.5 nM, SI of 29 toward MAO-B, 20e.I, Figure 6.I).  
From the observation that bulky C5 substituents generally increase potency and selectivity for 
the MAO-B isoform by increasing the molecular lipophilicity, Prins et al have studied a series 
of indole derivatives with bulky C5 susbtituents on hMAO-A and –B [62]. The most potent 
reversible MAO-B inhibitor, 20f.I (Figure 6.I), exhibited a Ki value of 30 nM and was also the 
most selective MAO-B inhibitor with a SI of 99 toward hMAO-B. An important observation 
was that chlorine substitution at the C5 phenyl side chain of the indoles enhances both MAO-
A and –B inhibition potencies.  
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1.6.2 -Carbolines 
 
-Carbolines (pyrido[3,4-b]indoles), naturally occurrent in South American plants as harmala 
alkaloids, contain an indole ring structure within their molecules. -Carboline alkaloids are 
psychopharmacologically active compounds that may occur in foods and endogenously in 
human tissues, including the brain and are reported to be potent inhibitors of MAO-A [65-66]. 
In the human organism they may be formed from the condensation of the biogenic amines 
tryptamine and serotonin with aldehydes or α-keto acids, respectively [67]. 
First experiments have shown that the -carboline derivatives were more effective inhibitors 
of MAO than their the 1,2,3,4-tetrahydro and 3,4-dihydro analogues [66, 68-69]. -carbolines 
reported in figure 7.I display a reversible competitive inhibition and are selective of MAO-A. 
Norharman (21a.I) is a weak inhibitor of purified MAO-A and –B (Ki hMAO-A = 3.34 µM 
[69], Ki hMAO-B = 1.12 µM [55]). Methylation in the 1-position of norharman to give 
harman (21b.I, Ki hMAO-A = 0.26 µM [69]) results in a 13-fold decrease in the Ki value. 
Furthermore, the introduction of a 7-methoxy group (harmine, 3.I, Ki hMAO-A = 5 nM [69]) 
decreases the Ki further by 50-fold compared to harman (21b.I). The ring reduction of 
harmine to give harmaline (21c.I, Ki hMAO-A = 48 nM [69]) results in a 10-fold increase in 
the Ki value whereas the 6-methoxy substitution of harmalan (21d.I, Ki hMAO-A = 0.39 µM 
[69]) is less effective (8-fold) compared to 7-methoxy derivative (harmaline, 21c.I).  
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Figure 7.I. Chemical structures of -carbolines (21a-d.I and 3.I).  
  
Recently, the crystal structure of hMAO-A in complex with harmine has been solved 
(2Z5X.pdb) [3]. Furthermore, Herraiz et al have identified two -carboline alkaloids, 
norharman (21a.I) and harman (21b.I) in tobacco smoke [55] and coffee [70] which inhibited 
MAO-A (norharman and harman) and –B (norharman) isozymes with a competitive 
inhibition. The presence of MAOIs like -carbolines in smoke and coffee might play a role in 
the neuroactive actions including a purported neuroprotection (i.e., a lower risk for developing 
PD) associated with coffee consumption and smoke. Indeed, norharman (21a.I) might act as a 
             21a.I                   21b.I                        3.I                               21c.I                         21d.I   
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potential neuroprotective agent by its MAO-B inhibition ability (resulting in a higher 
dopamine and lower hydrogen peroxide, a ROS). Further research is needed to clarify this 
topic.  
 
 
1.6.3 5H-Indeno[1,2-c]pyridazin-5-ones 
 
First studies on 5H-indeno[1,2-c]pyridazin-5-one scaffold (Table 2.I) as MAOIs performed by 
the Testa‘s team have shown that 5H-indeno[1,2-c]pyridazin-5-one (22a.I) is a moderate 
selective inhibitor of MAO-B (IC50 rMAO-B = 27.5 µM, SI of 4 toward rMAO-B) [71]. The 
substitution in the 3-position with a phenyl group (22b.I, IC50 rMAO-B = 21.0 µM) increases 
slightly the inhibition on MAO-B compared to 22a.I and methylated derivative (22c.I, IC50 
rMAO-B = 74.4 µM) which abolishes the inhibition. Reduction of the carbonyl group to a 
methylene group (22d.I, IC50 rMAO-B = 23.4 µM) shows a MAO-B inhibition comparable to 
corresponding carbonyl derivative (22b.I) [71]. This suggests that the presence of carbonyl 
group is not a critical requisite for MAO-B inhibition. Interestingly, the loss of carbonyl 
group produces a measurable MAO-A inhibition (compared to 22b.I).  
 
Table 2.I. Chemical structures of 5H-indeno[1,2-c]pyridazin-5-one derivatives (22a-m.I).  
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Compound X R3 R7 R8 IC50 (µM) 
22a.I CO H H H 27.5 (rMAO-B) 
22b.I CO Ph H H 21.0 (rMAO-B) 
22c.I CO Me H H 74.4 (rMAO-B) 
22d.I CH2 Ph H H 23.4 (rMAO-B) 
22e.I CO 4‘-CF3-Ph H H 0.090 (rMAO-B) 
22f.I CO 3‘-CF3-Ph H H 0.280 (rMAO-B); 
0.0085 (hMAO-B) 
22g.I CO 4‘-NO2-Ph H H 0.500 (rMAO-B) 
22h.I CO 4‘-OMe-Ph H H 3.22 (rMAO-B) 
22i.I CO Me H OCH2Ph 0.170 (rMAO-B) 
22j.I CO Me H OCH2CH2CH2CF3 0.014 (baMAO-B) 
22k.I CO Me H OCH3 >1 (rMAO-B) 
22l.I CO 3‘-CF3-Ph OCH3 H 0.038 (baMAO-B) 
22m.I CO 3‘-CF3-Ph H OCH3 0.0001 (baMAO-B) 
22a-m.I 
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Derivative 22b.I was thus taken as a lead compound and its activity optimized by variously 
substituting the 3-phenyl ring in the 2', 3', and/or 4'-positions [72]. Results show that a given 
substituent was more favorable in the meta or para than in the ortho position. Para-substituted 
derivatives (e.g., 22e.I, IC50 rMAO-B = 90 nM) generally appeared as slightly more active 
than the meta-substituted analogues (e.g., 22f.I, IC50 rMAO-B = 280 nM). Moreover, the 
introduction of an electron-withdrawing group like nitro (22g.I, IC50 rMAO-B = 500 nM) or 
trifluoromethyl (22e.I, IC50 rMAO-B = 90 nM) is more favorable for activity on MAO-B 
compared to an electron-donating methoxy group (22h.I, IC50 rMAO-B = 3.22 µM) on the 
phenyl ring.  
More recently, Novaroli et al have evidenced important species-dependent differences in 
MAO-B inhibitor specificity between human and rat for 5H-indeno[1,2-c]-pyridazin-5-one 
derivatives [73]. Indeed, these derivatives show a greater inhibitory potency toward hMAO-B 
than toward rMAO-B (e.g., 22f.I, IC50 rMAO-B = 280 nM and IC50 hMAO-B = 8.5 nM). 
Molecular docking simulations of 22f.I into the active site of hMAO-B show that the 3-
phenyl moiety points to the substrate cavity [73].  
Other studies performed by our group on 5H-indeno[1,2-c]pyridazin-5-one scaffold bearing 
lipophilic and bulky side chains in the 8-position show that groups like benzyloxy (22i.I, IC50 
rMAO-B = 170 nM) and trifluorobutyloxy (22j.I, IC50 baboon MAO-B (IC50 baMAO-B) = 14 
nM) increase the selectivity and inhibitory potency on MAO-B compared to methoxy 
derivative (22k.I, IC50 rMAO-B >1 µM), and 22a.I [74-75]. Furthermore, both benzyloxy and 
trifluorobutyloxy derivatives do not inhibit MAO-A. Investigation of the regioisomeric 
structures established that substitution of the 5H-indeno[1,2-c]pyridazin-5-one core in the 7 vs 
8-positions dramatically influences the MAO-inhibiting properties of these compounds (e.g., 
22l.I, IC50 baMAO-B = 38.0 nM and 22m.I, IC50 baMAO-B = 0.10 nM) [74]. Moreover, 
neither compounds inhibited MAO-A confirming their very good selectivity profile. These 
data show thus differences in MAO-B inhibitory potency of these indeno[1,2-c]pyridazin-5-
one regioisomers. Molecular docking simulations for 22j.I in hMAO-B revealed that 
compound positions in the vicinity of the FAD cofactor with the trifluorobutoxy side chain 
settling within the entrance cavity lined with hydrophobic amino acid residues [75].  
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1.6.4 Other inhibitors 
 
1.6.4.1 Azines 
 
Carotti et al have recently extended the study of condensed azines on the MAO effects to the 
families of indeno-fused, pyrimidines (23a.I, Figure 8.I) and 1,2,4-triazines (23b-c.I, Figure 
8.I) [76]. The preference toward the MAO isoenzymes proved to be dependent on the type of 
azine-containing tricyclic scaffold. Indeed, 23b.I (21% of rMAO-A inhibition at 10 µM and 
IC50 rMAO-B = 6.31 µM) is a selective MAO-B inhibitor more potent than the 5H-
indeno[1,2-c]pyridazin-5-one analogue (22b.I, IC50 rMAO-B = 21.0 µM, Table 2.I) whereas 
the indeno-pyrimidinone fusion isomer (23a.I, IC50 rMAO-A = 2.37 µM with a SI of 5 toward 
MAO-A) moderately inhibits both MAO isoenzymes with a preference toward MAO-A. A 
major outcome of this study was the identification of 23c.I as a new promising MAO-B 
selective inhibitor (IC50 rMAO-B = 80 nM).  
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Figure 8.I. Chemical structures of azine derivatives (23a-c.I). 
 
 
1.6.4.2 Benzopyran and benzofuran derivatives 
 
a) Coumarins 
Coumarins are benzopyrones which have been intensively studied for their MAO inhibitory 
activity [4-5, 73, 77-84]. Variations mainly in the 3, 4, and 7-positions of the coumarin core 
revealed that most of the compounds acted preferentially on MAO-B with IC50 and Ki values 
in the micromolar to low-nanomolar range. 7-Benzyloxy-3,4-dimethylcoumarin (24a.I, Figure 
9.I, IC50 hMAO-B = 1.1 nM) is a potent reversible and selective inhibitor toward hMAO-B 
[73] whereas high inhibitory activities toward rMAO-A were also measured for sulfonic acid 
esters as 24b.I (Figure 9.I, IC50 rMAO-A = 10.7 nM with a SI of 1349 toward rMAO-A) [77, 
79]. These results demonstrate a key role of the 7-substituent, the ether derivatives being 
MAO-B selective but the sulfonic acid esters displaying MAO-A selectivity [77]. The study 
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of coumarin-3-carboxamides reported potent and selective inhibitors of hMAO-B with IC50 
values in the nanomolar range (e.g., 24c.I, Figure 9.I, IC50 = 1.4 nM with a SI of 6664 toward 
hMAO-B) [5]. Recently, structures of hMAO-B in complex with two coumarin derivatives 
(24d.I and 24e.I, Figure 9.I) were determined by X-ray crystallography at high resolution (1.7 
and 2.0 Ǻ respectively) [4]. These compounds competitively inhibit hMAO-B with Ki values 
of 0.10 and 0.40 µM respectively with a SI of 27 and 157 toward hMAO-B. Furthermore, 
24d.I is an in vivo potent and selective MAO-B inhibitor. In ex vivo experiments, it showed a 
rapid blood-brain barrier penetration, short-acting and reversible inhibitory activity, and low 
in vitro toxicity [83]. On the basis of this preliminary preclinical profile, this inhibitor could 
be viewed as a promising clinical candidate for the treatment of neurodegenerative diseases. 
Santana et al have recently discovered that the introduction of bulky groups in the 7-acetonyl 
substituent of coumarin scaffold increases MAO-A selectivity [81]. 24f.I (Figure 9.I) is a 
potent MAO-A inhibitor (IC50 hMAO-A = 7.2 nM) and displays a high MAO-A specificity 
(1000-fold higher compared to MAO-B). The introduction of bulky groups such as cyclohexyl 
or phenyl in the 3,4-positions of the 7-acetonyl derivatives increases both MAO-A and –B 
inhibitory activities with concomitant loss of selectivity, whereas the replacement of the 
acetonyl substituent in the 7-position by the bromoallyloxy group (24g.I, Figure 9.I, IC50 
hMAO-B = 1.5 nM) shows a high activity and selectivity for MAO-B (1600-fold higher 
compared to hMAO-A) [81]. More recently, 24h.I (Figure 9.I) was found to be a potent 
inhibitor of hMAO-B (IC50 hMAO-B = 0.80 nM) and inactive at 100 µM on hMAO-A [82]. 
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Figure 9.I. Chemical structures of coumarin derivatives (24a-h.I). 
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b) Chromone, flavanone and xanthone derivatives 
Chromone-3-carboxylic acid (25a.I, Figure 10.I) was identified as a potent hMAO-B inhibitor 
(IC50 hMAO-B = 48 nM) with a high degree of selectivity for hMAO-B compared to hMAO-
A (SI >2083 toward hMAO-B) [56]. A recent study on flavone, thioflavone and flavanone 
derivatives as potential MAOIs has shown that the most active series was the flavanone one 
with higher selective inhibitory activity for hMAO-B [85]. 25b.I (Figure 10.I) was identified 
as the most potent and selective hMAO-B inhibitor within this series (IC50 hMAO-B = 0.13 
µM with a SI >769 toward hMAO-B). The introduction of a double bond in the flavones and 
of the sulfur in the thioflavones leads to a relevant decrease in the inhibitory activity although 
keeping a hMAO-B selectivity. The xanthone derivatives are known for their ability to 
reversibly inhibit MAO [86]. 25c.I (Figure 10.I, IC50 hMAO-A = 40 nM with a SI of 825 
toward hMAO-A) emerged as a potent and selective inhibitor.  
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Figure 10.I. Chemical structures of chromone (25a.I), flavanone (25b.I) and xanthone (25c.I) 
derivatives. 
 
 
c) Benzofuran derivatives 
From the observation that bulky C5 substituents in indole scaffold generally increase potency 
and selectivity for the MAO-B isoform by increasing the molecular lipophilicity, Prins et al 
have studied a series of benzofuran derivatives with bulky C5 susbtituents on hMAO-A and –
B [62]. 26.I (Figure 11.I) was the most potent reversible MAO-B inhibitor in this series with a 
Ki value of 0.19 µM but is less selective (SI of 5 toward hMAO-B).  
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Figure 11.I. Chemical structure of benzofuran derivative (26.I). 
PF 9601N (21) 
PF 9601N (21) 
25a.I          25b.I      25c.I 
26.I 
29 
 
An important observation is that chlorine substitution at the C5 phenyl side chain of the 
benzofuran enhances both MAO-A and –B inhibition potencies.  
 
 
1.6.4.3 Chalcone derivatives 
 
A large series of substituted chalcones have been tested in vitro for their ability to inhibit 
hMAO-A and –B [87]. While all the compounds show hMAO-B selective activity in the 
micro- and nanomolar ranges, the most active compound (27.I, Figure 12.I, IC50 hMAO-B = 
4.4 nM) also shows the highest MAO-B selectivity (SI >11364 toward hMAO-B). 
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Figure 12.I. Chemical structure of chalcone derivative (27.I). 
 
 
1.6.4.4 Caffeine and benzimidazole derivatives 
 
While the caffeine is only a weak inhibitor of MAO-B (Ki = 3.6 mM), several studies have 
evidenced that substitution in the 8-position by a styryl group enhances affinity of caffeine 
analogues acting as moderate to very potent competitive inhibitors of MAO-B [38, 88-90]. 
(E)-8-(3-Chlorostyryl) caffeine (CSC, 28a.I, Figure 13.I) and 28b.I (Figure 13.I) with Ki 
baMAO-B values of 128 nM and 36 nM respectively were the most potent members of the 
series [38, 91]. By analogy to CSC (28a.I), 28c.I (Figure 13.I) displayed promising baMAO-
B inhibition with a Ki value of 181 nM [92]. Based on results of (E)-8-styrylcaffeinyl 
analogues, a series of 8-benzyloxycaffeinyl analogues were evaluated as MAOIs [93]. They 
inhibited reversibly both MAO isoforms. The most potent MAO-A inhibitor was 8-(3-
methylbenzyloxy)caffeine (28d.I, Figure 13.I, Ki hMAO-A = 140 nM with a SI of 1.3 toward 
hMAO-A) while 8-(3-bromobenzyloxy)caffeine (28e.I, Figure 13.I,  Ki hMAO-B = 23 nM 
with a SI of 14.5 toward hMAO-B) was the most potent MAO-B inhibitor. Furthermore, these 
results confirm that the styryl and benzyloxy side chains have similar properties with respect 
to binding to MAO-B and probably exhibit similar binding modes within the active site of 
MAO-B. Modeling studies have also evidenced that the benzyloxy side chains of the 
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inhibitors are rotated in hMAO-A to avoid unfavourable interactions with the side chain of 
Phe208 [93].  
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Figure 13.I. Chemical structures of caffeine (28a-e.I) and benzimidazole (28f.I) derivatives. 
 
A study on (E)-2-styryl-1-methylbenzimidazole analogues identified 28f.I (Figure 13.I) as the 
most potent inhibitor with a Ki value of 430 nM [38]. The potency of MAO-B inhibition by 
(E)-8-styrylcaffeines and (E)-2-styrylbenzimidazoles may possibly also be explained by a 
similar mode of binding that involves traversing both the entrance and substrate cavities [38, 
94]. These inhibitors possibly bind to MAO-B with the benzimidazole or caffeine ring located 
in the substrate cavity of the active site while the styryl substituent extends into the entrance 
cavity.  
 
 
1.6.4.5 Pyrole and pyrazole derivatives 
 
Among the most potent pyrole derivatives, 29a.I (Figure 14.I, Ki boMAO-A = 24 nM with a 
SI of 12500 toward boMAO-A) shows high selectivity for MAO-A while 29b.I (Figure 14.I, 
Ki boMAO-B = 20 nM with a SI of 175 toward boMAO-B) was highly selective for the B 
isoenzyme [95-96]. 
The pyrazole derivatives have been widely studied for their ability to inhibit reversibly MAO-
A and –B [97-106]. Among them, N1-acetyl pyrazoline derivatives display higher activity on 
MAO-A compared to MAO-B [97-98]. For example, 29c.I (Figure 14.I) is a potent and 
selective MAO-A inhibitor (IC50 boMAO-A = 8.6 nM with a SI of 12500 toward boMAO-A) 
[98]. N1-Thiocarbamoyl pyrazole derivatives show high activity on both isoforms. For 
example, 29d.I (Figure 14.I) is a potent and selective MAO-B inhibitor (Ki boMAO-B = 1.5 
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nM with a SI of 21 toward boMAO-B) while 29e.I (Figure 14.I) inhibits selectively MAO-A 
(Ki boMAO-A = 6.0 nM with a SI of 166 toward boMAO-A) [99]. 2-Thiocarbamoyl indazole 
derivatives show high activity on both rMAO-A (e.g., 29f.I, Ki rMAO-A = 4.2 nM with a SI 
of 294 toward rMAO-A) and rMAO-B (e.g., 29g.I, Ki rMAO-B = 0.90 nM with a SI >3322 
toward rMAO-B) isoforms [103]. 
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Figure 14.I. Chemical structures of pyrole (29a-b.I) and pyrazole (29c-g.I) derivatives. 
 
 
1.6.4.6 Thiazolylhydrazone derivatives 
 
2-Thiazolylhydrazone derivatives have been investigated for their ability to inhibit selectively 
the in vitro activity of hMAO-A and –B [107-109]. Among the most active and selective 
derivatives toward hMAO-B, 30a.I (Figure 15.I, assessed as mixture of E and Z conformers), 
displays an IC50 value of 3.8 nM with a SI of 119 toward hMAO-B [108]. It was evident that 
the anti-MAO activity and selectivity were strongly associated with the presence of a 
heterocyclic or a bicyclic moiety on the hydrazonic nitrogen. For example, 30b.I (Figure 15.I) 
(assessed as mixture of E and Z conformers), displays both low inhibitory activity and the best 
selectivity toward hMAO-A (IC50 hMAO-A = 874.7 nM with a SI >115 toward hMAO-A) 
[108]. 
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Figure 15.I. Chemical structures of thiazolylhydrazone derivatives (30a-b.I). 
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1.6.4.7 Thiazolidinedione derivatives 
 
Recently, it was shown that the anti-diabetic drug pioglitazone (31a.I, Figure 16.I, IC50 
hMAO-B = 298 nM) was protective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) parkinsonian mouse model [110-112]. The neuroprotective mechanism of 
pioglitazone was shown to be, at least in part, through its inhibition of MAO-B which 
prevents the conversion of MPTP to its toxic metabolite MPP+ [110]. Further study has 
identified the thiazolidinedione scaffold as a novel scaffold which can be used for the 
inhibition of the hMAO-B enzyme [112]. From this study, inhibition assays identified two 
thiazolidinedione derivatives (A6355 (31b.I) and L136662 (31c.I)) which inhibit hMAO-B 
with IC50 values of 82 and 195 nM, respectively (Figure 16.I). 
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Figure 16.I. Chemical structures of pioglitazone (31a.I), A6355 (31b.I) and L136662 (31c.I). 
 
 
1.6.4.8 Quinoxaline derivatives 
 
Recently, a series of 3-benzylquinoxaline derivatives was investigated for their MAO 
inhibitory property [1, 113]. The results revealed that all 3-benzylquinoxaline derivatives 
studied display a MAO-A selectivity. 32.I was the most potent and selective inhibitor (Figure 
17.I, IC50 boMAO-A = 2.8 nM with a SI of 3.0 x 10
6 
toward boMAO-A).  
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Figure 17.I. Chemical structure of quinoxaline derivative 32.I. 
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1.6.4.9 Nicotinamide derivatives 
 
Iproniazid (6.I, Figure 5.I) was the prototype of potent MAOI introduced in therapy of 
depression in 1957 [114]. However, due to its side interactions with other drugs and certain 
food, the therapeutic applications of iproniazid (6.I) have been diminished. Moclobemide (9.I, 
Figure 5.I) was the first nonhydrazine, reversible MAO-A selective inhibitor approved for use 
as an antidepressant drug. Although it is a potent MAO-A inhibitor in vivo, it is only a weak 
inhibitor in vitro. For pursuing more potent and less toxic MAO-A inhibitors as antidepressant 
agents, a series of nicotinamide derivatives which merges both picolinate and morpholine 
moieties of two antidepressant drugs iproniazid and moclobemide respectively were designed 
and have been tested on rMAO-A and –B [114]. Most of these compounds proved to be 
potent, and selective inhibitors of rMAO-A rather than of rMAO-B. 33a.I (Figure 18.I) 
displays the highest rMAO-A inhibitory potency (IC50 rMAO-A = 45 nM) and a good 
selectivity (SI of 578 toward rMAO-A), whereas 33b.I (Figure 18.I) is the most potent 
rMAO-B inhibitor with an IC50 value of 0.32 µM, but it was not selective (SI of 26 toward 
MAO-B).  
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Figure 18.I. Chemical structures of nicotinamide derivatives (33a-b.I). 
 
 
1.6.4.10 Phenylethylamine derivatives 
 
Several phenylethylamine derivatives, particularly α-methylphenylethylamines with a single 
alkoxy or alkylthio substituent in the para position, have proved to be potent and selective 
MAO-A inhibitors with negligible activity on MAO-B (e.g., 34a.I, Figure 19.I, Ki hMAO-A = 
22 nM with a SI of 208 toward hMAO-A) [115]). Recently, the study of rigid 
phenylethylamine analogues (2-(4‘alkoxyphenyl)thiomorpholine derivatives) has shown that 
fixing the amine chain in an extended six-membered ring conformation might lead to 
increased potency as MAO-B inhibitors [116]. Indeed, 34b.I (Figure 19.I) was the most 
PF 9601N (21) 
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potent and selective inhibitor of hMAO-B (Ki hMAO-B = 38 nM with a SI >2600 toward 
hMAO-B).  
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Figure 19.I. Chemical structures of phenylethylamine derivatives (34a-b.I). 
 
 
1.6.4.11 Safinamide derivatives 
 
Leonetti et al have studied safinamide analogues for their MAO inhibitory activity and 
selectivity [117]. All the compounds bound MAO-B isoform with higher affinity than MAO-
A. 35a.I (Figure 20.I) proved to be a more potent MAO-B inhibitor than safinamide (1.I, 
Figure 20.I) (IC50 rMAO-B = 33 nM vs 98 nM) but with a lower MAO-B selectivity (SI of 
3455 vs 5918). The highest MAO-B inhibitory potency (IC50 rMAO-B = 17 nM) and a good 
selectivity (SI of 2941) were displayed by 35b.I (Figure 20.I), a tetrahydroisoquinoline 
analogue of safinamide. 
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Figure 20.I. Chemical structures of safinamide (1.I) and derivatives (35a-b.I). 
 
 
1.6.4.12 Tranylcypromine derivatives 
 
Tranylcypromine (5.I, Figure 2.I) is a very potent antidepressant that has been in clinical use 
since the 1960s. However, side effects associated with this compound preclude its use as a 
first-line drug and it is prescribed in cases where other therapies do not work, for example, for 
the treatment of resistant depressions [118-119]. So, new studies have been performed to 
develop highly active and more selective inhibitors of MAO-A and –B using tranylcypromine 
as a lead compound which would have fewer side effects [119]. Recently, Binda et al have 
PF 9601N (21) 
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evidenced that two tranylcypromine enantiomers inhibited differently hMAO-B (36a.I, Figure 
21.I, Ki hMAO-B = 4.4 µM and 36b.I, Figure 21.I, Ki hMAO-B = 89 µM) [120]. Moreover, 
36c.I (Figure 21.I) displays a good inhibition on hMAO-B (Ki hMAO-B = 0.4 µM) and 36d.I 
(Figure 21.I) displays a good inhibition and selectivity toward hMAO-A (Ki hMAO-A = 1.2 
µM and no inhibition at 133 µM on hMAO-B). 
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Figure 21.I. Chemical structures of tranylcypromine derivatives (36a-d.I). 
 
 
2. INDOLEAMINE 2,3-DIOXYGENASE (IDO) 
 
2.1 Biological actions of IDO 
 
Indoleamine 2,3-dioxygenase (IDO) is an extrahepatic cytosolic heme-containing 
dioxygenase that catalyzes the conversion of tryptophan (Trp) to N-formylkynurenine (NFK), 
by the addition of oxygen across the C-2/C-3 double bond of the indole ring of tryptophan 
(Scheme 4.I) [121-122].  
NH3
+
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H
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H
NH3
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Scheme 4.I. Reaction catalyzed of Trp by IDO [124].  
 
In the active form of IDO, the heme iron is in its ferrous state (Fe
2+
), while in its inactive 
form, the heme iron is in the ferric state (Fe
3+
). The catalytic cycle of IDO does not alter the 
oxidation state of the iron. However, IDO is prone to autoxidation, and therefore, a reductant 
is necessary in the enzymatic assay to maintain enzyme activity. Cytochrome b5 has been 
suggested to be responsible for IDO reduction in vivo [123]. Besides Trp, IDO displays a wide 
       Trp       NFK 
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specificity of substrates. IDO degrades indoleamines such as L-Trp, D-Trp, serotonin (a 
MAO-A substrate) and tryptamine [125-126]. 
 
 
2.2 Kynurenine pathway 
 
IDO is implicated in the metabolism of Trp (Scheme 5.I). Of the dietary Trp that is not used 
in protein synthesis, most is metabolized by IDO through the kynurenine pathway, and a 
small amount of it is used to synthesize the neurotransmitter serotonin (serotonergic pathway) 
[127]. IDO catalyzes the initial and rate-limiting step in the catabolism of the essential amino 
acid Trp along the kynurenine pathway, which leads to biologically active metabolites such as 
quinolinic acid and nicotinamide.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 5.I. Pathways of Trp metabolism. Of the dietary Trp that is not used in protein 
synthesis, 99% is metabolized along the kynurenine pathway (bold arrow). Alternative 
pathway is the conversion of Trp to serotonin (serotonergic pathway, dotted arrow) [127]. 
 
A second heme-containing dioxygenase, tryptophan 2,3-dioxygenase (TDO) catalyses the 
same reaction than IDO (Scheme 5.I). However, TDO and IDO enzymes are tissue specific, 
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with the former being confined almost exclusively to the liver, whereas IDO is found in most 
other tissues, including the CNS [127]. As the major dietary tryptophan not used in protein 
synthesis is metabolized by IDO/TDO through the kynurenine pathway, consequently, IDO 
and TDO play a critical role in determining the relative Trp flux in the serotonergic and 
kynurenine pathways [122]. Previous studies have shown the interest to use TDO inhibitors as 
serotonergic antidepressants [128]. Furthermore, MAO and IDO share a same substrate 
(serotonin). So, this similarity in substrate between IDO and MAO, and the implication of 
IDO/TDO and MAO in the serotonergic and kynurenine pathways lead us to study the 
selectivity of our compounds against the three enzymes and especially in our study between 
IDO and MAO. 
 
 
2.3 Physiological and pathological roles of IDO 
 
IDO is expressed ubiquitously but predominately in cells within the immune system where it 
is specifically induced in dendritic cells and macrophages at the sites of inflammation by 
cytokines, most importantly by interferon-γ (IFNγ) [129]. The expression of IDO can be 
inductible [130] or constitutive [131], according to the type of cell.  
 
Roles of IDO; 
 
- Its first role consists in the immune defense. It was shown that IDO was overexpressed 
in presence of infectious agents. Indeed, certain microorganisms are dependent on 
exogenous Trp. So, the growth of these microorganisms will be restricted by the lack 
in Trp generated by the action of IDO [130, 132]. 
- The second role of IDO— the most studied —is its implication in the regulation of the 
immune system. Various studies showed that IDO regulated the activity of T 
lymphocytes [133]. By depleting Trp, resulting from the action of IDO, this last one 
blocks the proliferation of T lymphocytes. This inhibition of T lymphocytes will allow 
a tolerance of IDO-expressing cells against the immune system (Figure 22.I). 
Furthermore, it was shown that kynurenine, the metabolite of IDO, was able to lead to 
the apoptosis of some lymphocytes; this has an influence on the immune response 
(Figure 22.I) [134]. In addition, IDO has also been involved as an immunosuppressive 
agent, contributing to maternal tolerance toward the allogeneic fetus [135]. Indeed, the 
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survival of the fetus is described as resulting from the capacity of this one to be able of 
protecting itself from T lymphocytes of the mother, by expressing IDO. 
 
  
Figure 22.I. Depiction of the involvement of IDO in the regulation of the immune system 
[136]. 
 
Uyttenhove et al have previously shown that human tumor cells of various origins also 
constitutively expressed active IDO [137]. Table 3.I reports the relationship between the 
samples of tumors containing IDO (IDO-positive) and all the tested samples of tumors, for 
several types of tumors.  
 
Table 3.I. Expression of IDO in human tumors [137]. 
 
Tumor type IDO-positive tumor samples/Tested 
samples 
Prostatic carcinomas 11/11 
Pancreatic carcinomas 10/10 
Cervical carcinomas 10/10 
Colorectal carcinomas 10/10 
Non-small-cell lung carcinomas 9/11 
Breast carcinomas 3/10 
 
The highest proportions were observed in prostatic, colorectal, pancreatic and cervical 
carcinomas [137]. By expressing IDO, tumor cells suppress immune responses by blocking T 
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lymphocyte proliferation locally. So, it is important to identify inhibitors of this protein. 
Indeed, by promoting antitumor immune responses in combination with immunotherapy or 
chemotherapy, IDO inhibitors may offer a drug-based strategy to more effectively attack 
systemic cancer. Until now, the tests of therapeutic vaccines failed because they focused only 
on the stimulation of the immune systems of the patients against the tumor cells [136]. So, use 
of IDO inhibitors would allow working also on the mechanism by which tumors can resist 
immune rejection. Other studies also suggest that immune modulation via IDO inhibition can 
significantly increase the efficacy of a variety of traditional chemotherapeutic drugs [138]. In 
several preclinical models of cancer, single-agent therapy with an IDO inhibitor is only 
marginally efficacious, at best slowing tumor growth [137, 139]. In contrast, regression of 
established tumors can be achieved by combining an IDO inhibitor with a cytotoxic 
chemotherapeutic drug [139]. 
It is also known that IDO is overexpressed in a variety of diseases, including 
neurodegenerative disorders (e.g., Alzheimer‘s disease [140] and Huntington‘s disease [141]), 
or still in psychiatric diseases such as the depression [142]. Furthermore, infection by HIV 
increases the activity of IDO in the brain. It is then suggested that compound neurotoxins 
(quinolinic acid) resulting from the kynurenine pathway would contribute to the 
neuropathology associated with the HIV [143]. 
 
 
2.4 Three-dimensional structure and active site 
 
Previously, the crystal structures of human IDO (hIDO) in complex with 4-phenylimidazole 
(PIM, 37.I, Figure 26.I, right) (2D0T.pdb), a non-competitive IDO inhibitor or with the 
cyanide ion (2D0U.pdb) have been solved with resolutions of 2.3 Å and 3.4 Å respectively 
[144]. The two cocrystals also show two molecules of crystallization buffer, 2-(N-
cyclohexylamino)ethane sulfonic acid (CHES). Crystal structures of hIDO, obtained as 
dimers, unveil the presence of two folding domains containing mainly alpha-helices (Figure 
23.I); 
 
- The large domain (green) is an all-helical domain and is comprised of 13 α-helices and 
two 310 helices. Four long helices (A, B, C, and D) in the large domain run parallel to 
the heme plane and interact with the neighboring helix by hydrophobic interactions. 
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The heme-binding pocket is created mainly by these four helices and three other 
helices (F, G and H, cyan). The side chains of helices F, G and H also contribute to 
heme–protein interactions and connect the two domains. 
- The small domain (blue) and a long loop (red) connecting the two domains above the 
sixth coordination site of the heme (distal side) cover the top of the heme pocket. The 
small domain consists of six α-helices, two short -sheets, and three 310 helices.  
Contact between these two domains is very extensive with a buried surface area of 3.100 Å
2
. 
The interface is formed by a combination of hydrophobic interactions, salt bridges, or 
hydrogen bonds mediated by the side chains of amino acid residues [144].  
 
 
Figure 23.I. Three-dimensional structure of hIDO [144]. 
 
A loop is also present on the outside of the heme pocket, between two α-helices (D and E) of 
the large domain (residues 360-380) [144]. This loop being flexible, the electron density is 
poorly defined and it does not allow the observation of this loop. However, it was suggested 
by theoretical calculations that this flexible loop allows the closing and the opening of the 
active site of the enzyme [145]. This allows to regulate the access of the substrate to the 
catalytic site and to regulate the release of product. The theoretical studies of various types of 
complexes (enzyme-O2; enzyme-substrate and enzyme-O2-substrate) showed that Arg231 was 
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Small domain 
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also subject to a conformational shift allowing an interaction with the 7-propionate of the 
heme, according to the type of complexe [145]. These two aspects (flexible loop and 
conformational shift of Arg231) are reported in figure 24.I. So, the conformational states of 
both the electrostatic gate, constituted by Arg231 and the 7-propionate moiety of the heme, 
and the flexible loop (residues 360–380) are key elements that control the conformational 
shift of the enzymes from the inactive to the active form. Figure 24a.I shows an unbound 
inactive form of the enzyme, endowed by both an open electrostatic gate and region 360–380. 
This form would be adopted by the complexes enzyme-O2 and enzyme-substrate. Figure 24b.I 
shows an active state, as that observed by the complex enzyme-substrate-O2 where the 
electrostatic gate is closed onto the substrate and region 360–380 is packed over the catalytic 
site [145].  
    
 
Figure 24.I. Proposed model of substrate recognition by IDO. (a) Unbound inactive form 
of the enzyme: both the electrostatic gate and region 360–380 are open. (b) Substrate 
bound active state of the enzyme: the electrostatic gate is closed onto the substrate and 
region 360–380 is packed over the catalytic site [145]. 
 
As regards the environment of the heme pocket, this one consists of two sides: the proximal 
and the distal heme pockets (Figure 25.I, left) [144].  
 
- The proximal side of the heme is occupied by only side chains from the large domain. 
The heme iron is connected with the protein by His346. The heme is also stabilized by 
residues of the protein such as Arg343 which interacts by coulomb interactions with 
the 6-propionate of the heme. 
- The distal side of the heme, which is a coordination site of the heme iron for the sixth 
external ligand, consists of a combination of the small domain, the large domain and 
the loop connecting the two domains. The distal side mainly consists of residues: 
Tyr126, Cys129, Phe163, Phe164, Ser167, Phe226, Phe227, Arg231 and Ser263 
(Figure 25.I, right). These residues mainly apolar, favor the hydrophobic interactions 
between the ligand and the enzyme. Furthermore, the active site contains no water 
molecule. 
L-Trp, O2 
(a) (b) 
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Figure 25.I. Environment of the heme pocket (left) and the active site of hIDO (right) 
(2D0T.pdb).  
 
In a structural comparison between the PIM (37.I) and the cyanide-bound forms (Figure 26.I, 
left), the connecting loop exhibits a large conformational change in the main chain with a 1.3 
Å displacement. So, it was suggested that the ligand and/or substrate binding induces a 
conformational change in the main chain of the connecting loop [144]. 
 
 
Figure 26.I. (Left) Comparison of the PIM (PI) and CN
-
-bound hIDO viewed from the 
distal side [144]. The PIM and CN
-
-bound structures are shown as stick models in green 
and blue, respectively. (Right) Chemical structure of PIM (37.I). 
 
 
2.5 IDO inhibitors 
 
Several IDO inhibitors have been reported to date (Figure 27.I). Most of the IDO inhibitors 
are directly derived from Trp. It is the case of the competitive 1-methyltryptophan (1MT, 
38.I) inhibitor, the most frequently used inhibitor which displays a weak Ki of 35 µM [146]. A 
clinical trial is currently investigating the efficacy of 1MT in the treatment of advanced 
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malignancies [126, 147]. 1MT has long been known to be a competitive IDO inhibitor [148] 
but there remains a discussion concerning the efficacy of the two stereoisomers. L-1MT 
inhibits IDO in a cell-free assay with a Ki of 19 μM, while D-1MT is inactive [126, 146]. 
However, in vivo the D-isomer has been reported to be more efficacious as an anticancer agent 
in chemo-immunotherapy regimens [146]. The reason for this discrepancy is still being 
vigorously debated [126, 149-152]. The oxygen (39.I, Ki = 25 µM) and sulfur (40.I, Ki = 70 
µM) analogues of Trp display similar inhibitory potency compared to 1MT (38.I) and are 
always competitive [148]. Brassinin (41.I, Ki = 97.7 µM) is a moderately active competitive 
inhibitor and studies on brassinin dithiocarbamate analogues evidenced 42.I (Ki = 11.6 µM) as 
a competitive IDO inhibitor [153]. Methyl-thiohydantoin-tryptophan (43.I, MTH-trp, Ki = 
11.6 µM)
 
also displays a good inhibition on IDO [139]. Recently, with the aim of discovering 
novel IDO inhibitors, a virtual screen was undertaken by our group and led to the discovery of 
the keto-indole derivative 44.I endowed with an in vitro inhibitory potency in the micromolar 
range (IC50 = 65 µM) [154]. Detailed kinetics were performed and revealed an uncompetitive 
inhibition profile. Pharmacomodulations around the indol-2-yl ethanone scaffold show that a 
fivefold improvement in potency (IC50 = 13 µM) could be achieved by introducing a 
trifluoromethoxy group in the 5-position of the indole nucleus (45.I) [155]. Moreover, 45.I 
and 44.I are both endowed with 12-13% IDO inhibition at a 20 µM concentration in the 
cellular assay, which indicates reasonable cell penetration. β-carbolines are also reported as 
IDO inhibitors. To date, 3-butyl-β-carboline (46.I, Ki = 3.3 µM) is the most potent known 
non-competitive β-carboline inhibitor of IDO [156].  
 
Various other scaffolds have also shown an interest for inhibition of IDO.  
A structure-based study of PIM (37.I)-derived compounds led to the discovery of inhibitors 
with low micromolar activities (e.g., 47.I, Ki = 4.8 µM), a 10-fold decrease compared to that 
of the parent compound [157]. Kumar et al. also worked on the naphthoquinone core of 
annulin B and designed new derivatives, partly based on structural modeling, with IC50 values 
of up to 60 nM (e.g., 48.I, IC50 = 55 nM) [158]. Exiguamine A (49.I), a natural molecule, 
revealed a potent IDO inhibitor (Ki = 41 nM) [159]. Carr et al. identified tryptamine quinone 
as the core pharmacophore of exiguamine A and described a series of derivatives, the best 
displaying a Ki of 200 nM (50.I) [159]. More recently, new potent competitive inhibitors 
including a hydroxyamidine motif (e.g., 51.I, IC50 = 67 nM) have also been described [160].  
In 2010, three new series of IDO inhibitors have been reported: benzothiazoles (e.g., 52.I, 
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IC50 = 50 µM), phenylthiazoles (e.g., 53.I, IC50 = 50 µM) and triazoles
 
(e.g., 54.I, IC50 = 60 
µM) [126]. These compounds display good results in vitro as well as in cellular tests with low 
cytotoxicity. Furthermore, in cellular assays, 4-alkylamino-1-naphthol derivatives such as 55.I 
(IC50 = 2.5 µM) exhibit good activity on IDO and low cytotoxicity. The dimerized form (56.I) 
showed an IC50 of 450 nM in vitro. In cellular assays, however, this compound shows slightly 
worse result than reduced 55.I [126].   
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Figure 27.I. Chemical structures of selected IDO inhibitors. 
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3. LYSINE SPECIFIC DEMETHYLASE 1 (LSD1) 
 
Eukaryotic DNA is packaged within a nucleic acid–protein complex termed chromatin. The 
basic structural unit of chromatin is the nucleosome, which consists of 146 base pairs of DNA 
wrapped around a histone octamer (reported in Cat.# 53200 (histone demethylase assay), 
Active Motif, Inc). The histone octamer consists of two copies each of the core histones H2a-
H2b dimers and a tetramer of H3-H4. A linker histone, histone H1, binds chromatin outside 
the nucleosome unit to regulate chromatin structure. Histone modifications such as 
phosphorylation, acetylation and methylation at specific amino acid residues on the histone 
tails that extend beyond the core nucleosome have been found to influence and regulate 
transcription, chromosome packaging and DNA damage repair. While histone acetylation 
occurs only on lysine residues, histone methylation occurs at both lysine and arginine residues 
on the N-terminal histone tails. Histone lysine methylation is of particular interest given its 
association with transcriptional activation and repression, DNA damage response and X 
chromosome inactivation [161-163]. Histone methyltransferases (HMTs) and histone 
demethylases (HDMs) regulate histone methylation. There are currently two classes of 
HDMs: the lysine specific demethylase (LSD1 and 2) class and the jumonji (JmjC)-domain-
containing class. Each class of HDM uses a different reaction mechanism, which leads to 
different substrate specificity and requires the use of different cofactors for enzymatic 
activity. 
 
 
3.1 Biological actions of LSD1 
 
Mammals contain two lysine specific demethylases: LSD1 and LSD2. LSD1, also known as 
KDM1 for lysine demethylase 1, is a nuclear enzyme which uses a flavin adenine dinucleotide 
(FAD)-dependent amine oxidase domain for its demethylase activity. It catalyzes the specific 
removal of methyl groups from mono and dimethylated Lys4 of histone H3 (H3K4), although 
an androgen receptor-controlled activity on H3K9 has also been reported [164]. LSD1 
catalyzes oxidative cleavage of the C–N bond by a two-electron reduction of the FAD 
coenzyme, which produces an imine intermediate that is then non-enzymatically hydrolyzed 
to release a formaldehyde molecule (Scheme 6.I) [165]. Reduced FAD can be reoxidized by 
molecular oxygen, which generates hydrogen peroxide and makes the enzyme available for a 
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new catalytic cycle. If a dimethyl H3K4 substrate is used, the demethylation reaction will 
produce a monomethyl H3K4 substrate that is then able of undergoing a subsequent reaction 
to become unmethylated. A formaldehyde molecule will be released at each step [164]. LSD1 
is not active on trimethylated Lys4, which is consistent with the flavin-catalyzed amine 
oxidation reaction that requires a lone pair of electrons on the lysine amino group [165]. 
LSD2, like LSD1, displays a strict specificity for mono- and dimethylated Lys4 of H3. 
However, the biology of LSD2 is proposed to differ from that of LSD1 since LSD2 does not 
bind CoREST. LSD1 and LSD2 share a similar catalytic domain (45% sequence identity) 
[120]. 
 
 
 
Scheme 6.I. Reaction catalyzed by LSD1 [164]. 
 
 
3.2 Physiological and pathological roles of LSD1 
 
Genes coding for LSD1 proteins exist only in eukaryotes and have undergone distinct 
evolutionary development in plants and animals [166]. LSD1 plays a key role in the 
regulation of the expression of the active gene working as a corepressor or a coactivator of the 
transcription [167]. In non-neural cells, LSD1 in complex with the CoREST removes the 
transcriptionally activate mark of H3K4 methyl groups, thereby repressing neuron-specific 
genes [168]. LSD1 can also act as a transcriptional activator. Androgen receptor and LSD1 
form a complex in a ligand-dependent manner and remove the transcriptionally repressive 
H3K9 methyl groups, thereby de-repressing androgen-receptor-target genes [168]. 
Consequently, LSD1 can target various lysine residues and regulate transcription positively or 
negatively depending on its partners of binding. The enzyme is an interesting target for 
epigenetic medicines as suggested by its implication in the regulation of many cancer cells, 
such as breast, colon, prostate and neural cancer cells [169-174]. LSD1 is also implicated in 
viral gene activation [175] and its association to the histone deacetylase 1, a medicine target 
validated and thus is regarded as a promising drug target protein. 
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3.3 Three-dimensional structure and active site 
 
Currently, several X-ray structures of human LSD1 (hLSD1) alone or in complex are reported 
in the data bank with resolutions in the range of 2.25-3.30 Å. X-ray structures of hLSD1 were 
solved in complex with the C-terminal domain of CoREST [168, 176-178], bound to a histone 
H3 peptide (residues 1–16 of the N-terminal tail) [179] or a peptide of the transcription factor 
SNAIL1, mimicking the H3 tail [180]. Furthermore, X-ray structures of hLSD1 were also 
solved in complex with suicide inhibitors such as tranylcypromine derivatives [120, 168, 181-
182] or with a suicide inhibitor consisting of a 21-residue histone H3 peptide in which K4 is 
modified by an N-methylpropargyl group [183].  
 
LSD1 forms an elongated structure with three major parts (Figure 28.I) [184]:  
 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 28.I. (a) Depiction of the LSD1-CoREST crystal structure in complex with a histone 
H3 peptide (2V1D.pdb) [165] [179]. LSD1, CoREST, FAD and histone H3 peptide (residues 
1–16 of the N-terminal tail) are in blue, cyan, yellow and magenta respectively. (b) Depiction 
of the potential association of LSD1–CoREST with nucleosomal DNA [186]. The figure 
shows a nucleosome with the core histone octamer in the center and the associated DNA 
double helix in blue. 
 
- The N-terminal SWIRM domain. The SWIRM domain is a motif commonly found in 
chromatin enzymes and is responsible for protein–protein and DNA–protein 
interactions [165].  
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- The amine oxidase domain (AOD) consists of two subdomains (the substrate-binding 
and FAD-binding domains) [165]. The SWIRM and AOD domains pack against each 
other to form a globular structural core [184]. So far, LSD1 is unique among the AOD 
proteins in catalyzing an amine oxidation reaction in the chromatin environment. As 
expected, the AOD of LSD1 has a fold highly similar to conventional FAD-dependent 
amine oxidases. The AOD of LSD1 is homologous to equivalent domains found in 
MAO-A and –B (17.6% identity) [185]. Despite the similar overall folding topology in 
the AOD enzymes, there is significant variability in the size and shape of their 
substrate-binding sites [165]. The active site of LSD1 lies at the interface of the two 
domains and forms a large cavity. The isoalloxazine ring of FAD is located at the base 
of this cavity. The volumes of the cavities are 637 and 1736 Å
3
 for MAO-B and 
LSD1, respectively. In LSD1, the substrate-binding site is represented by a large 
funnel that originates from the flavin and opens wide towards the outside to 
accommodate the histone substrate (Figure 29a.I). In contrast to other histone-
modifying enzymes, the mechanism of histone tail recognition by LSD1 is complex 
and highly specific. The structure of the enzyme in complex with a histone peptide 
revealed that the histone tail adopts a folded conformation when bound to the enzyme 
and creeps deep into the funnel cavity, establishing a network of interactions with the 
active site residues [165]. These specific interactions act together to fix the histone tail 
in the correct register, which positions Lys4 (the site of the demethylation reaction) in 
front of the flavin cofactor.  
- The Tower domain, formed by the two antiparallel helices belonging to the insert 
between the two AOD domains, provides the binding platform for CoREST [184]. The 
CoREST linker folds into a long helix and stimulates the binding and activity of LSD1 
toward nucleosomes by binding to nucleosomal DNA. The SANT2 domain of 
CoREST which is crucial for nucleosome demethylation is located at the tip of the 
stalk and far away from the active site of LSD1. Interestingly, the Tower domain 
originates on the surface of the AOD structure that corresponds (with respect to the 
position of the FAD coenzyme) to the area where the transmembrane helix branches 
off in MAO-A and –B (Figure 29a.I) [165].  
 
Despite differences in the shape of the substrate-binding site, the details of the active sites of 
flavin amine oxidases are strikingly conserved (Figure 29b.I) [165]. MAO and LSD1 show a 
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lysine residue on top of the flavin, bridged to the N5 atom of the coenzyme via a water 
molecule, which is proposed to have a role in the enzymatic activity. Another conserved 
feature in the structure of the AOD active site is the so-called ‗aromatic cage‘. The substrate 
binds in front of the FAD cofactor, which has alongside one or two aromatic amino acids that 
form a sort of cage together with the flavin ring. In MAO-A and –B, the cage is composed of 
a Tyr–Tyr couple. In LSD1 one of these aromatic residues is conserved, with the other being 
replaced by a Thr residue (Figure 29b.I). Although the role of Tyr761 in the histone 
demethylation reaction has not been clarified, it could be involved in recognition of the 
methylated Lys4 amino group.  
LSD1 is a multidomain protein and its involvement in many diverse gene-expression 
programs [187] is strictly related to its domain organization [165]. In addition to the SWIRM 
domain, whose role in the interaction with chromatin proteins is well known, the N-terminal 
part of LSD1 is of interest. This 200-residue segment is predicted to be disordered and, some 
studies suggest that this N-terminal putative disordered domain may have a role in providing 
the enzyme with the necessary flexibility to target different chromatin proteins and to adapt 
LSD1 enzymatic activity to distinct gene transcription events [165]. 
 
 
 
 
 
 
 
 
 
 
 
Figure 29.I. a) Comparative structural analysis of hMAO-B (left, 1GOS.pdb) and hLSD1 
(right, 2V1D.pdb) [165]. The AOD and FAD are in blue and yellow respectively. In each 
structure, the cavity representing the substrate-binding site is drawn as a gray surface. The 
MAO-B C-terminal segment responsible for anchoring the protein to the outer mitochondrial 
membrane is depicted in green. In LSD1, the Tower domain and SWIRM domain are in green 
and red respectively. b) Overview of the active site surrounding the flavin cofactor in hMAO-
B (left) and hLSD1 (right). The conserved water molecule H-bonded with the flavin N5 atom 
is represented as a cyan sphere. The substrate-binding site cavity is drawn as gray surface 
[165].  
 
 
a b 
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The architecture of the substrate-binding site in hLSD1 is characterized by the presence of 
various niches that accommodate the side chains of the histone peptide (Figure 30.I) [187]. In 
particular, the polar residues Arg2, Thr6, Arg8, Lys9 and Thr11, in addition to the N-terminal 
amino group of Ala1 (N-term pocket), lie in well defined pockets, thereby establishing 
specific interactions with the surrounding protein residues. Biochemical evidence indicates 
that substrate recognition by LSD1 requires a peptide comprising at least the first 20 N-
terminal amino acids of H3 – that is, peptides of shorter length bind poorly to the enzyme and 
are not demethylated. Moreover, the side chain of Arg2 is crucial for stabilization of the 
folded conformation of the LSD1-bound H3 peptide, being at the heart of a network of 
intrapeptide hydrogen bonds (shown as dashed lines in figure 30.I). These interactions 
underlie the LSD1 specificity for H3K4 and position the methylated Lys4 side chain in 
proximity to the flavin for oxidative demethylation. The addition of epigenetic markers 
introduces steric and electrostatic perturbations which alter this network of interactions 
predictably, thus explaining the negative effect that nearly all epigenetic modifications have 
on LSD1–H3 binding.  
 
Figure 30.I. Defining features of the histone peptide-binding site in LSD1. LSD1 side chains 
involved in substrate binding are indicated. Histone H3 peptide (residues 1–16 of the N-
terminal tail) and CoREST are in green and red respectively [187]. 
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3.4 LSD1 inhibitors 
 
To date, only a few types of LSD1 inhibitors were identified (Figure 31.I). Because of the 
AOD of LSD1 shares moderate sequence similarity with MAO, MAOIs such as phenelzine 
(8.I, Figure 5.I), tranylcypromine (5.I, Figure 2.I) and pargyline (57.I), were reported as 
inhibitors of LSD1, although their inhibitory potency and selectivity for LSD1 are very weak 
[169, 188]. Modifications of these three MAOIs have led to the development of potent LSD1 
inactivators. N-Propargyl lysine-containing H3 peptides have been reported to be LSD1-
selective inhibitors [183, 189]. Recently, Yang et al. cocrystallized the enzyme with a suicide 
inhibitor consisting of a 21-residue histone H3 peptide in which K4 is modified by an N-
methylpropargyl group (58.I, Ki = 107 nM [190]) [183]. The hydrazine containing H3 peptide 
(59.I, structurally derived from phenelzine) was found as a potent suicide inactivator of LSD1 
(Ki = 4.35 nM [190]).  
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Figure 31.I. Chemical structures of selected LSD1 inhibitors. 
 
Chemical substitutions on the phenyl ring of tranylcypromine (5.I, Figure 2.I) have greatly 
improved the potency and selectivity of this class of LSD1 inhibitors [120, 182, 190-191]. For 
57.I          58.I          59.I 
60.I          61.I          62.I 
63.I                         64.I 
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example, 60.I displays a Ki value of 1.3 µM on LSD1 and is selective of LSD1 compared to 
MAO-B (no inhibition at 133 µM) but displays a weak selectivity compared to MAO-A (Ki = 
1.2 µM) [120]. Compound 61.I is selective of LSD1 (Ki = 0.61 µM) compared to MAO-A (Ki 
= 110 µM) and –B (Ki = 17 µM) [182] and 62.I (IC50 = 1.9 μM with a SI of 150 and >520 
toward LSD1 compared to MAO-A and –B respectively) is more potent and selective than 
tranylcypromine (5.I, IC50 = 32 μM with a SI of 0.23 and 0.13 toward LSD1 compared to 
MAO-A and –B respectively) on LSD1 compared to MAO-A and –B [191].  
Recently, a series of bisguanidine and biguanide polyamine analogues were tested for 
inhibitory activity on LSD1 [173]. The in vitro analysis of the two most potent inhibitors (63.I 
and 64.I) exhibits non-competitive inhibition kinetics at concentrations < 2.5 µM, suggesting 
that, although the polyamine compounds could be considered analogues of the natural methyl 
lysine substrate of LSD1, they do not appear to compete with H3K4me2 at the active site. 
Interestingly, these compounds proved successful in reactivating the expression of silenced 
genes associated with tumor suppression, hinting at the therapeutic potential of LSD1 
inhibition in the treatment of cancer. 
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As previously mentioned, monoamine oxidases are attractive targets for a broad range of 
treatments against pathologies including depression, anxiety disorders, Parkinson’s and 
Alzheimer’s diseases. Most current monoamine oxidase inhibitors lead to side effects by a 
lack of affinity and selectivity towards one of the isoforms. So, it remains fundamental to 
design new more potent, reversible and selective inhibitors of MAO-A and –B.  
With this aim in view, the main objective of this work was the design, synthesis and 
evaluation of potential inhibitors of MAO. Therefore, we designed new MAO-A and –B 
inhibitors derived from β-carbolines, indoles and 5H-indeno[1,2-c]pyridazin-5-ones following 
a classical strategy including experimental (synthesis and biological evaluation) and 
theoretical (molecular modeling) approaches (Scheme 1.II). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1.II. Schematic depiction of the strategy used for this work. 
* Available in the department of pharmacy  
 
The -carboline template displays a reversible competitive inhibition and is selective of 
MAO-A. Currently, harmine (3.I, Ki hMAO-A = 5 nM, Figure 1.II) is described as the most 
potent inhibitor of this series on MAO-A [69]. Moreover, the crystal structure of hMAO-A in 
complex with harmine has been recently solved [3] and shows that nearby the methoxy group 
of harmine, a lipophilic pocket is left vacant. So, the objective was to optimize the β-carboline 
template for hMAO-A inhibition in order to study this lipophilic pocket. Thus, a series of β-
carboline derivatives (2a-5.III) mainly substituted in the 7-position with lipophilic and bulky 
groups was synthesized.  
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The 5H-indeno[1,2-c]pyridazin-5-one template displays a reversible competitive inhibition 
and is selective of MAO-B. Currently, analogues 22f.I (IC50 hMAO-B = 8.5 nM [73]) and 
22j.I (IC50 baMAO-B = 14.0 nM [74]) reported in figure 1.II, are described among the most 
potent inhibitors of this series on MAO-B. Moreover, the docking studies of 22f.I and 22j.I 
with hMAO-B reported from the literature [73, 75] suggest that these two 5H-indeno[1,2-
c]pyridazin-5-one analogues could be the starting point for the design of novel and potentially 
more potent MAO-B inhibitors. Thus, in order to design new, selective and more potent 
MAO-B inhibitors, a series of 5H-indeno[1,2-c]pyridazin-5-one derivatives substituted both 
in the 3 and 8-positions by lipophilic groups has been synthesized (22m.I, 28a-b.III and 30a-
b.III).  
Previous studies have shown that indole derivatives may be used for the design of potent anti-
MAO agents [57-62]. So, in order to identify new potential MAO-A and –B inhibitors 
including an indole core, a series of indole analogues including bulky and/or lipophilic groups 
in the 3 or 5-positions from the department of Pharmacy (Prof. Masereel, FUNDP, Belgium) 
was evaluated. 
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Figure 1.II. Chemical structures of harmine (3.I), 22f.I and 22j.I. 
 
The involvement through a same metabolic pathway for MAO-A and IDO as well as their 
similarity for serotonin like substrate and the similarity in the structural properties of MAO 
and LSD1 led us to evaluate the inhibitory potency and selectivity of the -carboline and 5H-
indeno[1,2-c]pyridazine-5-one inhibitors of MAO against IDO and LSD1 (Scheme 2.II). 
Furthermore, the -carboline scaffold is also present in IDO inhibitor 3-butyl--carboline 
(46.I, Ki = 3.3 µM, Scheme 1.II). So, starting from a same strategy than the one used on MAO 
(Scheme 1.II), we are also interested in design of new 3-substituted--carboline analogues 
directly derived from 3-butyl--carboline (46.I) and potentially more active on IDO. These 
derivatives display an amino group in the 3-position which should allow to establish 
supplementary interactions (coulomb interactions) with 7-propionate of the heme in the 
pocket B of IDO which are missing with 3-butyl-β-carboline.  
 
 
  3.I           22f.I             22j.I 
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Scheme 2.II. Pathways of Trp metabolism. Of the dietary Trp that is not used in protein 
synthesis, 99% is metabolized along the kynurenine pathway (bold arrow). Alternative 
pathway is the conversion of Trp to serotonin (serotonergic pathway, dotted arrow) [127]. 
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1. MAO 
 
As mentioned in the introduction, the -carboline template displays a reversible competitive 
inhibition and is selective of MAO-A. Currently, harmine (3.I, Table 1.III) with a Ki value of 
5 nM on hMAO-A is described as the most potent inhibitor of this series on MAO-A [69]. 
Moreover, the crystal structure of hMAO-A in complex with harmine has been recently 
solved [3]. So, we considered harmine as the starting point for the design of novel and more 
potent MAO-A inhibitors.  
 
 
1.1 Structure-based rational design 
 
In the cocrystal structure (2Z5X.pdb), harmine is located in the active center cavity of MAO-
A. It interacts with Tyr69, Asn181, Phe208, Val210, Gln215, Cys323, Ile325, Ile335, Leu337, 
Phe352, Tyr407, Tyr444, and FAD (Figure 1.III) [3].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.III. Binding mode of harmine in the cocrystal structure (2Z5X.pdb). Only amino 
acids directly implicated in the active site are displayed and labeled in cyan. Harmine is in 
green. FAD is in yellow. The water molecules are displayed as red spheres. The hydrogen 
bonds discussed in the text are depicted as dashed blue lines. 
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Seven water molecules occupy the space between the inhibitor and these groups. Both 
nitrogen atoms of harmine establish also hydrogen bonds (depicted as dashed blue lines in 
figure 1.III) with two water molecules. Furthermore, the pyridine moiety is stabilized by the 
aromatic cage (Tyr407, Tyr444 and FAD) by π-π interaction. The amide group of the Gln215 
side chain interacts tightly with harmine by a π-π interaction. Moreover, nearby the methoxy 
group of harmine, a lipophilic pocket formed by Val93, Leu97, Phe108, Ala111, Phe208, 
Cys323 and Ile325 is left vacant. 
So, the objective was to optimize the β-carboline template for hMAO-A inhibition in order to 
study this lipophilic pocket. Thus, a series of β-carboline derivatives (2a-5.III) was 
synthesized and is reported in table 1.III. Previous works by our group carried out on 5H-
indeno[1,2-c]pyridazin-5-ones (Figure 2.III) as MAO-B inhibitors have shown it is possible to 
increase the inhibitory potency in this series by substituting the heterocycle core in the 8-
position by lipophilic and bulky side chains like benzyloxy (22i.I, IC50 rMAO-B = 170 nM) 
and trifluorobutyloxy (22j.I, IC50 baMAO-B = 14 nM) compared to a methoxy side chain 
(22k.I, IC50 rMAO-B >1 µM) which are stabilized in the lipophilic entrance cavity of MAO-
B [74-75]. Therefore, by structural analogy with 5H-indeno[1,2-c]pyridazin-5-ones, a series 
of β-carboline derivatives (2a-l.III) substituted in the 7-position with lipophilic and bulky 
groups including benzyloxy (2g.III) and trifluorobutyloxy (2e.III) groups, was synthesized. 
Three compounds including more hydrophilic groups such as dimethylaminoethyl, 
dimethylaminopropyl and ethylmorpholine (2m-o.III) were also synthesized to increase the 
solubility of compounds by keeping the ability to establish hydrophobic interactions into the 
active site. Compounds 3-5.III were synthesized to study the impact of benzyl group in the 2, 
7 and 9-positions on inhibition compared to mono-benzylated 2g.III. Their human 
monoamine oxidase A and B inhibitory potency was investigated. The IC50 values of the most 
potent compounds were evaluated and Ki values were estimated using Cheng-Prusoff equation 
[192]. 
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Figure 2.III. Chemical structures of 5H-indeno[1,2-c]pyridazin-5-one derivatives (22i-k.I). 
 
22i.I                                               22j.I      22k.I 
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Table 1.III. Envisioned pharmacomodulations around -carboline scaffold. Chemical 
structures of harmine (3.I) and synthesized β-carboline analogues (2a-5.III) tested on hMAO-
A and –B.  
 
N
N
O
R3
R2
R1
 
 
 
Compound R1 R2 R3 Yield 
(%)
 
XRD Solubility in phosphate 
buffer, pH 7.4 at RT 
(µM) 
Mp (°C)
 
harmine / H CH3 / / 328 262.0 
2a.III / H CH2CH=CH2 75 * / 173.9 
2b.III / H CH2CH(CH3)2 87 /
 
150 202.9
 
2c.III / H (CH2)2OCH3 70 / / 175.8 
2d.III / H (CH2)2OH 58 * / 264.4 
2e.III / H (CH2)3CF3 72 * < 3  284.3
 
2f.III / H CH2C6H11 85 * < 3  231.8 
2g.III / H CH2C6H5 70 * 5 212.3
 
2h.III / H (CH2)2C6H5 72 / 21 139.7
 
2i.III / H CH2-2’-pyridyl 90 / / 187.5 
2j.III / H CH2-3’-pyridyl 91 * 37 226.6 
2k.III / H CH2-4’-pyridyl 62 / 71 232.5 
2l.III / H CH2-2’-naphthyl 82 * / 238.6
 
2m.III / H (CH2)2N(CH3)2 44 * / 218.3 
2n.III / H (CH2)3N(CH3)2 52 / / 179.5 
2o.III / H (CH2)2-morpholine 38 * >500  
 
174.3 
3.III CH2C6H5 H CH2C6H5 31 * / 257.3 
4.III / CH2C6H5 CH2C6H5 84 * / 155.7 
5.III CH2C6H5 CH2C6H5 CH2C6H5 36 * / 261.8 
 
 
 
influence of substitution introduction of 
various substituents 
influence of substitution 
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1.2 Synthesis of -carboline analogues 
 
Compounds 2a-o.III were synthesized following an original two steps procedure including 
the demethylation of harmine (3.I) to the corresponding harmol (1.III) followed by a re-
alkylation of harmol (1.III) to the corresponding β-carboline derivative (Scheme 1.III). The 
key intermediate, harmol (1.III), was generated by cleavage of the methyl ether present in 
harmine (3.I) with hydrobromic acid in quantitative (100%) yield. Finally, compounds 2a-
o.III were obtained by O-alkylation of harmol (1.III) in the presence of cesium carbonate 
with the corresponding alkyl halide in 38-92% yield [193]. Compound 3.III was synthesized 
by N-benzylation of 2g.III with benzyl bromide in 31% yield (Scheme 1.III). Compound 4.III 
was prepared by O,N-benzylation of harmol (1.III) in the presence of potassium hydroxide 
with benzyl bromide in 84% yield (Scheme 1.III). Compound 4.III was then N-benzylated 
with benzyl bromide to afford compound 5.III in 36% yield (Scheme 1.III). X-ray diffraction 
was used to unambiguously establish the position of the benzyl groups in the β-carboline 
template. ORTEP views of the conformations of 2g.III and 3-5.III, with their atomic 
numbering scheme are depicted in figure 3.III.  
The structure of the synthesized compounds was determined by 
1
H NMR, 
13
C NMR, mass 
spectrometry (MS) and their purity was assessed by elemental analyses and HPLC. The data 
are reported in the chapter Materials and Methods. 
 
N
N
H
HO N
N
H
O
RN
N
H
O
HBr, HAc, reflux 
overnight
HBr. 2H2O
N
N
H
O N
N
H
O
N
N
O N
N
O
BnBr (10.0 eq.), THF, 48h
 reflux
KOH (3.2 eq.), BnBr (2.1 eq.) 
DMF, 4h, r. t.
Br
Br
Ph Ph
Ph
Ph
PhN
N
H
HO
HBr. 2H2O
Ph
Ph
PhBnBr (10.3 eq.), THF, 48h
reflux
Cs2CO3, RX, DMF
r. t./ heat
Yield = 38-92%
Yield = 31%
Yield = 84% Yield = 36%
Yield = 100%
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Figure 3.III. ORTEP diagram (50% probability) of compounds 2g.III and 3-5.III.  
 
4.III 
5.III 
2g.III 
3.III 
68 
 
1.3 Biological evaluation 
 
Now that compounds are synthesized, our objective is to evaluate the human monoamine 
oxidase A and B inhibitory potency of β-carboline derivatives to establish structure-activity 
relationships for both activity and selectivity of compounds on the two isoforms of MAO. 
Hence, the ability to measure MAO activity and the effects of test compounds on that activity 
is critical for selecting specific MAOIs. Current methods for assaying MAO activity have 
several disadvantages [194]. Direct methods that use HPLC and/or radiochemical detection 
are common but are generally expensive and time-consuming. Methods that monitor changes 
in absorbance can be rapid and simple but are not very sensitive. Fluorescent assays, although 
both simple and sensitive, often are confounded by the spectroscopic interference of test 
compounds [194]. In addition, any indirect methods that monitor the formation of H2O2 [195-
196] are not specific for MAO and can be misleading because a variety of enzymes and 
cellular processes can change the concentration of H2O2. To overcome these limitations, we 
have adapted a high-throughput screening assay (MAO-Glo™ assay) from Promega 
Corporation that couples the activity of MAO to the production of light by luciferase in a 
convenient two-step format (Figure 4.III) [194]. This bioluminescent assay is a simple, 
homogeneous, and robust method for the sensitive and rapid measurement of MAO activity 
and the effects of test compounds on that activity. The MAO-A and –B enzymes used in this 
study were purchased from Sigma-Aldrich (Cat.# M7316 and M7441 respectively) in the 
form of microsomal protein prepared from insect cells infected with recombinant baculovirus 
containing cDNA inserts for the human MAO genes. The recombinant MAO enzymes were 
provided under microsomes at a protein concentration of 5 mg.mL
-1
.  
To evaluate our test compounds, the first step was the optimization of the MAO-Glo™ assay 
parameters in our conditions. After the optimization of parameters, we have validated the 
activity test on hMAO-A and –B using competitive inhibitors, harmine (3.I, Table 1.III, Ki = 5 
nM [69]) and isatin (4.I, Figure 2.I, Ki = 3 µM [17]) respectively which are commercially 
available from Sigma-Aldrich.  
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1.3.1 Inhibition study of MAO-A and –B 
 
a) Description of MAO-Glo™ assay (Promega) [194] 
 
The MAO-Glo™ assay is performed in two steps (Figure 4.III): 
 
Step 1. The MAO reaction: the MAO enzyme is incubated with a luminogenic MAO 
substrate. The substrate of the MAO-Glo™ assay is a derivative of beetle luciferin ((4S)-4,5-
dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid). The MAO enzyme oxidizes 
the amine to an imine (reaction 1), which is subsequently hydrolyzed by water to the 
corresponding aldehyde (reaction 2). The aldehyde then spontaneously undergoes a β-
elimination reaction to generate methyl ester luciferin (reaction 3). Since the latter two 
reactions are not rate limiting, the amount of methyl ester luciferin produced is proportional to 
the activity of MAO. 
 
Step 2. The luciferin detection: after the MAO reaction has been performed, the 
reconstituted luciferin detection reagent (LDR) inactivates MAO and provides both the 
enzymes and cosubstrates necessary to convert the product of step 1 into a luminescent signal. 
As shown in figure 4.III (reactions 4–5), an esterase converts the methyl ester luciferin into 
luciferin, which is subsequently consumed by luciferase to yield oxyluciferin and light. This 
addition initiates a stable glow-type luminescent signal with a half-life greater than 5 h. The 
amount of light produced is directly proportional to the activity of MAO. 
 
 
Figure 4.III. Description of MAO-Glo™ assay [194]. 
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The activity on the MAO-A and –B isoforms can be estimated using this test. However, 
MAO-A and –B are affected differently by environmental conditions (Promega). So, while 
the DMSO in a final concentration from 0.5 to 25% decreases the activity of MAO-A, it 
increases that of MAO-B (Figure 5.III) (Promega). 
 
Figure 5.III. The effect of DMSO concentration on MAO activity (Promega). 
 
The temperature also has a much greater effect on the MAO-B reaction compared to the 
MAO-A reaction (Figure 6.III) (Promega). A decrease of the temperature from 35°C to 25°C 
decreases in a more important way the activity of MAO-B than that of MAO-A (Promega). 
 
Figure 6.III. The effect of temperature on MAO activity; dashed line: T = 25°C and 
continuous line: T = 35°C (Promega). 
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b) Optimization of MAO-Glo™ assay 
 
Parameters to be optimized 
 
- Inhibitor concentration and percentage of DMSO: as the most of our test compounds 
display a relatively weak solubility, the addition of DMSO was required to solubilize them in 
the enzymatic test. An arbitrary concentration of 50 µM was fixed for a first screening of 
compounds on both isoforms of MAO. So, the DMSO concentration was optimized to use 
only a minimum of DMSO in the enzymatic tests. 
 
- Contact time between the enzyme and the inhibitor: we have fixed a contact time 
between the enzyme and the inhibitor of 2.5 min. As a result of the fact that our test 
compounds have to act more probably by a competitive binding assay compared to harmine 
(3.I, Table 1.III), this contact time displays no impact on their inhibitory potency. 
 
- Reaction time: the reaction time for the first step of MAO-Glo™ assay (Figure 4.III: 
reactions 1-3) was fixed at 1 h (t1 = 1h) in agreement with the available data in the technical 
bulletin of the MAO-Glo™ assay (Promega). The optimal reaction time for the second step 
(Figure 4.III: reactions 4-5) was determined by a kinetic measure of the luminescent signal 
appearance. This reaction time corresponds to the necessary time to have a stable luminescent 
signal.  
 
- Reaction temperature: we have fixed a temperature of 37°C to maximize the luminescent 
signal. 
 
- Intensity of the luminescent signal: to quantify the inhibitory potency of our test 
compounds on MAO-A and –B, it is required to measure a luminescent signal of sufficient 
intensity for the enzymatic reaction without test compound (100% initial activity). Thus, an 
intensity of 10 RLU (relative luminescence unit) was fixed like minimun intensity to be 
reached without test compound. 
 
- Enzyme concentration: to study the selectivity of our test compounds, we have decided to 
work with the same "quantity" of MAO-A and –B expressed in specific activity (activity unit 
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by mg of proteins) such as specified by the supplier. 1 enzymatic unit is defined as the 
quantity of enzyme which deaminates 1 nanomol of kynuramine per minute in pH 7.4 at 37 
°C. Human MAO-A (M7316) and –B (M7441) display a specific enzymatic activity of 75 
U.mg
-1
 and 34 U.mg
-1
, respectively.  
 
- Substrate concentration: we have decided to work with a substrate concentration equal to 
the Michaelis constant (Km) for both isoforms of MAO to be in experimental conditions where 
the Michaelis-Menten kinetics are respected. So, the evaluation of Km was performed for both 
isoforms of MAO. 
 
Evaluation of the minimun DMSO concentration  
 
An arbitrary concentration of 50 µM was fixed for a first screening of test compounds on both 
isoforms of MAO. Thus, a solubility test was performed on β-carboline and 5H-indeno[1,2-
c]pyridazine-5-one derivatives displaying a high hydrophobicity. This solubility test was 
performed in the same proportions that the enzymatic assay (discussed in the section 
―Optimized parameters and protocol”): 12.5 µL of test compound (200 µM) in a final volume 
of 50 µL (12.5 µl of test compound + 25.0 µl of enzyme + 12.5 µL of substrate). In solubility 
test, the enzyme and substrate were substituted by the buffer of reaction (100 mM Hepes pH 
7.5 and 5% glycerol). To solubilize all test compounds, a stock solution of test compound 
(200µM) in a mixture buffer/DMSO (1:1) was required. Thus, a final DMSO percentage of 
12.5% is brought in the enzymatic assay by the test compound. This percentage of DMSO 
introduced by the test compound was fixed for all the enzymatic assays. It is also to note that 
the substrate is also dissolved in DMSO and so, introduces an additional percentage of DMSO 
in the enzymatic assay dependent on the substrate concentration. 
 
Evaluation of the optimal MAO-A and –B concentration   
 
To quantify the inhibitory potency of our test compounds, an evaluation of the optimal MAO-
A and –B concentration was required to measure a luminescent signal of sufficient intensity 
for the enzymatic reaction without test compound (100% initial activity). So, we have varied 
the MAO-A and –B concentration from 0.3 to 0.7 U.mg-1 and fixed a substrate concentration 
of 100 µM for MAO-A and 20 µM for MAO-B. These substrate concentrations were selected 
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to be in large excess compared to the enzyme (non-limiting substrate concentrations; enzyme 
working at Vmax) on the basis of the Michaelis-Menten curves supplied in the technical 
bulletin of the MAO-Glo™ assay (Promega). 
First, the kinetic evolution of the luminescent signal at various enzyme concentrations 
depicted in figure 7.III (MAO-A; top, MAO-B; bottom), allows to optimize the reaction time 
of the second step (Figure 4.III, reactions 4-5). Indeed, we observe that a time of 20 min is 
required to have a stable luminescent signal. Thus, the reaction time of the second step was 
fixed at 20 min (t2 = 20 min) for all assays. It is to note that the luminescent signal has been 
systematically checked before the addition of LDR required to the second step of the 
enzymatic assay (Figure 4.III). This one was nearly zero excluding a luminescent side effect 
of the step 1 (Figure 4.III). 
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Figure 7.III. Kinetic evolution of the luminescent signal at various hMAO-A (top) and –B 
(bottom) concentrations.
 
Results are expressed as mean ± SD (n = 2).  
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We also note that the luminescent signal varies linearly with the enzyme concentration 
(Figure 8.III, MAO-A; blue, MAO-B; red). Furthermore, for an unchanged enzyme 
concentration, the signal obtained is the same for both isoforms. In conclusion, to quantify the 
inhibitory potency of our test compounds and to have an unchanged specific activity for both 
enzymes, we have decided to work with a specific activity fixed at 0.5 U.mg
-1
 for inhibition 
assays (559 nM/U, determined from the specific activity and the molecular weight of the 
protein sequences (59682 g.mol
-1
 for MAO-A (expasy: P21397) and 58763 g.mol
-1
 for MAO-
B (expasy: P27338))).  
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Figure 8.III. Effect of enzyme concentration on the luminescent signal (t2 = 20 min). Results 
are expressed as mean ± SD (n = 2). 
 
Evaluation of the optimal substrate concentration  
 
As mentioned above, we have decided to work with a substrate concentration equal to the 
Michaelis constant (Km) for both isoforms of hMAO. So, the evaluation of Km was performed 
for the two isoforms of MAO (Figure 9.III). We have fixed the enzyme concentration at 0.5 
U.mg
-1
 (evaluated previously) for the two isoforms and we have varied the substrate 
concentration from 0 to 250 µM for MAO-A and from 0 to 60 µM for MAO-B by keeping an 
unchanged percentage of DMSO (6.25% for the substrate and 12.5% for the test compound).  
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Figure 9.III. Michaelis-Menten curves of hMAO-A (top) and -B (bottom). Results are 
expressed as mean ± SD (n = 2).  
 
The table 2.III reports the kinetic parameters measured for the two enzymes. Km values of 
116.1 µM and 14.6 µM were measured for hMAO-A and –B, respectively. Thus, we observe 
that the substrate displays a better affinity for MAO-B than for MAO-A (8-fold). By 
comparison, the Km values evaluated in the technical bulletin of the MAO-Glo™ assay 
(Promega) for MAO-A and –B were 40 and 4 µM (10-fold), respectively. These close data 
tend to validate our experimental approach. In conclusion, for inhibition assays, we have fixed 
the substrate concentration at 120 and 15 µM for hMAO-A and –B, respectively.  
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Table 2.III. Kinetic parameters of hMAO-A and –B. 
 
Kinetic parameters
a 
hMAO-A hMAO-B 
   
Vmax (RLU) 27.2 (20.8 – 33.6) 44.0 (40.9 – 47.1) 
Km (µM) 116.1 (56.8 – 175.3) 14.6 (12.1 – 17.1) 
R
2
 0.9568 0.9905 
 
a 
Results are expressed as mean with 95% confidence intervals in brackets (n=3). 
 
Optimized parameters and protocol  
 
The MAO-Glo™ assay is performed in 96-wells plates at 37°C (Table 3.III).  
 
1) Recombinant MAO enzyme (25.0 µL, final concentration of 0.5 U.mg-1) is first 
incubated with the test compound (12.5 µL, final concentration of 50 µM (12.5% of 
DMSO)) or with a mixture buffer (100 mM Hepes pH 7.5 and 5% glycerol)/DMSO 
(1:1) (12.5 µL, final DMSO percentage of 12.5%) for 2.5 min.  
2) Then, the substrate (12.5 µL, final concentration of 120 µM (final DMSO percentage 
of 3.0%) and 15 µM (final DMSO percentage of 0.4%) for MAO-A and –B, 
respectively) is added to the mixture.  
3) Finally, after 1 h of reaction, 50.0 µL of LDR is added to the wells.  
4) The luminescent signal is measured 20 min after the addition of the LDR with a 96-
wells luminometer Fluoroskan FL (Thermo Fisher Scientific).  
 
Now that the parameters of MAO-Glo™ assay are optimized for our assays, the next step is 
the validation of the inhibition assay on hMAO-A and –B using known competitive inhibitors, 
harmine (Ki = 5 nM [69]) and isatin (Ki = 3 µM [17]), respectively.  
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Table 3.III. Optimized MAO-Glo™ assay protocol. 
 
Components (µL) 100% Initial activity Inhibition assay 
 
Buffer/DMSO (1: 1) 
 
12.5 
 
/ 
Test compound / 12.5 
Enzyme (hMAO-A or –B) 
(1.0 U.mg
-1
) 
25.0 25.0 
Substrate (480 µM (hMAO-
A); 60 µM (hMAO-B)) 
12.5 12.5 
LDR 50.0 50.0 
Final volume 100.0 100.0 
 
 
1.3.2 Inhibition constant (Ki) evaluation of harmine on MAO-A and –B 
 
The Ki evaluation of harmine (3.I, Table 1.III) is required to validate the inhibition assay on 
hMAO-A but also to position our test compounds structurally derived from harmine 
compared to the latter. Furthermore, to date, no data concerning the hMAO-B inhibitory 
potency of harmine is available. First, IC50 values of harmine on hMAO-A and –B were 
evaluated using the optimized MAO-Glo™ assay and we have varied harmine concentration 
from 10
-3
 to 10
-9
 M. Inhibition percentages at each concentration were calculated as follows: I 
(%) = 100 x {1 – (luminescent signal with harmine/luminescent signal without harmine)}. 
The inhibition percentages were plotted against the logarithms of harmine molar 
concentrations. The IC50 values were calculated from normalized sigmoidal dose-response 
non-linear regression curves using the GraphPad Prism 5.01 software. Then, Ki values were 
estimated from the IC50 values using the Cheng–Prusoff equation depicted below [192].  
 
Ki = IC50/(1 + [S]/Km) 
 
Dose-response curves and the inhibition parameters of harmine (3.I) on hMAO-A and –B are 
depicted in figure 10.III and table 4.III. 
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Figure 10.III. Dose-response curves of harmine (3.I) on hMAO-A (●) and –B (▲). Results 
are expressed as mean ± SD (n = 3). 
  
Table 4.III. Inhibition parameters of harmine (3.I) on hMAO-A and –B. 
 
Inhibition parameters
a 
hMAO-A hMAO-B 
   
IC50  34.4 (27.8 – 42.7) nM  244.9 (192.3 – 312.0) µM 
Ki  16.9 (13.7 – 21.0) nM  120.8 (94.9 – 153.9) µM 
R
2
 0.9882  0.9886  
 
a
 Results are expressed as mean with 95% confidence intervals in brackets (n=3). 
 
As expected, harmine (3.I) is a strong and selective hMAO-A inhibitor (Ki = 16.9 nM) 
whereas it poorly inhibits hMAO-B (Ki = 120.8 µM). This selectivity of harmine for the 
MAO-A isoenzyme can be explained with the superimposition of the crystal structures of 
hMAO-A in complex with harmine (2Z5X.pdb [3]) and hMAO-B (2V5Z.pdb [4]) (Figure 
11.III). The relative geometry of the harmine molecule in hMAO-A could not be 
accommodated into hMAO-B because of steric overlap with Tyr326 of hMAO-B [3]. Indeed, 
the Tyr326 side chain in hMAO-B produces a restriction that is less pronounced in hMAO-A 
where Ile335 occupies that position. Thus, Ile335 in hMAO-A and Tyr326 in hMAO-B play a 
crucial role in inhibitor selectivity in agreement with previous results [2]. Furthermore, the 
evaluated Ki value of harmine (3.I) on hMAO-A is in agreement with the literature [69] which 
allows to validate our inhibition assay on hMAO-A.  
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Figure 11.III. Superimposition of the crystal structures of hMAO-A (cyan, 2Z5X.pdb [3]) in 
complex with harmine and hMAO-B (green, 2V5Z.pdb [4]). Harmine and FAD are in green 
and yellow, respectively. Only amino acids directly implicated in the active site are displayed 
and labeled in cyan (MAO-A) and in green (MAO-B).  
 
 
1.3.3 Ki evaluation of isatin on MAO-B 
 
Isatin (4.I) was used to validate the inhibition assay on hMAO-B. IC50 and Ki values of isatin 
on hMAO-B were evaluated using the same approach than for harmine (3.I). Dose-response 
curve and the inhibition parameters of isatin on hMAO-B are depicted in figure 12.III and 
table 5.III. Isatin displays a Ki value of 32.6 µM on hMAO-B, which confirms its weak 
affinity for MAO-B. Although the evaluated Ki is 10-fold higher than the literature value (Ki = 
3 µM [17]) and potentially underestimates the inhibitory potency on MAO-B, we have 
decided to validate the inhibition assay on hMAO-B. Consequently, the inhibitory potency of 
new β-carboline analogues can be assessed on hMAO-A and –B. 
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Figure 12.III. Dose-response curve of isatin (4.I) on hMAO-B. Results are expressed as 
mean ± SD (n = 3).  
 
Table 5.III. Inhibition parameters of isatin (4.I) on hMAO-B. 
 
Inhibition parameters
a 
hMAO-B 
  
IC50  66.0 (57.0 – 76.4) µM 
Ki  32.6 (28.1 – 37.7) µM 
R
2
 0.9925 
 
a
 Results are expressed as mean with 95% confidence intervals in brackets (n = 3). 
 
 
1.3.4 Inhibitory potency of β-carboline analogues  
 
The inhibitory potency of the newly synthesized -carbolines was assessed in vitro using the 
inhibition assay previously validated on hMAO-A and –B. First, the IC50 values of the most 
potent were evaluated on hMAO-A and –B. Then, the Ki values were estimated from the IC50 
values using the Cheng–Prusoff equation [192]. The inhibitory potency of harmine (3.I) and 
the synthesized related -carbolines (2a-5.III) on hMAO-A and –B are reported in table 6.III.  
All the tested compounds (2a-3.III) except the derivatives 4.III and 5.III, present a higher 
inhibitory potency on MAO-A than MAO-B. O-Alkylation of the compounds by lipophilic 
groups like aliphatic chains (2a.III, 2b.III, 2e.III), cyclohexyl (2f.III) and phenyl (2g.III, 
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2h.III) allows to significantly increase inhibition of MAO-A compared to harmine (3.I). N-
Benzylations (3-5.III) of compound 2g.III abolish inhibition of MAO-A compared to 2g.III. 
Extension of the methoxy group by a methoxyethoxy group (2c.III) decreases the inhibition. 
The substitution of methoxy group of compound 2c.III by a hydroxyl group (2d.III) does not 
improve the inhibition. Substitution by a pyridyl group (2i-k.III) decreases the inhibition 
compared to harmine (3.I) and compound 2g.III. The substitution of a phenyl group (2g.III) 
by a naphthyl group (2l.III) decreases the inhibition. Introduction of more hydrophilic groups 
like dimethylaminoethyl, dimethylaminopropyl and ethylmorpholine (2m-o.III) highly 
decreases the inhibition. Compound 2e.III, with the trifluorobutyloxy group, is the most 
active and selective within this series, with a Ki on MAO-A of 3.6 nM (Figure 13.III). The 
solubility of some β-carbolines in phosphate buffer (pH 7.4) at room temperature reported in 
table 1.III, was evaluated following a protocol developed by our group [197]. We observe that 
the introduction of more lipophilic groups decreases the solubility compared to harmine. 
Interestingly, although the compound 2o.III (Ki = 255.7 nM) containing an ethylmorpholine 
group is less active compared to 2e.III, it is a potent and selective inhibitor of MAO-A, and 
displays also a higher solubility compared to 2e.III. Compound 2o.III is totally soluble for 
concentrations higher than 500 µM compared to 2e.III (<3 µM). Moreover, several 
compounds (2b.III, 2e.III, 2g.III, 2h.III, 3-5.III) show a better inhibition of MAO-B (Ki 
>500 nM) compared to harmine (3.I, Ki = 120.8 µM). Interestingly, compound 2f.III 
displayed the best inhibitory activity on MAO-B with a Ki value of 221.6 nM (Figure 13.III). 
This cyclohexyl bearing analogue is also a potent MAO-A inhibitor with a Ki value of 4.3 nM.  
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Figure 13.III. Dose-response curve of harmine (3.I) on hMAO-A (●) and –B (▲), of 
compound 2e.III on hMAO-A (■) and of compound 2f.III on hMAO-B (▼). Inhibition 
percentages are shown as mean ± SD with n = 3. 
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Table 6.III. Structure and inhibitory potency of harmine (3.I) and the synthesized related -
carbolines (2a-5.III) on hMAO-A and –B. 
 
 
N
N
O
R3
R2
R1
 
 
 
Ki (nM)
a
 
Compound R1 R2 R3 hMAO-A
 
hMAO-B
 
harmine / H CH3 16.9 (13.7 – 21.0) 120800 (94900 – 
153900) 
2a.III / H CH2CH=CH2 5.0 (4.5 – 5.6) NI
b
 
2b.III / H CH2CH(CH3)2 3.9 (2.0 – 7.7) >500
c 
2c.III / H (CH2)2OCH3 29.5 (24.0 – 36.3) NI  
2d.III / H (CH2)2OH 28.4 (20.0 – 40.3) NI  
2e.III / H (CH2)3CF3 3.6 (2.6 – 5.0) >500
 
2f.III / H CH2C6H11 4.3 (3.2 – 5.6) 221.6 (145.1 – 338.3) 
2g.III / H CH2C6H5 12.6 (11.6 – 13.7) >500
 
2h.III / H (CH2)2C6H5 5.0 (4.0 – 6.2) >500
 
2i.III / H CH2-2’-pyridyl ≈ 500 NI  
2j.III / H CH2-3’-pyridyl 24.9 (20.1 – 30.7) NI  
2k.III / H CH2-4’-pyridyl 35.4 (18.9 – 66.5) NI  
2l.III / H CH2-2’-naphthyl 100 < Ki < 500  NI
 
2m.III / H (CH2)2N(CH3)2 1023.8 (920.0 – 1139.4) NI  
2n.III / H (CH2)3N(CH3)2 684.0 (558.6 – 836.9) NI  
2o.III / H (CH2)2-morpholine 255.7 (196.7 – 324.5)  NI  
3.III CH2C6H5 H CH2C6H5 ≈ 500 >500 
4.III / CH2C6H5 CH2C6H5 NI >500 
5.III CH2C6H5 CH2C6H5 CH2C6H5 NI >500 
a 
Results are expressed as mean with 95% confidence intervals in brackets (n = 3).  
b 
NI : no inhibition at 1 µM.  
c 
>500: Inhibition percentage at 1 µM are shown as mean with ± SD in brackets (n = 3), 2b.III = 14% (±6%), 
2e.III = 24% (±4%), 2g.III = 42% (±2%), 2h.III = 39% (±2%), 3.III = 34% (±3%), 4.III = 46% (±2%), 5.III = 
29% (±5%). 
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With the aim of rationalizing the inhibitory potencies obtained for -carbolines on hMAO-A 
and –B, molecular docking studies of compounds 2e.III and 2f.III were performed and are 
discussed in the next section.  
 
 
1.4 Structural approach 
 
1.4.1 X-ray crystal analysis  
 
With the aim of trying to understand the types of interactions that the compounds 2e.III and 
2f.III can establish within the binding site of MAO-A and –B, the molecular structure of these 
compounds was determined by X-ray crystallographic analysis. ORTEP diagram and 
crystalline cohesion pattern of compounds 2e.III and 2f.III are depicted in figure 14.III. 
 
a) Compound 2e.III 
Single crystals of compound 2e.III were obtained by slow evaporation at room temperature of 
a solution in dichloromethane/ethanol. The compound crystallizes in the trigonal,  space 
group (R1 = 0.0617). The planar aromatic β-carboline ring is prolonged by the lateral 
trifluorobutyloxy chain that adopts a anti, anti, gauche, anti conformation [torsion angles are 
C6-C7-O15-C16 = -176.6(2)°, C7-O15-C16-C17 = 176.6(2)°, O15-C16-C17-C18 = 66.5(3)°, 
C16-C17-C18-C19 = -174.2(3)°]. The C7-O15-C16 bond angle 117.3(2)° is indicative of a 
sp
2 
character of the oxygen underlining electronic delocalization from the β-carboline ring to 
the alkoxy chain. Crystal packing results from antiparallel arrangement of molecules. The 
crystalline cohesion is further maintained by hydrogen bonds formed between N9-H…N2 
(2.054 Å), weak CH-π(C(sp2)) hydrogen bonds (in the range of 2.8 Å) and weak C-H…F 
hydrogen bonds (in the range of 2.6 Å).  
 
b) Compound 2f.III 
Single crystals of compound 2f.III were obtained by slow evaporation at room temperature of 
a solution in dichloromethane/ethanol. The compound crystallizes in the trigonal,  space 
group (R1 = 0.0642). The C7-O15-C16 bond angle 118.6(6)° is indicative of a sp
2 
character of 
the oxygen underlining electronic delocalization from the β-carboline ring to the cyclohexyl 
chain. Crystal packing results from antiparallel arrangement of molecules. The crystalline 
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cohesion is further maintained by hydrogen bonds formed between N9-H…N2 (2.076 Å), 
weak CH-π(C(sp2)) hydrogen bonds (in the range of 2.8 Å) and weak hydrogen bonds 
between the methylene groups of cyclohexyl chains (in the range of 2.3 Å).  
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
 
Figure 14.III. ORTEP diagram (50% probability) and crystalline cohesion pattern of 
compounds 2e.III (a) and 2f.III (b).  
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1.4.2 Validation of docking studies on MAO-A and –B 
 
Before to study the binding mode of -carboline derivatives on hMAO-A and –B, it is 
required to validate the docking procedures. Thus, X-ray crystallography structures of hMAO-
A and –B in complex with harmine (3.I, 2Z5X.pdb [3]) and safinamide (1.I, 2V5Z.pdb [4]) 
respectively, were used as case studies. The selection of these structures was guided by the 
quality of the crystallographic data and the fact that safinamide (1.I) in 2V5Z X-ray 
crystallography is a non-covalent ligand crossing the entire binding site of MAO-B. As a 
consequence, the side chain of key residue Ile199 is oriented such as the entrance and 
substrate cavities are merged. This structural prerogative is essential to model the binding of 
β-carboline derivatives that must be accommodated by both cavities. Seven water molecules 
which occupy the space between harmine and FAD were conserved from X-ray 
crystallography (2Z5X.pdb) into the MAO-A model (Figure 15.III, left). In the MAO-B 
model, three conserved water molecules are buried in the vicinity of FAD and proved to be 
important for docking simulation of MAO-B selective ligand [73]. So these water molecules 
are kept inside the binding site as an integral part of the protein structure during the whole 
computational procedure (Figure 15.III, right).  
 
 
Figure 15.III. Superimposition of, (left) the crystal structure of hMAO-A (2Z5X.pdb) in 
complex with harmine (3.I, cyan) and the top docking solution of harmine in hMAO-A model 
(magenta), and (right) the crystal structure of hMAO-B (2V5Z.pdb) in complex with 
safinamide (1.I, cyan) and the top docking solution of safinamide in hMAO-B model 
(magenta). The water molecules are displayed as red spheres. 
FAD FAD 
Ile199 
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The structures of ligands are built and geometry optimised at physiological pH within 
Discovery studio
®
 2.5 software (Accelrys Software Inc., San Diego, USA). The interaction 
sphere in the docking was centered on the N5 atom of the flavin (FAD) in the catalytic site of 
the protein (MAO-A and –B) and delimited by a 20 Å radius. A total of twenty-five docking 
solutions were generated using GOLD (version 3.2) software and the scoring function used to 
rank the docking was Goldscore. All docking solutions obtained for harmine (3.I) and 
safinamide (1.I) displayed a similar binding mode compared to the crystal structures of 
complexes with hMAO-A and –B (2Z5X.pdb and 2V5Z.pdb) respectively (Figure 15.III). The 
RMSD calculated between the crystal structure and the top solution coordinates for ligand 
heavy atoms is 0.39 Å and 0.46 Å for harmine (3.I) and safinamide (1.I) on hMAO-A and –B 
respectively.  
 
 
1.4.3 Molecular docking studies of compound 2e.III on MAO-A 
 
Analysis of the optimal binding mode for compound 2e.III (Figure 16.III)—identified from 
the docking study— revealed that this compound is located in the vicinity of the FAD 
cofactor. The -carboline derivative incorporates in the active site with harmine-like 
interactions. In comparison with the harmine interactions, the hydrogen bonds with two water 
molecules are conserved. The π-π interaction between the amide group of the Gln215 side 
chain and harmine is also conserved. The binding mode adopted by compound 2e.III allows 
the trifluorobutyloxy side chain to settle within a cavity lined with hydrophobic amino acid 
residues. This hydrophobic pocket includes Val93, Leu97, Phe108, Ala111, Phe208, Val210, 
Cys323 and Ile325. All docking solutions show a similar binding mode but the trifluorobutyl 
chain is flexible and adopts several conformations. Among these conformations, we selected 
the anti, anti, gauche, anti conformation which also corresponds to the geometry observed in 
the crystal structure. These data may explain the increase of MAO-A inhibitory potency of 
compound 2e.III (Ki = 3.6 nM) compared to harmine (3.I, Ki = 16.9 nM). Furthermore, the 
hydrophobic aspect of the cavity around the lateral chain may also explain the increase of 
inhibition for the compounds with lateral chains displaying lipophilic groups like cyclohexyl 
(2f.III) or aliphatic chains (2a.III, 2b.III, 2e.III). The presence of aromatic amino acids in 
this cavity also allows to favour π-π interactions with phenyl groups (2g.III, 2h.III). The fact 
that the cavity is highly hydrophobic may be one plausible explanation for the decrease in 
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inhibition seen with hydrophilic groups (2m-o.III) compared to harmine (3.I). Finally, the 
inhibition decrease of compounds (3-5.III) substituted in the 2 and 9-positions by benzyl 
groups compared to 2g.III is probably due to the loss of hydrogen bonds with water 
molecules and the lack of space available for the substituents. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16.III. Binding mode of compound 2e.III in the active site of hMAO-A (2Z5X.pdb). 
Only amino acids directly implicated in the active site are displayed and labeled in cyan. 
Compound 2e.III and FAD are in green and yellow respectively. The water molecules are 
displayed as red spheres. The hydrogen bonds discussed in the text are depicted as dashed 
blue lines. 
 
 
1.4.4 Molecular docking studies of compound 2f.III on MAO-A and –B 
 
The interesting result obtained for compound 2f.III on hMAO-B led us to study the potential 
binding mode of this -carboline derivative with hMAO-A and –B. The results of docking 
simulations are represented in figure 17.III.  
Compound 2f.III in MAO-A adopts a similar binding mode compared to derivative 2e.III 
with the cyclohexyl chain pointing to the hydrophobic cavity and stabilization of the -
carboline moiety through two hydrogen bonds and π-π interaction. 
Docking simulations for compound 2f.III performed on hMAO-B show that the β-carboline 
core incorporates into the substrate cavity with a shift of the β-carboline orientation compared 
to docking solution on MAO-A because of steric clash caused by Tyr326. Compared to 
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hMAO-A, the β-carboline core is stabilized by only one hydrogen bond between one of the 
nitrogen atoms of -carboline and one water molecule. The pyridine moiety is also stabilized 
with the aromatic cage (Tyr407, Tyr444 and FAD) by π-π interaction but the interaction of the 
β-carboline with the lateral chain of Gln206 is less favorable. This may explain the better 
inhibitory activity of our compounds on hMAO-A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17.III. Binding mode of compound 2f.III in the active site of hMAO-A and –B. Only 
amino acids directly implicated in the active site are displayed and labeled in cyan (MAO-A) 
and in green (MAO-B). Compound 2f.III is in green (MAO-A) and magenta (MAO-B). FAD 
is in yellow. The water molecules involved in MAO-B are displayed as red spheres. The 
hydrogen bond discussed in the text is depicted as a dashed blue line. 
 
In the case of -carboline derivative 2f.III, the lateral chain occupies a hydrophobic pocket of 
the entrance cavity coated by Phe103, Trp119, Leu164, Leu167, Phe168, and Ile316 where it 
is stabilized in agreement with an enhanced inhibitory potency towards hMAO-B compared to 
harmine (3.I). So, docking simulations allow to explain the stabilization of the cyclohexyl 
chain in the hydrophobic pocket but also of the aliphatic groups like trifluorobutyl (2e.III) or 
isobutyl (2b.III). The presence of aromatic amino acids in the hydrophobic pocket allows to 
understand the inhibition increase for compounds including phenyl groups (2g.III and 2h.III) 
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compared to harmine (3.I). As well as with MAO-A, the fact that the cavity where the lateral 
chain incorporates is hydrophobic may be related to the absence of inhibition with hydrophilic 
groups (2m-o.III). 
 
 
1.4.5 β-Carboline analogues binding sites on MAO-A and –B 
 
Figure 18.III shows the schematic diagram of the β-carboline analogues binding sites in 
hMAO-A and –B respectively.  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18.III. Schematic diagram of the β-carboline derivatives binding sites on hMAO-A 
(top) and hMAO–B (bottom). The strongest interactions stabilizing the β-carboline core are 
represented in blue. The amino acids forming the pocket available for the lateral chain are 
labeled in cyan (MAO-A) and in green (MAO-B). Hydrogen-bond interactions are 
represented by a blue line with an arrow head directed towards the electron donor.  
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The docking studies on MAO-A and –B have revealed that -carboline derivatives are located 
in the vicinity of the FAD cofactor. In both enzymes, the -carboline core is stabilized by π-π 
interactions with the aromatic cage (Tyr407-Tyr444 in MAO-A, Tyr398-Tyr435 in MAO-B 
and FAD). In contrast to Gln215 in MAO-A, π-π interaction of the -carboline core with the 
equivalent amide group of Gln206 in MAO-B is less favorable. Furthermore, the -carboline 
core is stabilized by two hydrogen bonds with water molecules in MAO-A compared to only 
one hydrogen bond in MAO-B. So, the stabilization of the -carboline core by the π-π 
interaction with the amide group of the Gln215 and the two hydrogen bonds may explain the 
selectivity of the β-carboline derivatives towards MAO-A compared to MAO-B.  In hMAO-
A, the lateral chain occupies a hydrophobic pocket including Val93, Leu97, Phe108, Ala111, 
Phe208, Val210, Cys323 and Ile325. As previously mentioned, the active site of hMAO-A 
differs from hMAO-B in that it has a monopartite cavity with a total volume of ~550 Å
3
 [20]. 
The substrate cavity in hMAO-B has a volume of ~400 Å
3
 and that of the entrance cavity is 
~300 Å
3
. The combined volume of the two cavities when the gating Ile199 is in its open 
conformation is ~700 Å
3
. The Tyr326 side chain in MAO-B, although not directly involved in 
the partition of the two cavities, does produce a restriction that is less pronounced in hMAO-
A where Ile335 occupies that position [2]. Therefore, the MAO-A Phe208-Ile335 and MAO-
B Ile199-Tyr326 pairs appear to be major determinants in dictating the differential substrate 
and inhibitor specificities of the two enzymes. In hMAO-B, the lateral chains of studied -
carboline derivatives point to a hydrophobic pocket coated by Phe103, Trp119, Leu164, 
Leu167, Phe168, and Ile316.   
 
 
2. IDO 
 
2.1 Biological evaluation 
 
Now that the activity of -carbolines on both isoforms of MAO was evaluated, some being 
very potent and selective MAO-A inhibitors, our objective is to evaluate the inhibitory 
potency and selectivity of these derivatives on hIDO. Indeed, as mentioned in the 
introduction, some β-carbolines are known as IDO inhibitors (e.g., 3-butyl- -carboline 46.I, 
Ki = 3.3 µM). Furthermore, the similarity in substrate (serotonin) between IDO and MAO, and 
the implication of IDO and MAO in the serotonergic and kynurenine pathways lead us to 
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study the selectivity of our β-carboline derivatives on IDO. Plasmid coding for human IDO 
was obtained from Van Den Eynde’s team of the UCL university (Woluwe-Saint-Lambert, 
Belgium). The recombinant plasmid, phIDO, encodes a histidine tag at the N-terminus of 
IDO. Escherichia coli strain BL21 (DE3) (Invitrogen) was used for overexpression of IDO 
and transformed with the phIDO plasmid. The enzyme was purified by IMAC using Ni
2+
 and 
an IMAC Hitrap column (GE Healthcare). The overexpression and purification of IDO were 
performed by Jenny Pouyez and Céline Meinguet (Biological Structural Chemistry 
Laboratory, FUNDP, Belgium). 
The IDO inhibition assay was performed by a colorimetric method as described by Takikawa 
et al [198] with some modifications and was adapted by Céline Meinguet within the 
framework of her final report. 1-Methyl-L-tryptophan (L-1MT, 6.III, commercially available 
from Sigma-Aldrich, Figure 19.III), a competitive IDO inhibitor (Ki = 19 μM [146]) was used 
as reference and validation drug in IDO inhibition assay. 
  
 
2.1.1 Inhibition study of IDO 
 
a) Description of IDO assay  
 
As mentioned above, the IDO inhibition assay was performed by a colorimetric method as 
described by Takikawa et al [198] with some modifications. It is based on the conversion of 
L-Trp to N-formylkynurenine (NFK), followed by hydrolysis to produce kynurenine (Scheme 
2.III).  
 
              
 
 
 
 
 
 
 
 
 
Scheme 2.III. Description of IDO assay. pDMAB = para-dimethylaminobenzaldehyde. 
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The IDO heme is first reduced from its ferric state to ferrous state (active form of IDO) by 
adding a premix solution (ascorbic acid and methylene blue). The conversion of L-Trp to 
NFK is then initiated by the addition of substrate (L-Trp) on the enzyme. NFK is then 
hydrolysed to kynurenine by adding a solution of trichloroacetic acid (TCA). The 
measurement of IDO activity in this method relies on quantifying the amount of kynurenine 
produced in the assay through an indirect mean. It relies on absorption at λ = 490 nm of the 
imine (Schiff base) produced by the reaction of the aromatic amino group of kynurenine with 
para-dimethylaminobenzaldehyde (p-DMAB).  
 
b) Optimized parameters and protocol of IDO assay 
 
The IDO inhibition assay adapted by Céline Meinguet within the framework of her final 
report, was performed in 96-wells plates at 37°C (Table 7.III).  
 
1) Human IDO (20.0 µL, 50 µg.mL-1) is first incubated with the reaction mixture 
containing, a premix solution (100.0 µL of a solution containing ascorbic acid (20 
mM) and methylene blue (17 μM) in potassium phosphate buffer (50 mM, pH 6.5)), 
potassium phosphate buffer (60.0 µL, 50 mM, pH 6.5), and the test compound diluted 
in DMSO (10.0 µL, final DMSO percentage of 5%) or a DMSO solution (10.0 µL, 
final DMSO percentage of 5%) for 2.5 min. 
2) Then, L-Trp (10.0 µL, 2 mM) is added to the mixture.  
3) After 10 min of incubation at 37°C, the reaction is stopped by addition of 30% (w/v) 
TCA (40.0 μL).  
4) Finally, after 30 min of reaction at 37°C, 100.0 μL of reaction mixture are transferred 
to 100.0 µL of a solution of p-DMAB 2% in a 96-wells plate to form a yellow schiff 
base. So, the absorption of the Schiff base is detected at λ = 490 nm with a 96-wells 
microplate absorbance reader (Model 680 BIO-RAD).  
  
For each test compound, an enzyme control (substitution of L-Trp by potassium phosphate 
buffer (50 mM, pH 6.5)) is performed and subtracted from the measured absorbance.  
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Table 7.III Optimized IDO inhibition assay protocol. 
 
Components (µL) 100% Initial activity Inhibition assay Enzyme control 
 
Premix solution 
 
100.0 
 
100.0 
 
100.0 
buffer  60.0 60.0 70.0 
L-Trp (2 mM) 10.0 10.0 / 
DMSO  10.0 / / 
Test compound / 10.0 10.0 
IDO (50 µg.mL
-1
) 20.0 20.0 20.0 
Final volume 200.0 200.0 200.0 
 
 
Validation of the inhibition assay on hIDO was performed using L-1MT (6.III, Ki = 19 μM 
[146]).  
 
 
2.1.2 IC50 evaluation of L-1MT on IDO 
 
The IC50 evaluation of L-1MT (6.III) was required to validate the inhibition assay on hIDO 
but also to position our compounds compared to a reference inhibitor. IC50 value of L-1MT on 
hIDO was evaluated using the optimized IDO inhibition assay. The inhibition percentages at 
each concentration were calculated as follows: I (%) = 100 x {1 – (absorbance signal with L-
1MT/absorbance signal without L-1MT)}. The inhibition percentages were plotted against the 
logarithm of L-1MT molar concentrations. The IC50 value was calculated from normalized 
sigmoidal dose-response non-linear regression curves using the GraphPad Prism 5.01 
software.  
Dose-response curve and the inhibition parameters of L-1MT on hIDO are depicted in figure 
19.III and table 8.III. 
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Figure 19.III. Dose-response curve of L-1MT (6.III) on hIDO. Results are expressed as mean 
± SD (n = 3). 
 
Table 8.III. Inhibition parameters of L-1MT (6.III) on hIDO. 
 
Inhibition parameters
a 
hIDO 
  
IC50  79.3 (68.8 – 91.4) µM  
R
2
 0.9940  
 
a
 Result is expressed as mean with 95% confidence intervals in brackets (n = 3). 
 
As expected, L-1MT is a weak hIDO inhibitor (IC50 = 79.3 µM) in agreement with the 
literature (Ki = 19 μM [146]) which allows to validate the IDO inhibition assay.  
 
 
2.1.3 Inhibitory potency of β-carboline analogues  
        
The inhibitory potency of harmine (3.I) and the synthesized -carbolines (2a-5.III) was 
assessed in vitro at 25 µM in triplicate using the inhibition assay previously validated on 
hIDO. L-1MT was used as reference inhibitor (58% of inhibition at 100 µM). Results revealed 
that test compounds display no inhibition on hIDO at this concentration. The data of β-
carboline derivatives both on hIDO, hMAO-A and –B are reported in table 9.III and show 
unambiguous that synthesized β-carbolines (2a-5.III) are selective of MAO and especially of 
MAO-A. 
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Table 9.III. Structure and inhibitory potency of harmine (3.I) and the synthesized related -
carbolines (2a-5.III) on hMAO-A, hMAO-B and hIDO. 
 
 
N
N
O
R3
R2
R1
 
 
 
Ki (nM)
a
 
 
Inhibition 
percentage 
Compound R1 R2 R3 hMAO-A
 
hMAO-B
 
hIDO 
at 25 µM 
harmine / H CH3 16.9 (13.7 – 21.0) 120800 (94900 
– 153900) 
NI
d 
2a.III / H CH2CH=CH2 5.0 (4.5 – 5.6) NI
b
 NI 
2b.III / H CH2CH(CH3)2 3.9 (2.0 – 7.7) >500
c 
NI 
2c.III / H (CH2)2OCH3 29.5 (24.0 – 36.3) NI  NI 
2d.III / H (CH2)2OH 28.4 (20.0 – 40.3) NI  NI 
2e.III / H (CH2)3CF3 3.6 (2.6 – 5.0) >500
 
NI 
2f.III / H CH2C6H11 4.3 (3.2 – 5.6) 221.6 (145.1 – 
338.3) 
NI 
2g.III / H CH2C6H5 12.6 (11.6 – 13.7) >500
 
NI 
2h.III / H (CH2)2C6H5 5.0 (4.0 – 6.2) >500
 
NI 
2i.III / H CH2-2’-pyridyl ≈ 500 NI  NI 
2j.III / H CH2-3’-pyridyl 24.9 (20.1 – 30.7) NI  NI 
2k.III / H CH2-4’-pyridyl 35.4 (18.9 – 66.5) NI  NI 
2l.III / H CH2-2’-naphthyl 100 < Ki < 500  NI
 
NI 
2m.III / H (CH2)2N(CH3)2 1023.8 (920.0 – 
1139.4) 
NI  NI 
2n.III / H (CH2)3N(CH3)2 684.0 (558.6 – 
836.9) 
NI  NI 
2o.III / H (CH2)2-morpholine 255.7 (196.7 – 
324.5)  
NI  NI 
3.III CH2C6H5 H CH2C6H5 ≈ 500 >500 NI 
4.III / CH2C6H5 CH2C6H5 NI >500 NI 
5.III CH2C6H5 CH2C6H5 CH2C6H5 NI >500 NI 
a 
Results are expressed as mean with 95% confidence intervals in brackets (n = 3).  
b 
NI: no inhibition at 1 µM.  
c 
>500: Inhibition percentage at 1µM are shown as mean with ± SD in brackets (n = 3), 2b.III = 14% (±6%), 
2e.III = 24% (±4%), 2g.III = 42% (±2%), 2h.III = 39% (±2%), 3.III = 34% (±3%), 4.III = 46% (±2%), 5.III = 
29% (±5%).  
d 
NI: no inhibition at 25 µM. 
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With the aim of rationalizing the results obtained with the β-carboline derivatives (3.I and 2a-
5.III) evaluated on hIDO, we are interested in binding mode described of two known IDO 
inhibitors, belonging to β-carboline series (norharman (7.III) and 3-butyl-β-carboline (46.I), 
Figure 20.III) which is discussed in the next section [126].  
 
                      
N
H
N
N
H
N
 
 
Figure 20.III. Chemical structures of norharman (7.III) and 3-butyl- -carboline (46.I). 
 
 
2.2 Molecular modeling 
 
2.2.1 Validation of docking studies on IDO 
 
Before to study the binding mode of norharman (7.III) and 3-butyl-β-carboline (46.I) on 
hIDO, it is required to validate the docking procedure. Thus, 4-phenylimidazole (PIM)-bound 
X-ray structure (2D0T.pdb, chain A) was used as a scaffold, because it has a higher resolution 
and provides a larger binding site than the cyanide-bound structure (2D0U.pdb) [144]. In 
addition to PIM (37.I), there are two molecules of CHES bound at the entrance of the binding 
site. Since they are likely to interfere with the binding modes of ligands other than PIM, they 
were removed for docking studies [126]. The structure of ligand is built and geometry 
optimised at physiological pH within Discovery studio
®
 2.5 software (Accelrys Software Inc., 
San Diego, USA). The interaction sphere in the docking was centered on the heme in the 
catalytic site of IDO and delimited by a 7 Å radius. A total of twenty-five docking solutions 
were generated using GOLD (version 3.2) software and the scoring function used to rank the 
docking was Goldscore. All docking solutions obtained for PIM displayed a similar binding 
mode compared to the crystal structure of hIDO in complex with the PIM (2D0T.pdb). Figure 
21.III depicts the superimposition of the crystal structure of hIDO (2D0T.pdb [144]) in 
complex with the PIM and docking solution of PIM in hIDO model. The RMSD calculated 
between the crystal structure and the top solution coordinates for ligand heavy atoms is 0.48 
Å for PIM on hIDO. In conclusion, the docking procedure is validated. 
7.III                                    46.I 
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Figure 21.III. Superimposition of the crystal structure of hIDO (2D0T.pdb [144]) in complex 
with the PIM (37.I, gray) and the top docking solution of PIM in hIDO model (cyan). 
 
 
2.2.2 Molecular docking studies of β-carboline analogues on IDO 
 
Molecular docking studies of norharman (7.III) and 3-butyl- -carboline (46.I) revealed a 
same binding mode for both compounds within hIDO (2D0T.pdb). Analysis of the binding 
mode for 3-butyl- -carboline (46.I) within IDO reported in figure 22.III suggests that the β-
carboline scaffold incorporates into the active site. Figure 22.III reveals two pockets (A and 
B) constituting the active site of IDO. Pocket A is located into the center of the active site 
whereas pocket B is located into the entrance of the active site in proximity of the protein 
surface. Pocket A which includes the β-carboline core displays mainly a hydrophobic 
character because of aromatic amino acids coating the active site (Tyr126, Cys129, Val130, 
Phe163, Phe164, Ser167, Leu234 and Ala264). Pocket B displays both a hydrophobic 
(Phe226, side chain of Arg231 and Ile354) and hydrophilic (Ser263 and 7-propionate of the 
heme) character. The β-carboline core is stabilized in pocket A by various interactions; the 
heme iron is complexed by pyridin nitrogen of β-carboline scaffold in the range of 2 Å as 
previously described in Cambridge structural database (CSD) between N-terminal pyrrolidine 
and porphyrin iron [199]. The indole NH of β-carboline core is also stabilized by a hydrogen 
bond with Ser167. Pocket A consisting mainly of hydrophobic residues, the β-carboline core 
is mainly stabilized by Van der Waals interactions (Tyr126, Cys129, Val130, Phe163, 
Phe164, Leu234 and Ala264). 
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Figure 22.III. Simulated binding mode of 3-butyl- -carboline (46.I) in the active site of 
hIDO (2D0T.pdb). Only amino acids directly implicated in the active site are displayed and 
labeled. Two perpendicular views are presented. 
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Figure 22.III shows also that the substitution in the 3-position of β-carboline scaffold by a 
butyl side chain allows to fit pocket B [126] lined with hydrophobic amino acid residues 
which is in agreement with literature data which display a higher inhibition on IDO with 3-
butyl-β-carboline (46.I, Ki = 3.3 µM) compared to norharman (7.III, Ki = 178 µM) [156]. 
Indeed, butyl side chain establishes Van der Waals interactions with Phe226, side chain of 
Arg231 and Ile354. 
These observations evidence that the substitution in the 7-position (2a-o.III), 2 and/or 9-
positions (3-5.III) are not tolerated. Indeed, from the conformation of 3-butyl-β-carboline 
(46.I), steric clashes can be observed between substituents in the 2, 7 and 9-positions and the 
amino acid residues of the active site. So, these substitutions lead to a new binding mode of β-
carboline scaffold which is not stabilized into the active site in agreement with weak obtained 
inhibition percentages. Furthermore, we observe that the presence of a methyl group in the 1-
position of synthesized β-carbolines prevents the complexation between the pyridin nitrogen 
and the heme iron.  
Figure 23.III shows the lipophilic potential of pocket B calculated by Sybyl 8.1 software 
(Tripos International, Missouri, USA). The hydrophilic moiety comes mainly from 7-
propionate of the heme (1) whereas the hydrophobic moiety comes from apolar residues 
(Phe226, side chain of Arg231 and Ile354) (2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23.III. Hydrophobic and lipophilic potential of pocket B. Colour scale is provided 
on the left. 
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2.3 Structure-based rational design of 3-substituted- -carboline analogues 
 
Recently, Rohrig et al investigated the modes of binding of all known IDO inhibitors. On the 
basis of the observed docked conformations, they developed a pharmacophore model which 
concluded that a good ligand should contain some or all of the following features [126]; 
 
- An aromatic fragment, at least bicyclic, to fill pocket A in the binding site 
- An atom with a free electron pair that can coordinate to the heme iron, such as oxygen, 
nitrogen, or sulfur 
- A group that can form van der Waals interactions with pocket B 
- Groups that can hydrogen bond to Ser167, Gly262, Ala264, and Arg231 (possibly a 
negatively charged group that can form a salt bridge) or to the heme 7-propionate 
(possibly a positively charged group that can form a salt bridge) 
 
From results of synthesized β-carbolines (2a-5.III), docking studies of 3-butyl-β-carboline 
(46.I) and the pharmacophore model on IDO, we are interested in the synthesis of new 3-
substituted-β-carbolines potentially more potent compared to 3-butyl-β-carboline (46.I) 
(Scheme 3.III). Indeed, it can be interesting to add an amino group and/or a carboxylate group 
in the 3-position which should allow to establish supplementary interactions with 7-
propionate of the heme and Arg231 in the pocket B respectively which are missing with 3-
butyl-β-carboline. In this study, we are focused on the synthesis of two new compounds 
containing an amino group; N-ethyl-3-methylamino-β-carboline (8.III) and 3-methylamino-β-
carboline (9.III).  
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3.III. Chemical structures of 3-substituted-β-carbolines proposed; N-ethyl-3-
methylamino-β-carboline (8.III) and 3-methylamino-β-carboline (9.III). 
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These two derivatives should incorporate in the active site with 3-butyl-β-carboline-like 
interactions but display also a positive charge at physiological pH which should allow to 
establish a coulomb interaction with 7-propionate of the heme in agreement with molecular 
docking studies reported in figure 24.III. Furthermore, besides adding a coulomb interaction 
between 7-propionate of the heme and amino group, compound 8.III should allow to establish 
Van der Waals interactions with the hydrophobic residues coating the pocket B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24.III. Simulated binding mode of N-ethyl-3-methylamino-β-carboline (8.III, top) 
and 3-methylamino-β-carboline (9.III, bottom) in the active site of hIDO (2D0T.pdb). Only 
amino acids directly implicated in the active site are displayed and labeled. 
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The next section reports the synthesis of compounds 8.III and 9.III as well as the first steps 
leading to 3-butyl-β-carboline (reference inhibitor, 46.I). This synthesis was performed in the 
frame of a graduate thesis (Sylvain Arcidiacono, Paul Lambin institute, Belgium). 
 
 
2.4 Synthesis of 3-substituted- -carboline analogues 
 
The strategy used to synthesize the 3-substituted- -carboline derivatives (8-9.III and 46.I) is 
depicted in scheme 4.III. The synthetic pathway of three compounds follows two-four steps 
procedures from the common ethyl β-carboline-3-carboxylate (10.III) intermediate 
(commercially available from Sigma-Aldrich). 
 
N
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N
N
H
N
N
H
N
N
H
N
N
H
NH2O
O
2 steps 4 steps
3-4 steps
 
 
Scheme 4.III. Synthetic pathway to 3-substituted- -carboline analogues 8-9.III and 46.I. 
 
 
2.4.1 Synthesis of N-ethyl-3-methylamino-β-carboline (8.III) 
 
The synthetic pathway to amino derivative 8.III follows a two steps procedure from the ethyl 
β-carboline-3-carboxylate (10.III) intermediate (Scheme 5.III). This intermediate 10.III is 
successively transformed in N-ethyl-3-carboxamide-β-carboline (11.III) intermediate and 
finally in the corresponding secondary amine 8.III. 
 
8.III                                            10.III       9.III                                 
46.I 
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Scheme 5.III. Synthetic pathway to N-ethyl-3-methylamino-β-carboline (8.III). 
 
The synthesis of amide 11.III was previously reported in the literature in one step from the 
methyl β-carboline-3-carboxylate (12.III) intermediate [200] (Scheme 6.III). The intermediate 
12.III was reacted with ethylamine (used as solvent and reagent) to produce the amide 11.III 
in 45% yield.   
 
N
H
N
O
O
N
H
N
N
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O
EtNH2
     r.t., 18 h
Yield = 45%  
 
 
Scheme 6.III. Synthesis of N-ethyl-3-carboxamide-β-carboline (11.III) reported from the 
literature [200].   
 
So, the synthesis of amide 11.III was performed following scheme 6.III with some 
modifications (temperature and time of reaction). After optimization, ethyl β-carboline-3-
carboxylate (10.III) was reacted with ethylamine in methanol for 72 h at reflux to give 
quantitatively the N-ethyl-3-carboxamide-β-carboline (11.III) (Scheme 5.III). The secondary 
amine 8.III was then obtained by reduction of amide 11.III with LiAlH4 in THF overnight at 
room temperature [201]. After purification by semi-preparative HPLC, N-ethyl-3-
methylamino-β-carboline (8.III) was obtained in modest 22% yield. 
 
 
2.4.2 Synthesis of 3-methylamino-β-carboline (9.III) 
 
The synthetic pathway to amino derivative 9.III follows a four steps procedure from the ethyl 
β-carboline-3-carboxylate (10.III) intermediate (Scheme 7.III). This carboxylate intermediate 
10.III is first reduced in alcohol 13.III. Alcohol group is then transformed in a good leaving 
group such a chloride or a triflate group (14.III and 15.III, respectively) which are substituted 
  10.III                                                                     11.III                                                              8.III 
 12.III                                                      11.III 
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by SN2 to form the azide derivative 16.III. Finally, compound 16.III is reduced by a 
Staudinger reaction in the corresponding primary amine 9.III. 
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N
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N
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O
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N
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X = Cl
N
H
N
N
H
N
NH2
PPh3 (1.0 eq.), H2O
THF, r.t., overnight
X = OTf
Yield = 52%
Yield = 24%Yield = 38%  
 
Scheme 7.III. Synthetic pathway to 3-methylamino-β-carboline (9.III). 
 
The reduction of carboxylate derivative 10.III in alcohol 13.III was already described in the 
literature [202]. This reduction is described in using NaBH4 as reducing agent for 12 h in 81% 
yield. However, we observe that the conversion in corresponding alcohol is very low. So, we 
have substituted the NaBH4 for LiAlH4 which is a classical reducing agent for reduction of 
ester in corresponding alcohol. Ethyl β-carboline-3-carboxylate (10.III) was then reacted with 
LiAlH4 in THF for 24 h at room temperature to give the 3-hydroxymethyl-β-carboline (13.III) 
in 52% yield. The transformation of alcohol in azide group was performed in two steps. The 
first step is the formation of a good leaving group. Primary alcohol 13.III was first 
transformed in primary chloride (14.III) using thionyl chloride (used as solvent and reagent). 
This reaction is described for 1 h at reflux [202]. However, we observe the formation of a 
second product containing a same retention factor (Rf) compared to derivative 14.III. The 
second product was not identified but might come from indole NH group which is known to 
react with thionyl chloride. Furthermore, the reaction of solution containing the derivative 
14.III with sodium azide in DMF at 100°C for 1 h gave the compound 16.III and a by-
product containing a same retention factor compared to derivative 16.III. Finally, Staudinger 
reaction gave also two products with a same retention factor including compound 9.III which 
could be purified by HPLC.  
Consequently, an alternative approach was the substitution of thionyl chloride by 
trifluoromethanesulfonic anhydride. So, alcohol derivative 13.III was reacted with 
   10.III                                                 13.III 
   9.III                                                         16.III 
14.III 
15.III 
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trifluoromethanesulfonic anhydride in pyridine for 3 h at room temperature to give the 3-
(trifluoromethanesulfonate)methyl-β-carboline (15.III). Only product 15.III is formed and 
directly reacted with sodium azide in DMF at 100°C for 1 h to obtain the azide product 16.III 
in 24% yield. Furthermore, no by-product is formed and the product can be used without 
further purification for the last step. Finally, the primary amino derivative 9.III is formed 
from azide derivative 16.III by a Staudinger reaction. This reaction is performed using 
triphenylphosphine and water in THF at room temperature overnight. After an acid-base 
extraction, 3-methylamino-β-carboline (9.III) was obtained in 38% yield. 
 
 
2.4.3 Synthesis of 3-butyl-β-carboline (46.I) 
 
The synthesis of 3-butyl-β-carboline (46.I) was previously reported in the literature in two 
steps from the intermediate 10.III (Scheme 8.III) [203]. First, carboxylate derivative 10.III is 
transformed using n-propyllithium (Grignard reaction) in corresponding propyl ketone 17.III. 
Finally, compound 46.I is synthesized by Wolff-Kishner reduction of propyl ketone 17.III. 
However, this synthetic pathway was not retained because of the difficulty to synthesize n-
propyllithium.  
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N
O O
THF, r.t., 3 h
TMSCl (8.1 eq.), n-PrLi (3.8 eq.)
N
H
N
HO(CH2)2OH, Reflux, 20 h
(NH2)2.H2O, NaOH
Yield = 42% Yield = 33%
Scheme 8.III. Synthetic pathway to 3-butyl-β-carboline (46.I) reported from the literature 
[203]. 
 
So, the synthetic pathway depicted in scheme 9.III was adopted. This synthetic pathway 
follows a four steps procedure from the ethyl β-carboline-3-carboxylate (10.III) [204]. First, 
carboxylate derivative 10.III is reduced using DIBAL-H in corresponding aldehyde 18.III. 
Grignard reaction is then performed using n-propylmagnesium bromide to obtain 3-(butan-1-
ol)-β-carboline (19.III). This one can be transformed in 3-(but-1-enyl)-β-carboline (20.III) by 
elimination of alcohol group. Finally, the reduction of 20.III by hydrogenation gives the 
compound 46.I. Furthermore, this synthetic pathway leads to the formation of 3-(butan-1-ol)-
β-carboline (19.III) intermediate which could be a potential IDO inhibitor. Indeed, this 
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intermediate displays both an alcohol group and a propyl side chain which might interact with 
pocket B establishing interactions with 7-propionate of the heme and hydrophobic residues, 
respectively.  
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Scheme 9.III. Modified synthetic pathway to 3-butyl-β-carboline (46.I). 
 
Here, we show the first results of this synthetic pathway (Scheme 10.III). Carboxylate 
derivative 10.III was reduced with DIBAL-H in dichloromethane for 45 min at -50°C to give 
the 3-carbaldehyde-β-carboline (18.III) in almost quantitative (93%) yield. A first assay of 
Grignard reaction using n-propylmagnesium bromide and aldehyde 18.III evidenced the 
formation of 3-(butan-1-ol)-β-carboline (19.III). However, this result was not reproduced 
because of the stability and availability of Grignard reagent.  
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O
CH2Cl2, -50°C, 45 min
THF, r.t., 18 h
PrMgBr
Yield = 93%  
 
Scheme 10.III. Synthetic pathway to 3-(butan-1-ol)-β-carboline (19.III). 
 
So, an optimization of Grignard reaction was required (Scheme 11.III). n-Propylmagnesium 
bromide was first synthesized in situ from 1-bromopropane and magnesium for 30 min at 
room temperature. Then, Grignard reaction using n-propylmagnesium bromide and 
benzaldehyde (21.III) as model reagent was performed. The addition of n-propylmagnesium 
bromide to a solution of benzaldehyde (21.III) for 3 h at room temperature gave the 1-
phenylbutan-1-ol (22.III) in 65% yield. Consequently, the Grignard reaction will be adapted 
for the synthesis of 3-(butan-1-ol)-β-carboline (19.III).   
 
10.III                   18.III        19.III                 20.III    46.I 
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Yield = 65%
Br Mg (1.0 eq.)
Et2O, r.t., 30 min
MgBr
O
H
PrMgBr (1.3 eq.)
Et2O, r.t., 3 h
OH
 
 
Scheme 11.III. Synthesis of n-propylmagnesium bromide and 1-phenylbutan-1-ol (22.III). 
 
The structure of the synthesized compounds (8-9.III) was determined by 
1
H NMR, 
13
C NMR 
and mass spectrometry (MS). The purity of compound 9.III must be yet confirmed by 
elemental analyses. The data are reported in the chapter Materials and Methods. 
 
 
2.4.4 Perspectives 
 
Several synthetic pathways are possible to synthesize the 3-butyl- -carboline (46.I) (Scheme 
12.III). Among these pathways, we propose; 
 
- Elimination of alcohol group from 3-(butan-1-ol)-β-carboline (19.III) using 
trifluoromethanesulfonic anhydride and a base such pyridine should give 3-(but-1-
enyl)-β-carboline (20.III) [205]. This one could be reduced by hydrogenation using 
palladium on activated charcoal as catalyst to form 3-butyl- -carboline (46.I) (Scheme 
12a.III) [206].  
- An alternative method is the Barton-McCombie reaction (Scheme 12b.III) [207]. The 
alcohol derivative 19.III is first converted to the thiocarbonyl derivative 23.III, and is 
then treated with Bu3SnH which reacts following a radicalar reaction to give 3-butyl-
-carboline derivative (46.I).  
- Wittig olefination of 3-carbaldehyde-β-carboline (18.III) could also be performed to 
give 3-(but-1-enyl)-β-carboline (20.III) which reduces by hydrogenation to give 3-
butyl- -carboline derivatve (46.I) (Scheme 12c.III) [204].  
 
 
21.III    22.III 
108 
 
N
H
N
r.t.
HO
Tf2O, Pyr.
N
H
N
H2, Pd/C
N
H
N
THF, r.t.
 
a)  
N
H
N
HO
N
H
N
O
S
S
N
H
N +
O
S
S
Bu3Sn
Bu3Sn-H, PhMe
AIBN,
NaH, THF, CS2
MeI, r.t.
 
b) 
N
H
N
H2, Pd/C
N
H
N
H
n-Buli, THF, reflux
N
H
N
O
PrPPh3Br
THF, r.t.
 
c) 
 
Scheme 12.III. Synthetic pathway (a-c) to 3-butyl-β-carboline (46.I).   
 
 
2.5 Preliminary biological evaluation 
 
The IDO inhibitory potency of the norharman (7.III) and N-ethyl-3-methylamino-β-carboline 
(8.III) was assessed in vitro in triplicate at 100 µM by Céline Meinguet using the colorimetric 
test previously validated on hIDO. The inhibition percentage obtained for norharman (7.III, 
43% (±4%)) is in agreement with literature data which display a weak inhibition on IDO (Ki = 
178 µM) [156]. Surprisingly, the results also reveal that the N-ethyl-3-methylamino-β-
carboline (8.III) displays no inhibition on IDO at this concentration. Although it was 
impossible to test the compound 9.III due to a lack of availability of this latter, the absence of 
inhibition observed for 8.III tends to show that the introduction of a positive charge is not 
tolerated. The result of compound 8.III must be yet confirmed again but this inactivity may be 
explained by a more hydrophobic character of the pocket B (Figure 23.III). So, from the result 
of compound 8.III and the pharmacophore model developed on IDO by Rohrig et al [126], it 
can be interesting to explore the possibility to synthesize of new 3-substituted-β-carbolines 
with a negatively charged group such as a carboxylate that can form a salt bridge with Arg231 
(Scheme 3.III).  
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3. LSD1 
 
3.1 Biological evaluation 
 
Besides the selectivity study of -carbolines (2a-5.III) on hIDO compared to MAO-A and –
B, we are also interested in the inhibitory potency of these compounds on hLSD1. Indeed, as 
mentioned in the introduction, the similarity in the catalytic and structural properties of MAO 
and LSD1 leads us to study the selectivity of -carbolines, inhibitors of monoamine oxydases 
as potential LSD1 inhibitors. Then, to evaluate the affinity of synthesized -carboline 
derivatives on LSD1, we have adapted a fluorometric screening assay (LSD1 inhibitor 
screening assay, Cat.# 700120) from Cayman Corporation with some modifications. 
Tranylcypromine (5.I, Figure 2.I, Cat.# 10010494, Cayman), an irreversible inhibitor of 
LSD1 which displays an IC50 value of 22 µM (Cayman), was used like reference and 
validation drug of LSD1 inhibition assay. 
 
 
3.1.1 Inhibition study of LSD1  
 
a) Description of LSD1 inhibitor screening assay (Cayman)  
 
The LSD1 inhibitor screening assay kit (Cayman) provides a convenient fluorescence-based 
method for screening LSD1-specific inhibitors. The assay is based on the multistep enzymatic 
reaction in which LSD1 first produces H2O2 during the demethylation of lysine 4 on a peptide 
corresponding to the first 21 amino acids of the N-terminal tail of histone H3 (Figure 25.III). 
In the presence of horseradish peroxidase (HRP), H2O2 reacts with ADHP (10-acetyl-3,7-
dihydroxyphenoxazine) to produce the highly fluorescent compound resorufin. Resorufin 
fluorescence can be analyzed with an excitation wavelength of 530-540 nm and an emission 
wavelength of 585-595 nm. A LSD1 inhibitor screening assay kit provides just the quantities 
required for a 96-wells plate. Thus, we are mainly interested in the activity study of our -
carboline derivatives (2a-5.III) on LSD1 compared to tranylcypromine (5.I). Before to 
evaluate the inhibitory potency of -carbolines, the study of some parameters was required 
such as the emission spectrum of -carbolines, the fluorescent signal of background and the 
intensity of the fluorescent signal (100% initial activity). 
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Figure 25.III. Description of LSD1 inhibitor screening assay (Cayman). HRP = horseradish 
peroxidase and ADHP = 10-acetyl-3,7-dihydroxyphenoxazine. 
 
b) Protocol of LSD1 inhibitor screening assay (Cayman) 
 
Analyzed parameters 
 
- The emission spectrum of -carbolines: to quantify the inhibitory potency of -carbolines, 
it is required to know if these compounds emit a fluorescent signal at an excitation 
wavelength of 535 nm. So, harmine (3.I, Table 1.III) was used as reference of this series.  
 
- The fluorescent signal of background: to study the fluorescent signal induced by the 
substrate and the enzyme on the 100% initial activity. The highest signal will be subtracted 
from 100% initial activity.   
 
- Intensity of the fluorescent signal: to quantify the inhibitory potency of our test 
compounds on LSD1, it is required to measure a fluorescent signal of sufficient intensity for 
the enzymatic reaction without test compound (100% initial activity). Thus, tranylcypromine 
(5.I) was used as reference inhibitor. It has been shown that this compound displays an IC50 of 
22 µM in the conditions of the LSD1 inhibitor screening assay. 
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Emission spectrum of harmine   
 
In the LSD1 inhibitor screening assay, the measurement of LSD1 activity is quantified by the 
amount of resorufin produced which is detected by fluorescence (λex 535 nm; λem 595 nm). 
Before to quantify the inhibitory potency of the -carbolines, it is required to know if these 
compounds emit a fluorescent signal (λex 535 nm) around 595 nm. Thus, the emission 
spectrum of harmine (3.I) in the range 500–700 nm (λex 535 nm, Figure 26.III) was 
performed.  
 
Figure 26.III. Emission spectrum of harmine (3.I; λex 535 nm). 
 
Emission spectrum of harmine (3.I) depicted in figure 26.III shows that harmine does not emit 
fluorescent signal at 595 nm. 
 
Fluorescent signal of background (substrate and enzyme controls) 
 
In the LSD1 inhibitor screening assay, a final percentage of 12.5% in DMSO introduced by 
the inhibitor was conserved compared to MAO-Glo™ assay. We have studied the fluorescent 
signal induced by the substrate and the enzyme on the 100% initial activity (Figure 27.III). 
The highest signal was the enzyme control and thus, will be subtracted from 100% initial 
activity for all experiments.   
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Figure 27.III. Kinetic evolution of the fluorescent signal, from 100% initial activity (■) and 
background (substrate (●) and enzyme (▲) controls) in LSD1 inhibitor screening assay. 
Results are expressed as mean ± SD (n = 2). 
 
Intensity of the fluorescent signal  
 
Our objective is to quantify the inhibitory potency of our test compounds on hLSD1. So, it is 
required to measure a fluorescent signal of sufficient intensity for the enzymatic reaction 
without test compound (100% initial activity). Tranylcypromine (5.I) was then used as 
reference inhibitor and was reported with an IC50 of 22 µM in the conditions of LSD1 
inhibitor screening assay kit (Cayman). The inhibition percentage of tranylcypromine was 
evaluated on LSD1 at 25 µM (47% (±7%), Figure 28.III) and is in agreement with IC50 value 
reported in the LSD1 inhibitor screening assay. In conclusion, the intensity of fluorescent 
signal is sufficient to quantify the inhibition of our compounds on LSD1, and we thus validate 
the LSD1 inhibitor screening assay for the study of -carbolines. 
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Figure 28.III. Evolution of the fluorescent signal in presence of tranylcypromine inhibitor 
(5.I, 25 µM) in hLSD1 inhibitor screening assay.
 
Results are expressed as mean ± SD (n = 2). 
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Parameters and protocol  
 
The LSD1 inhibition assay from Cayman Corporation was performed in 96-wells plates at 
37°C (Table 10.III).  
 
1) Human LSD1 (20.0 µL) was first incubated with the reaction mixture containing a 
buffer solution (105.0 µL; 50 mM Hepes, pH 7.5), a solution of HRP (20.0 µL), a 
solution of ADHP (10.0 µL) and the test compound dissolved in DMSO (25.0 µL, 
final DMSO percentage of 12.5%) or a DMSO solution (25.0 µL, final DMSO 
percentage of 12.5%) for 2.5 min. 
2) Then, the substrate (peptide; 20.0 µL, 1mM) was added to the mixture.  
3) The fluorescent signal of resorufin was measured during 30 min at 37°C with a 96-
wells Beckman Coulter DTX 880 Multimode Detector (λex 535 nm; λem 595 nm). 
 
Moreover, for each experiment, an enzyme control (substitution of substrate (peptide) by a 
buffer solution (50 mM Hepes, pH 7.5)) is performed and subtracted from the measured 
fluorescence of 100% initial activity.  
 
Table 10.III. LSD1 inhibitor screening assay protocol. 
 
Components (µL) 100% Initial activity Inhibition assay Enzyme control 
 
Buffer  
 
105.0 
 
105.0 
 
125.0 
HRP 20.0 20.0 20.0 
ADHP 10.0 10.0 10.0 
DMSO  25.0 / 25.0 
Test compound  / 25.0 / 
hLSD1 20.0 20.0 20.0 
Substrate (peptide)     
(1 mM) 
20.0 20.0 / 
Final volume 200.0 200.0 200.0 
  
The next step is the evaluation of inhibitory potency of β-carboline analogues on hLSD1. 
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3.1.2 Inhibitory potency of β-carboline analogues  
 
The inhibitory potency of harmine (3.I) and the synthesized -carbolines (2a-5.III) was 
assessed in vitro at 25 µM except compounds 3-5.III (at 50 µM) using the LSD1 inhibitor 
screening assay kit (Cayman). Tranylcypromine (5.I) was used as reference inhibitor (47% of 
inhibition at 25 µM). The data of β-carbolines both on hLSD1, hMAO-A and –B, and hIDO 
are reported in table 11.III. Results reveal that synthesized β-carbolines (2a-5.III) are weak 
inhibitors of LSD1. They are selective of MAO and especially of MAO-A. Inhibition 
percentages show high standard deviations on hLSD1. Nevertheless, interesting trends can be 
observed from these results. First, harmine (3.I) displays no inhibition at 25 µM and 50 µM 
on LSD1. The introduction of lipophilic and bulky groups like aliphatic (2c.III), cyclohexyl 
(2f.III), phenyl (2g.III, 2h.III and 3.III) and naphthyl (2l.III) groups allows to increase the 
inhibitory potency of -carboline scaffold on hLSD1 compared to harmine (3.I). Furthermore, 
these compounds display an inhibitory potency in the same range as tranylcypromine under 
the same test conditions. The introduction of more hydrophilic groups like 
dimethylaminoethyl and ethylmorpholine (2m.III and 2o.III) abolishes the inhibition. 
Finally, the N-benzylation of compound 2g.III in the 2-position (3.III) displays an inhibitory 
potency in the same range as 2g.III whereas the N-benzylation of 2g.III and 3.III in the 9-
position (4.III and 5.III, respectively) decreases their inhibitory potency.  
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Table 11.III. Structure and inhibitory potency of harmine (3.I) and the synthesized related -
carbolines (2a-5.III) on hMAO-A, hMAO-B, hIDO and hLSD1. 
 
 
N
N
O
R3
R2
R1
 
 
 
Ki (nM)
a
 
 
Inhibition 
percentage
d
 
Compound R1 R2 R3 hMAO-A
 
hMAO-B
 
hIDO 
 
hLSD1
 
harmine / H CH3 16.9 (13.7 – 21.0) 120800 (94900 
– 153900) 
NI
b 
NI
b 
2a.III / H CH2CH=CH2 5.0 (4.5 – 5.6) NI
b
 NI NDe 
2b.III / H CH2CH(CH3)2 3.9 (2.0 – 7.7) >500
c 
NI 37% (±10%) 
2c.III / H (CH2)2OCH3 29.5 (24.0 – 36.3) NI  NI 60% (±2%) 
2d.III / H (CH2)2OH 28.4 (20.0 – 40.3) NI  NI 42% (±21%) 
2e.III / H (CH2)3CF3 3.6 (2.6 – 5.0) >500
 
NI 35% (±17%) 
2f.III / H CH2C6H11 4.3 (3.2 – 5.6) 221.6 (145.1 – 
338.3) 
NI 74% (±18%) 
2g.III / H CH2C6H5 12.6 (11.6 – 13.7) >500
 
NI 58% (±45%) 
2h.III / H (CH2)2C6H5 5.0 (4.0 – 6.2) >500
 
NI 61% (±19%) 
2i.III / H CH2-2’-pyridyl ≈ 500 NI  NI 39% (±16%) 
2j.III / H CH2-3’-pyridyl 24.9 (20.1 – 30.7) NI  NI 19% (±27%) 
2k.III / H CH2-4’-pyridyl 35.4 (18.9 – 66.5) NI  NI 22% (±11%) 
2l.III / H CH2-2’-naphthyl 100 < Ki < 500  NI
 
NI 73% (±4%) 
2m.III / H (CH2)2N(CH3)2 1023.8 (920.0 – 
1139.4) 
NI  NI 6% (±11%) 
2n.III / H (CH2)3N(CH3)2 684.0 (558.6 – 
836.9) 
NI  NI ND 
2o.III / H (CH2)2-morpholine 255.7 (196.7 – 
324.5)  
NI  NI NI 
3.III CH2C6H5 H CH2C6H5 ≈ 500 >500 NI 79% (±10%)
f  
4.III / CH2C6H5 CH2C6H5 NI >500 NI 44% (±2%)
f
  
  
5.III CH2C6H5 CH2C6H5 CH2C6H5 NI >500 NI 19% (±8%)
f
   
 
a 
Results are expressed as mean with 95% confidence intervals in brackets (n = 3).  
b 
NI: no inhibition at 1 µM and 25 µM on MAO-A/MAO-B and IDO/LSD1, respectively.  
c 
>500: Inhibition percentage at 1µM are shown as mean with ± SD in brackets (n = 3). 2b.III = 14% (±6%), 
2e.III = 24% (±4%), 2g.III = 42% (±2%), 2h.III = 39% (±2%), 3.III = 34% (±3%), 4.III = 46% (±2%), 5.III = 
29% (±5%).  
d
 Inhibition percentages at 25 µM are expressed as mean with ± SD in brackets (n = 3). 
e 
ND: not determined. 
f
 Inhibition percentages at 50 µM are expressed as mean with ± SD in brackets (n = 3). 
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The IC50 value of compound 3.III on hLSD1 was evaluated. The dose-response curve is 
represented in figure 29.III. The result (IC50 = 31.5 µM (13.2 µM – 75.1 µM)) shows that 
compound 3.III presents a similar IC50 value on LSD1 compared to tranylcypromine (5.I, IC50 
= 22 µM) and could be an interesting scaffold for the design of new more potent and selective 
inhibitors of LSD1.  
 
 
 
 
 
 
 
 
 
 
 
Figure 29.III. Dose-response curve of compound 3.III (■) on hLSD1. Inhibition percentages 
are shown as mean ± SD with n = 3. 
 
The LSD1 inhibitor screening assay presents a major disadvantage. Indeed, the activity of 
LSD1 is unknown. Furthermore, to assay the inhibitory potency of -carbolines (IC50 values) 
and 5H-indeno[1,2-c]pyridazin-5-ones (discussed in the second part), a new batch of 
Cayman’s LSD1 inhibitor screening assay kit was used. However, the activity of the enzyme 
and so, the IC50 value of tranylcypromine have changed. Thus, this IC50 value has to be re-
evaluated which was not performed by Cayman Corporation. Consequently, we have decided 
to stop the LSD1 inhibitor screening assay at the moment. 
 
 
3.1.3 Perspectives 
 
To monitor the activity of the enzyme in the LSD1 inhibitor screening assay, it would be 
interesting to overexpress directly the enzyme in the laboratory. Furthermore, to date, no 
small, potent and non-irreversible inhibitor of LSD1 is known. Although the -carboline 
analogues displayed moderate activities on LSD1, compound 3.III (IC50 = 31.5 µM (13.2 µM 
– 75.1 µM)) could be an interesting scaffold for the design of new more potent inhibitors of 
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LSD1. Then, the purification of the enzyme and efforts in trying to obtain a crystal structure 
of LSD1 in complex with analogues of compound 3.III could be performed. 
 
          
4. CONCLUSION 
 
In order to design new and more potent MAO-A inhibitors related to harmine (3.I), a series of 
β-carboline analogues (2a-5.III) has been synthesized. Their inhibitory potency has been 
evaluated by a luminescent assay on hMAO-A and –B enzymes. The results show that the 
replacement of the methyl moiety in the 7-position of harmine by a lipophilic group like a 
cyclohexyl, a phenyl or an aliphatic chain increases the inhibition for MAO-A. Compound 
2e.III, with the trifluorobutyloxy group, is the most active of this series, with a Ki on MAO-A 
of 3.6 nM. Docking simulations into the active site of hMAO-A show that compound 2e.III 
incorporates into the active site with harmine-like interactions. The lateral chain points to the 
lipophilic pocket where it is stabilized in agreement with an enhanced inhibitory potency 
towards MAO-A. Interestingly, compound 2o.III (Ki = 255.7 nM) containing an 
ethylmorpholine group, although less active compared to 2e.III, is a potent and selective 
inhibitor of MAO-A, and displays a higher solubility in buffer (pH 7.4) (totally soluble at 
>500 µM) compared to 2e.III (<3 µM). Therefore, efforts in trying to obtain a crystal 
structure of hMAO-A in complex with 2o.III could be pursued. All the synthesized 
compounds are selective of MAO-A but some of them show also a moderate MAO-B 
inhibition (e.g., 2f.III, Ki = 221.6 nM) when compared to harmine (3.I). Docking simulations 
for compound 2f.III performed in hMAO-B show that the β-carboline core incorporates into 
the substrate cavity. A shift is observed for the β-carboline core orientation in MAO-B 
compared to MAO-A induced by the Tyr326 side chain in MAO-B which produces a 
restriction that is less pronounced in hMAO-A where Ile335 occupies that position. In 
contrast to Gln215 in MAO-A, π-π interaction of the -carboline core with the equivalent 
amide group of Gln206 in MAO-B is less favorable. In addition, the -carboline core is 
stabilized by two hydrogen bonds with water molecules in MAO-A compared to only one 
hydrogen bond in MAO-B which may explain the selectivity of the β-carboline derivatives 
towards MAO-A compared to MAO-B. Interestingly, the cyclohexyl chain of compound 
2f.III points to a lipophilic pocket in the entrance cavity where it is stabilized in agreement 
with an enhanced inhibitory potency towards MAO-B compared to harmine (3.I).   
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Secondly, the selectivity of β-carbolines was also established on hIDO, an enzyme involved 
in the serotonergic and kynurenine pathways and inhibited by 3-butyl- -carboline (46.I) (Ki = 
3.3 µM). IDO inhibitory potency of our original β-carbolines was determined by a 
colorimetric method. The results show that, at 25 µM, the synthesized β-carbolines display no 
inhibition of IDO. Thus, they are selective of MAO and especially of MAO-A. Molecular 
docking studies of 3-butyl- -carboline (46.I) suggest that the β-carboline core is stabilized in 
pocket A by Van der Waals interactions, complexation with the heme iron and a hydrogen 
bond while the butyl side chain points to pocket B lined with hydrophobic residues. This 
binding mode evidences that the substitutions in the 1, 2, 7 and 9-positions are not tolerated 
because of steric clashes within the active site of the enzyme. So, these substitutions lead to a 
new binding mode of β-carboline scaffold which is not stabilized into the active site in 
agreement with weak inhibition percentages obtained. From results of synthesized β-
carbolines, molecular docking studies of 3-butyl-β-carboline and the pharmacophore model 
developed on IDO by Rohrig et al, we are interested in the synthesis of two new 3-substituted-
β-carbolines (N-ethyl-3-methylamino-β-carboline (8.III) and 3-methylamino-β-carboline 
(9.III)) potentially more potent compared to 3-butyl-β-carboline (46.I). These new derivatives 
should incorporate in the active site with 3-butyl-β-carboline-like interactions but the side 
chain would display also a positive charge at physiological pH which might establish a 
coulomb interaction with the 7-propionate of the heme present in pocket B, as suggested by 
our docking studies. Compounds 8.III and 9.III were synthesized in two and four steps, 
respectively from the ethyl β-carboline-3-carboxylate (10.III) intermediate. Surprisingly, the 
results reveal that the N-ethyl-3-methylamino-β-carboline (8.III) displays no inhibition on 
IDO at 100 µM. Although it was impossible to test the compound 9.III due to a lack of 
availability of this latter, the absence of inhibition observed for 8.III tends to show that the 
introduction of a positive charge is not tolerated. The result of compound 8.III must be yet 
confirmed again but this inactivity maybe explained by a more hydrophobic character of the 
pocket B. So, from the result of compound 8.III and the pharmacophore model developed on 
IDO by Rohrig et al, it can be interesting to explore the possibility to synthesize of new 3-
substituted-β-carbolines with a negatively charged group such as a carboxylate that can form 
a salt bridge with Arg231.  
Finally, the selectivity of our β-carbolines was also established on hLSD1, an enzyme 
displaying a similarity in the catalytic and structural properties with MAO. LSD1 inhibitory 
potency of β-carbolines was determined by a fluorometric method. The results show that, at 
119 
 
25 µM, the synthesized -carbolines are weak inhibitors of LSD1. The introduction of 
lipophilic and bulky groups like aliphatic (2c.III), cyclohexyl (2f.III), phenyl (2g.III, 2h.III 
and 3.III) and naphthyl (2h.III) groups allows to increase the inhibitory potency of -
carboline scaffold on LSD1 compared to harmine (3.I, inactive at 50 µM). Thus, the 
synthesized β-carboline derivatives are selective of MAO-A. However, although the -
carboline analogues display moderate activities on LSD1, compound 3.III (IC50 = 31.5 µM) 
could be an interesting scaffold for the design of new more potent and selective inhibitors of 
LSD1.  
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1. MAO 
 
As mentioned in the introduction, the 5H-indeno[1,2-c]pyridazin-5-one template displays a 
reversible competitive inhibition and is selective of MAO-B. Currently, analogues 22f.I (IC50 
hMAO-B = 8.5 nM [73]) and 22j.I (IC50 baMAO-B = 14.0 nM [74]) reported in scheme 
13.III, are described among the most potent inhibitors of this series on MAO-B. Moreover, 
the docking studies of 22f.I and 22j.I with hMAO-B (Figure 30.III) reported from the 
literature [73, 75] suggest that these two 5H-indeno[1,2-c]pyridazin-5-one analogues could be 
the starting point for the design of novel and potentially more potent MAO-B inhibitors.  
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Scheme 13.III. Rational design of 5H-indeno[1,2-c]pyridazin-5-one analogues (28a-b.III and 
22m.I). 
 
 
1.1 Structure-based rational design 
 
Previous studies on 5H-indeno[1,2-c]pyridazin-5-one derivatives as MAO-B inhibitors 
revealed that the substitution of 5H-indeno[1,2-c]pyridazin-5-one scaffold in the 3-position 
with lipophilic and bulky groups such as meta-CF3-phenyl (22f.I, IC50 hMAO-B = 8.5 nM 
[73], scheme 13.III) increases the MAO-B inhibitory potency of this series [73, 76]. 
Molecular docking studies suggest that the meta-CF3-phenyl occupies the substrate cavity to 
22f.I 
IC50 hMAO-B = 8.5 nM 
 
22j.I 
IC50 baMAO-B = 14.0 nM 
 
Suggested derivatives  
 
 
28a.III R = (CH2)3CF3 
28b.III R = CH2C6H5 
22m.I   R = CH3 (IC50 baMAO-B = 0.10 nM) 
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reach the hydrophobic pocket (Tyr60, Phe343, Tyr398), finding a favorable environment [73] 
(Figure 30.III).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30.III. Docking solutions of compounds 22f.I (magenta [73]) and 22j.I (cyan [75]) in 
the active site of hMAO-B (2V5Z.pdb). Only amino acids directly implicated in the active site 
are displayed and labeled in green. FAD is in yellow and the water molecules are displayed as 
red spheres.  
 
Further studies performed by our group revealed that the substitution in the 8-position of the 
central heterocycle with lipophilic and bulky groups such as trifluorobutyloxy (22j.I, IC50 
baMAO-B = 14.0 nM [74], scheme 13.III) increases the MAO-B inhibitory potency of this 
series [74-75]. Docking studies suggest that this trifluorobutyloxy side chain occupies the 
entrance cavity (Figure 30.III) [75]. Interestingly, the inhibitory activity reported by our group 
on derivative 22m.I (IC50 baMAO-B = 0.10 nM, Scheme 13.III) bearing meta-CF3-phenyl and 
methoxy groups in the 3 and 8-positions, respectively [74] leads us to synthesize new 5H-
indeno[1,2-c]pyridazin-5-one derivatives containing lipophilic and bulky groups at both 
positions (28a-b.III, Scheme 13.III) including 22m.I as a reference drug. Their human 
monoamine oxidase A and B inhibitory potency was investigated. In addition, compounds 
Entrance cavity 
Substrate cavity 
Tyr60 
Leu164 
Phe103 
Tyr398 
 Phe343 
Gln206 
FAD 
Leu171 
Cys172 
Ile199 
Phe168 
Trp119 
Ile316 
Tyr326 
Tyr188 
Tyr435 Leu167 
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30a.III and 30b.III (Scheme 15.III), previously synthesized in the framework of a master’s 
thesis (Fabrice Camus, Biological Structural Chemistry Laboratory, FUNDP, Belgium) and 
structurally related to compound 22j.I, were also evaluated for their human monoamine 
oxidase A and B inhibitory potency. The IC50 values of the most potent compounds were 
evaluated and Ki values were estimated using the Cheng-Prusoff equation [192]. A 
competitive-type inhibition for the most potent inhibitor was confirmed from the Lineweaver–
Burk plots. The Ki value was in good agreement with the value deduced from the IC50. 
 
 
1.2 Synthesis of 5H-indeno[1,2-c]pyridazin-5-one analogues 
 
The strategy used to synthesize 8-(alkoxy)-3-(3’-(trifluoromethyl)phenyl)-5H-indeno[1,2-
c]pyridazin-5-one derivatives (28a-b.III and 22m.I) is depicted in scheme 14.III. This 
synthetic pathway follows a four steps procedure reported by our group from the common 5-
hydroxy-1-indanone (24.III) intermediate [74-75].  
5-Hydroxy-1-indanone (24.III) reacted with 1-tosyl-4,4,4-trifluorobutane in the presence of 
K2CO3 in acetonitrile for 4 h at 90°C to give the 5-(4,4,4-trifluoromethylbutyloxy)-1-
indanone (25a.III) in almost quantitative (96%) yield. 5-Benzyloxy-1-indanone (25b.III) was 
obtained by reaction between the indanone (24.III), K2CO3, benzyl bromide in DMF for 5 h 
at room temperature in almost quantitative (90%) yield. 5-(Methoxy)-1-indanone (25c.III) is 
commercially available. The alkoxyninhydrins (26a-c.III) were synthesized by selenium 
dioxide oxidation of 5-alkoxy-1-indanones (25a-c.III). A dioxane solution of 5-alkoxy-1-
indanone was mixed with selenium dioxide and refluxed for 3 h. This gave the 5-
alkoxyninhydrins 26a-c.III in 73-81% yield. A solution of 5-alkoxyninhydrin (26a-c.III) and 
3’-(trifluoromethyl)acetophenone in acetic acid was refluxed for 3 h to give the intermediate 
aldol adduct (27a-c.III). After cooling to room temperature, the mixture reacted with 
hydrazine overnight. After purification on a silica gel column, the 8-(alkoxy)-3-(3’-
(trifluoromethyl)phenyl)-5H-indeno[1,2-c]pyridazin-5-one (28a-b.III and 22m.I) regioisomer 
was obtained in 39-46% yield. X-ray diffraction was used to unambiguously establish the 
position of the alkoxy group in the 8-position of the 5H-indeno[1,2-c]pyridazin-5-one moiety. 
ORTEP views of the conformations of 28a.III and 28b.III, with their atomic numbering 
scheme are depicted in figure 31.III.  
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Scheme 14.III. Synthetic pathway to 5H-indeno[1,2-c]pyridazin-5-one analogues 28a-b.III 
and 22m.I.  
 
As mentioned previously, the synthesis of compounds 30a-b.III was reported in the master’s 
thesis of Fabrice Camus (Biological Structural Chemistry Laboratory, FUNDP, Belgium) and 
started from the phenol 29.III [74] (Scheme 15.III). Benzylation of 29.III was achieved upon 
reaction with 1-(bromomethyl)-3-chlorobenzene or 1-(bromomethyl)-3-methylbenzene in the 
presence of silver oxide in DMF at room temperature for 4 h. This provided 30a-b.III in 
modest yields (6-15% yield). In this thesis, the two compounds were fully characterized and 
again, X-ray diffraction was used to confirm the structure of 30a.III (Figure 31.III).  
The structure of the synthesized compounds was confirmed by 
1
H NMR, 
13
C NMR, mass 
spectrometry (MS) and their purity was assessed by elemental analyses. The data are reported 
in the chapter Materials and Methods. 
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Scheme 15.III. Synthetic pathway to 5H-indeno[1,2-c]pyridazin-5-one analogues 30a-b.III 
(Master’s thesis of Fabrice Camus, Biological Structural Chemistry Laboratory, FUNDP, 
Belgium).  
24.III     25a.III R = (CH2)3CF3 
     25b.III R = CH2C6H5 
     25c.III R = CH3 
26a.III R = (CH2)3CF3 
26b.III R = CH2C6H5 
26c.III R = CH3 
27a.III R = (CH2)3CF3 
27b.III R = CH2C6H5 
27c.III R = CH3 
28a.III R = (CH2)3CF3 
28b.III R = CH2C6H5 
22m.I R = CH3 
     29.III                         30a.III R = Cl 
                        30b.III R = CH3  
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Figure 31.III. ORTEP diagram (50% probability) of compounds 28a.III, 28b.III and 30a.III. 
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30a.III 
28b.III 
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1.3 Biological evaluation 
 
The inhibitory potency of the 5H-indeno[1,2-c]pyridazin-5-ones was assessed in vitro in 
triplicate at 10 µM using the inhibition assays previously validated on hMAO-A and –B. First, 
the IC50 values of the most potent were evaluated on hMAO-B. The Ki values of the most 
potent compounds were then estimated from the IC50 values using the Cheng-Prusoff equation 
[192]. The results of MAO inhibition studies are reported in tables 12.III and 13.III. 
Compounds 22m.I and 22j.I are known as inhibitors of MAO-B [72, 74] and were used as 
references. All the 5H-indeno[1,2-c]pyridazin-5-one analogues except 28b.III present a 
higher inhibitory potency on MAO-B than MAO-A. The MAO inhibitory potency of these 
compounds proved to be highly dependent on the alkyl/aryl-substituent in the 3-position. 
Analogues with a meta-CF3-phenyl group and a lipophilic group (methoxy, benzyloxy or 
trifluorobutyloxy) in the 3 and 8-positions respectively (28a-b.III and 22m.I) show moderate 
or no inhibition of MAO-B at 10 µM. Thus, the inhibitory activity of 22m.I is not in 
agreement with the data reported by our group on baboon enzyme [74]. However, it was 
evidenced in the literature that MAO affinity depends on species studied. In particular, 
Novaroli et al have evidenced important species-dependent differences in MAO-B inhibitor 
specificity between human and rat for 5H-indeno[1,2-c]-pyridazin-5-one derivatives [73]. 
Indeed, these derivatives show a greater inhibitory potency toward hMAO-B than toward 
rMAO-B (e.g., 22f.I, IC50 rMAO-B = 280 nM and IC50 hMAO-B = 8.5 nM) [73]. So, a 
difference of affinity between baboon and human enzymes can be conceivable. 
In contrast, the substitution of meta-CF3-phenyl group in the 3-position with a methyl group 
(30a.III, 30b.III and 22j.I) leads to better inhibition (in the submicromolar range) of hMAO-
B (Tables 12-13.III and figure 32.III). Compound 30a.III, with a chlorine meta-substituted 
benzyloxy group, is the most active and selective within this series, with a Ki on MAO-B of 
0.16 µM (Table 13.III and figure 32.III).  
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Table 12.III. Structure and inhibitory potency of synthesized 5H-indeno[1,2-c]pyridazin-5-
one derivatives on hMAO-A and –B. 
 
  Inhibition percentage
a
 
Compound Structure hMAO-A
 
hMAO-B  
 
28a.III 
   
NN
O
O
F3C
CF3
 
NI
b
 57% (±10%) 
 
28b.III 
NN
O
O
CF3
 
10% (±10%) 
 
7% (±3%) 
 
22m.I 
NN
O
O
CF3
 
NI
 36% (±2%) 
 
30a.III 
NN
O
O
Cl
 
15% (±5%) 
 
93% (±4%) 
 
30b.III 
NN
O
O
 
17% (±1%) 
 
90% (±0%) 
 
22j.I 
NN
O
O
F3C
 
NI 92% (±0%)
 
a
 Inhibition percentages at 10 µM are expressed as mean with ± SD in brackets (n = 3). 
b 
NI: no inhibition at 10 µM. 
 
Table 13.III. Ki values deduced from IC50/measured on hMAO-B for compounds 30a.III, 
30b.III and 22j.I. 
 
 Ki (µM) 
Compound Deduced from IC50
a
  Measured
b
 
30a.III  0.16 (0.14 – 0.19)  0.11  0.01 
30b.III  0.48 (0.42 – 0.55)  
22j.I  0.28 (0.26 – 0.30)
 
 
a
 Ki values are estimated from the experimentally measured IC50 values using the Cheng-Prusoff equation and are 
expressed as mean within brackets 95% confidence intervals (n = 3). 
b
 Ki value is measured from the Lineweaver-Burk representation and is expressed as the mean ± SD (n = 3). 
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Figure 32.III. Dose-response curve of compounds 30a.III (■), 30b.III (▲) and 22j.I (▼) on 
hMAO-B. Inhibition percentages are shown as mean ± SD with n = 3. 
 
To confirm the inhibition mode of MAO-B by 30a.III, the Lineweaver–Burk plots were 
obtained from incubations at four different substrate concentrations with and without three 
different inhibitor concentrations. Lineweaver-Burk representation for 30a.III on MAO-B 
demonstrates that its mechanism of inhibition is competitive (Figure 33.III). The Ki value for 
the inhibition of MAO-B by 30a.III was determined to be 0.11 µM which is in agreement 
with the Ki value estimated from the IC50 value using the Cheng-Prusoff equation (Table 
13.III) [192]. These results show that the substitution at both positions by lipophilic and bulky 
groups (28a-b.III and 22m.I) is not tolerated compared to analogues 30a.III, 30b.III and 
22j.I.  
 
 
 
 
 
 
 
 
 
 
 
Figure 33.III. Lineweaver-Burk plots of the inhibition of recombinant human MAO-B by 
30a.III. The lines were constructed in the absence (♦) and presence of 2 µM (■), 5 µM (▲) 
and 15 µM (●) of 30a.III with n = 3.  
1
/V
 
1/[S] 
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With the aim of understanding the role of an aryl group in the 3-position, molecular docking 
studies of compounds 30a.III were performed and discussed in the next section. 
 
 
1.4 Molecular modeling  
 
Analysis of the binding mode for compound 30a.III (Figure 34.III, top)—selected from the 
docking study as a plausible solution in agreement with docking solution of 22j.I ([75]) in the 
active site of hMAO-B (Figure 30.III)— revealed that 5H-indeno[1,2-c]pyridazin-5-one core 
is located in the vicinity of the FAD cofactor with the C-8 side chain projecting towards the 
entrance cavity of MAO-B. The substrate cavity is mainly hydrophobic, the only hydrophilic 
region being located between Tyr398, Tyr435 and the flavin which form an aromatic cage. 
The examination of the molecular electrostatic potential (MEP) distribution for compound 
30a.III shows the presence of two large attractive zones around the 5H-indeno[1,2-
c]pyridazin-5-one ring (Figure 34.III, bottom). The first one is centered on the carbonyl and 
the second one is centered on the endocyclic hydrazine. So, it is not surprising to observe that 
both regions are located within the hydrophilic region of the MAO-B substrate cavity. The 
5H-indeno[1,2-c]pyridazin-5-one ring is stabilized by π-π interactions with Tyr398 and 
Tyr435. The binding mode adopted by compound 30a.III allows the meta-chlorobenzyloxy 
side chain to settle within the entrance cavity lined with hydrophobic amino acid residues. 
This hydrophobic pocket is coated by Phe103, Trp119, Leu164, Leu167, Phe168, and Ile316. 
Interestingly, the introduction of a chlorine atom on the benzyl ring (30a.III, Ki = 0.16 µM) 
increases the inhibitory potency on MAO-B compared to the derivative bearing a methyl 
group (30b.III, Ki = 0.48 µM). Previous studies have shown that addition of a chlorine 
substituent on the phenyl group side chain enhances the lipophilicity of the inhibitor, and 
therefore its affinity and its selectivity on MAO-B establishing Van der Waals interactions in 
the hydrophobic entrance cavity [62]. Compound 22j.I (Ki = 0.28 µM) with the 
trifluorobutyloxy group displays a similar inhibition compared to 30a.III. The methyl group 
in the 3-position is stabilized within the hydrophobic cage formed by Tyr398, Tyr435 and 
FAD. The substrate cavity being more sterically constrained than the entrance cavity, the 
meta-CF3-phenyl group of compounds 28a-b.III and 22m.I cannot accommodate into the 
substrate cavity without modifying the binding mode of 5H-indeno[1,2-c]pyridazin-5-one 
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ring. So, these observations may explain the reduced inhibition of compounds 28a-b.III and 
22m.I compared to 30a.III, 30b.III and 22j.I. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34.III. (top) Simulated binding mode of compound 30a.III in the active site of 
hMAO-B (2V5Z.pdb). Only amino acids directly implicated in the active site are displayed 
and labeled (in green). Compound 30a.III and FAD are in cyan and yellow respectively. The 
water molecules in the active site are displayed as red spheres. (Bottom) Attractive molecular 
electrostatic potential (isovalue for surfaces = 10 kcal/mol) calculated around compound 
30a.III. (PBE1PBE, 6-311G**)   
Tyr60 
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Tyr398 
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2. IDO 
 
2.1 Biological evaluation 
 
In this study, we also appraised the selectivity of our 5H-indeno[1,2-c]pyridazin-5-one series 
on hIDO. The IDO inhibitory potency of these analogues was assessed in vitro in triplicate at 
25 µM using the colorimetric test previously validated on hIDO. The results of MAO and 
IDO inhibition studies are reported in table 14.III.  
 
Table 14.III. Structure and inhibitory potency of synthesized 5H-indeno[1,2-c]pyridazin-5-
one derivatives on hMAO-A, hMAO-B and hIDO. 
 
  Inhibition percentage
a
 
Compound Structure hMAO-A
 
hMAO-B        hIDO 
 
28a.III 
NN
O
O
F3C
CF3
 
NI
b
 57% (±10%) 
 
NI
b 
28b.III 
   
NN
O
O
CF3
 
10% (±10%) 
 
7% (±3%) 
 
17% (±1%) 
22m.I 
NN
O
O
CF3
 
NI
 36% (±2%) 
 
NI 
30a.III 
NN
O
O
Cl
 
15% (±5%) 
 
 93% (±4%) 
 
25% (±3%) 
30b.III 
NN
O
O
 
17% (±1%) 
 
90% (±0%) 14% (±2%) 
22j.I 
NN
O
O
F3C
 
NI 92% (±0%)
 
19% (±2%) 
  
a
 Inhibition percentages at 10 µM
 
and 25 µM on MAO-A/MAO-B and IDO respectively, are expressed as mean 
with ± SD in brackets (n = 3). 
b 
NI: no inhibition at 10 µM
 
and 25 µM on MAO-A/MAO-B and IDO, respectively. 
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The results reveal that the synthesized 5H-indeno[1,2-c]pyridazin-5-one analogues display no 
significant inhibition on IDO. So, 5H-indeno[1,2-c]pyridazin-5-one derivatives display a 
higher activity and selectivity on hMAO-B. 
 
 
3. CONCLUSION 
 
In order to design new, selective, and more potent MAO-B inhibitors, a series of 5H-
indeno[1,2-c]pyridazin-5-one derivatives substituted both in the 3 and 8-positions by 
lipophilic groups has been synthesized. X-ray diffraction technique was used to 
unambiguously establish the position of the alkoxy group on the phenyl ring of the 5H-
indeno[1,2-c]pyridazin-5-one moiety. Inhibitory potency of the compounds has been 
evaluated by a luminescent test on hMAO-A and –B. In this study, the selectivity of our series 
was also established on hIDO by a colorimetric method. The results show that, at 25 µM, the 
synthesized 5H-indeno[1,2-c]pyridazin-5-ones display no significant inhibition on IDO. All 
compounds, except 28b.III, display a higher activity and selectivity on MAO-B. 3-Methyl-8-
meta-chlorobenzyloxy-5H-indeno[1,2-c]pyridazin-5-one (30a.III), is the most active and 
selective within this series, with a Ki on MAO-B of 0.11 µM. Replacement of the methyl 
moiety in the 3-position by a lipophilic group like a meta-CF3-phenyl group (28a-b.III and 
22m.I) abolishes the inhibitory potency on MAO-B. So, the substitution of the 5H-
indeno[1,2-c]pyridazin-5-one core in the 3-position dramatically influences the MAO-
inhibiting properties of these compounds. Docking simulations of compound 30a.III in 
hMAO-B suggest that the 5H-indeno[1,2-c]pyridazin-5-one core incorporates into the 
substrate cavity with the meta-chlorobenzyloxy side chain extending towards a hydrophobic 
pocket of the entrance cavity space. Finally, it would be interesting to investigate the 5H-
indeno[1,2-c]pyridazine-5-one inhibitors of MAO as potential LSD1 inhibitors once the 
problem of the control of enzyme activity solved.  
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1. MAO 
 
1.1 Selection of compounds 
 
As mentioned in the introduction, previous studies have shown that indole derivatives may be 
used for the design of potent anti-MAO agents [57-62]. For example, the irreversible MAO-B 
inhibitor PF9601N (20a.I, Figure 35.III; Ki rMAO-B = 0.75 nM [60]) shows 
antioxidant/neuroprotective properties in an experimental model of PD [61].  
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Figure 35.III. Chemical structures of PF9601N (20a.I), N-(2-methyl-1H-indol-5-
yl)benzamide (48.III), harmine (3.I), isatin (4.I) and 7-(cyclohexylmethoxy)-1-methyl-β-
carboline (2f.III). 
 
In this study, we are interested in two series including bulky and/or lipophilic groups in the 3- 
(31-43.III, Figure 36.III) or 5-positions (44-47.III, Figure 36.III) and available at the 
department of Pharmacy (Prof. Masereel, FUNDP, Belgium). Though the compounds (31-
47.III) are already known, their potential inhibitory activity on MAO isoforms has never been 
described except for 680C91 (40.III). 680C91 is a potent (Ki = 51 nM) and selective TDO 
inhibitor with no inhibitory activity on MAO-A and –B [208].  
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Figure 36.III. Chemical structures of selected indole derivatives tested on hMAO-A and –B. 
 
The first series consists of 680C91 (40.III) analogues. Compounds 31-34.III include a 
thiosemicarbazone group instead of a pyridinyl vinyl group. We have also studied a series of 
3-(2-(pyridin-3-yl)vinyl)-1H-indol differently substituted (35-41.III) which are directly 
derived from 680C91 (40.III). Compounds 42.III and 43.III correspond to acrylic acid and 
ester derivatives. Finally, we have evaluated the inhibition of four indole derivatives (44-
47.III) substituted in the 5-position by a lipophilic group. Previous studies have indicated that 
bulky C-5 substituents (e.g., 20a.I [60] and 48.III (Ki hMAO-B = 1.65 µM [62]), Figure 
35.III) like the benzyloxy or phenyl moiety on the indole core generally increase potency and 
selectivity on MAO-B.  
 
  
 
  
 
 
 
 
     31.III          32.III              33.III         34.III 
     35.III          36.III              37.III         38.III 
     39.III          40.III              41.III         42.III 
     43.III          44.III              45.III         46.III 
     47.III        
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1.2 Biological evaluation 
 
The inhibitory potency of the indole derivatives was assessed in vitro in triplicate at 10 µM 
using the inhibition assays previously validated on hMAO-A and –B. The IC50 values of the 
most potent were evaluated on hMAO-A and –B. Then, the Ki values were estimated from the 
IC50 values using the Cheng–Prusoff equation [192]. The results of MAO inhibition studies 
are reported in table 15.III. The indole references used on MAO-A and –B were harmine (3.I, 
Ki = 16.9 nM) and isatin (4.I, Ki = 32.6 µM), respectively (Figure 35.III). The 
thiosemicarbazone compounds 31-34.III show weak inhibition of MAO-A and no inhibition 
at 10 µM of MAO-B except for compound 34.III which shows 50% of inhibition. Among the 
other indole derivatives, compound 41.III, a 3-(2-(pyridin-3-yl)vinyl)-1H-indol, substituted 
both in the N-1 position with a methyl group and at C-6 with a fluorine atom, is the most 
active inhibitor on MAO-A, with a Ki of 1.15 µM (Figure 37.III (top) and table 15.III). 
Interestingly, the unsubstituted 3-(2-(pyridin-3-yl)vinyl)-1H-indol (35.III) does not inhibit 
MAO-A at 10 µM. The introduction of a phenyl group in the 2-position (37.III) does not 
improve the inhibition on MAO-A. The extension to three cycles of the central aromatic ring 
(36.III) as well as the introduction of a nitrogen on the indole (38.III), a methyl group in the 
N-1 position (39.III) or a fluorine in the 6-position (40.III) does not significantly increase the 
inhibition of MAO-A compared to compound 35.III. Interestingly, the substitution of the 3-
(2-(pyridin-3-yl)vinyl)-1H-indol scaffold with both a methyl group at N-1 and a fluorine atom 
at C-6 significantly enhances the inhibitory potency of compound 41.III compared to 
unsubstituted analogue 35.III and the corresponding N-methyl and fluorine substituted 
compounds 39.III and 40.III.  
Concerning MAO-B, the ethyl ester derivative 43.III significantly inhibits MAO-B compared 
to its acid analogue 42.III. The 3-(2-(pyridin-3-yl)vinyl)-1H-indol compounds (35-41.III) do 
not inhibit MAO-B and so display a selectivity on MAO-A. Interestingly, the substitution in 
the 5-position of the indole core with a vinyl pyridin group (44-45.III) leads to relatively 
weak inhibitors of the two isoforms of MAO. The introduction of a benzyloxy group (46.III) 
instead of vinyl pyridin group increases both the inhibitory potency and the selectivity on 
MAO-B. This result is in agreement with previous studies which indicate that bulky C-5 
substituents including the benzyloxy moiety generally increase potency and selectivity on 
MAO-B [62, 209]. 
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Table 15.III. Inhibitory potency of indole derivatives on hMAO-A and –B.  
 
 Inhibition percentage
a
  Ki (µM)
b
 
Compound hMAO-A 
 
hMAO-B 
 
hMAO-A 
 
hMAO-B 
 
harmine    0.017 (0.014 – 0.021) 120.80 (94.90 – 153.90) 
Isatin    32.55 (28.11 – 37.68) 
31.III 4% (±4%) NI
c
  
32.III 11% (±1%) NI
 
 
33.III 20% (±3%) NI  
34.III 12% (±3%) 50% (±8%)  
35.III 5% (±6%) 9% (±6%)  
36.III 20% (±3%) 7% (±1%)  
37.III NI NI
 
 
38.III 9% (±5%) 6% (±7%)
 
 
39.III 22% (±1%) NI  
40.III 14% (±5%) 17% (±1%)  
41.III 73% (±2%) 27% (±3%)  1.15 (0.92 – 1.44)  
42.III 4% (±4%) NI
 
 
43.III 9% (±1%) 51% (±6%)  
44.III 15% (±2%) 42% (±2%)  
45.III 22% (±1%) 34% (±0%)  
46.III 6% (±2%) 66% (±1%)  2.91 (2.75 – 3.08) 
47.III 7% (±5%) 96% (±0%)   0.12 (0.11 – 0.14) 
a
 Inhibition percentages at 10 µM are expressed as mean with ± SD in brackets (n = 3). 
b 
Results are expressed as mean within brackets 95% confidence intervals (n = 3). 
c
 NI: no inhibition at 10 µM. 
 
Surprisingly, the introduction of a methyl group in the N-1 position (47.III) significantly 
increases the selectivity and the inhibitory potency on MAO-B compared to derivative 46.III. 
So, compound 47.III was found to be the most selective and moderately potent MAO-B 
inhibitor within this series with a Ki value of 0.12 µM compared to analogue 46.III which 
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displays a Ki value of 2.91 µM (Figure 37.III (bottom) and table 15.III). These Ki values show 
the crucial role played by the methyl group in the N-1 position on activity and selectivity of 
MAO-B compared to MAO-A. With the aim of trying to understand the role of this methyl 
group, a comparative study of packing from crystallography structures of compounds 46.III 
and 47.III, and molecular docking studies were performed and will be discussed in the next 
sections.    
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Figure 37.III. (Top) Dose-response curve of harmine (3.I, ●) and compound 41.III (▲) on 
hMAO-A. (Bottom) Dose-response curve of isatin (4.I, ■), compounds 46.III (♦) and 47.III 
(▲) on hMAO-B. Inhibition percentages are shown as mean ± SD with n = 3. 
 
 
1.3 X-ray crystallographic analysis 
 
The molecular structures of compounds 46.III and 47.III, were determined by X-ray 
crystallographic analysis. Compounds 46.III and 47.III crystallize in the trigonal  (R1 = 
0.0972) and the monoclinic P21 (R1 = 0.0354) space groups respectively. ORTEP diagram and 
crystalline cohesion pattern of compounds 46.III and 47.III are depicted in figure 38.III. The 
C5-O10-C11 bond angles 117.2(3)° and 116.6(9)° for 46.III and 47.III respectively are 
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indicative of a sp
2 
character of the oxygen underling electronic delocalization from the indole 
ring to the benzyloxy chain. The benzyloxy chains adopt a similar conformation with torsion 
angles C5–O10–C11–C12 and O10-C11-C12-C13 of 168.0(3)° and 114.9(5)° for compound 
46.III and of 174.3(1)° and 110.3(3)° for 47.III. Crystal packing of 46.III is mainly 
maintained by hydrogen bonds formed between N1-H…O10 (2.085 Å) and π-π interactions. 
For N-methyl analogue (47.III), the crystalline cohesion is mainly maintained by π-π 
interactions, weak CH-π(C(sp2)) hydrogen bonds (in the range of 2.8 Å) and weak C-H…O 
interactions (formed between C3-H…O10 (2.669 Å)). While hydrogen bonds such as CH-π 
and C-H…O interactions can be regarded as weak interactions compared to an ordinary 
hydrogen bond observed in the molecular structures of compound 46.III, these can play an 
important role because many CH groups can participate simultaneously. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38.III. ORTEP diagram (50% probability) and crystalline cohesion pattern of 
compounds 46.III (left) and 47.III (right).  
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1.4 Molecular modeling 
 
From this study on a series of indole analogues differently substituted, 5-benzyloxyindole 
(46.III) and N-methyl-5-benzyloxyindole (47.III) were found to be the most potent and 
selective MAO-B inhibitors. The encouraging result obtained for compounds 46.III and 
47.III as moderate inhibitors of MAO-B lead us to study the potential binding mode of these 
compounds with MAO-B and to try to explain the structure-activity relationships.  
Previously, in the β-carboline series, we have shown that 7-(cyclohexylmethoxy)-1-methyl-β-
carboline (2f.III, Figure 35.III) displayed the best inhibitory activity on MAO-B with a Ki 
value of 0.22 µM. Docking simulations of 2f.III within hMAO-B show that the β-carboline 
core incorporates into the substrate cavity (Figure 39.III, top). In addition, the -carboline 
core is stabilized by a hydrogen bond between nitrogen atom N2 (H bond acceptor) and a 
conserved water molecule (H bond donor). The pyridine ring is also stabilized within an 
aromatic cage (Tyr398-Tyr435 and FAD) by π-π interaction. The amide group of the Gln206 
side chain also interacts with the β-carboline core by π-π interaction but this interaction is less 
favorable compared to harmine (3.I) in hMAO-A. The cyclohexyl chain points to a 
hydrophobic pocket of the entrance cavity coated by Phe103, Trp119, Leu164, Leu167, 
Phe168, and Ile316 where it is stabilized in agreement with an enhanced inhibitory potency 
towards MAO-B compared to harmine.  
The result of docking simulations for 5-benzyloxyindole (46.III) is represented in figure 
39.III (bottom). Docking studies suggest that the indole core incorporates into the substrate 
cavity of MAO-B with the C-5 side chain extending towards the entrance cavity space. The 
indole ring is stabilized by a hydrogen bond between NH group (H bond donor) and a 
conserved water molecule (H bond acceptor). This hydrogen bond corresponds to the one 
observed with the -carboline derivative. The indole ring is stabilized by π-π interactions with 
the aromatic cage (Tyr398-Tyr435 and FAD). Compared to the -carboline derivative, the 
reduction to two cycles of the central aromatic ring leads to loss of the π-π interaction with the 
amide group of the Gln206 side chain. Moreover, the reduction of the size of the central 
aromatic linker prevents the benzyloxy group to extend into the entrance cavity compared to 
the -carboline derivative. So, the comparison of binding modes may explain the better 
inhibition of MAO-B by the -carboline derivative 2f.III compared to 5-benzyloxyindole 
(46.III).  
 
 
 
  
 
 
144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39.III. Simulated binding mode of 2f.III (top) and 46.III (bottom) in the active site of 
hMAO-B (2V5Z.pdb). Only amino acids directly implicated in the active site are displayed 
and labeled (in green). Compounds 2f.III and 46.III are in magenta and gray, respectively. 
FAD is in yellow. The water molecules involved in MAO-B are displayed as red spheres. The 
hydrogen bonds discussed in the text are depicted as dashed blue lines. 
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Interestingly, the introduction of a methyl group in the N-1 position (47.III, Ki = 0.12 µM) 
significantly increases the inhibitory potency on MAO-B compared to 5-benzyloxyindole 
(46.III, Ki = 2.91 µM). These Ki values thus show the crucial role played by the methyl group 
in the N-1 position on activity of MAO-B. Based on the docking simulation of 46.III with 
MAO-B, the effect of the methyl group is difficult to rationalize since the NH group of 
corresponding analogue 46.III is supposed to be implicated in a hydrogen bond with a 
conserved water molecule. The X-ray structures of compounds 46.III and 47.III show that the 
NH of compound 46.III establishes a hydrogen bond and the methyl group in the N-1 position 
of 47.III is implicated in π-hydrogen bonds. So, from the results of docking studies and X-ray 
crystal analysis of compounds 46.III and 47.III, it is currently impossible to explain 
beneficial effect on the introduction of a methyl group on the nitrogen atom of the indole. The 
biological data suggest that either 47.III binds differently to the active site of MAO-B than 
46.III or that the structure of the complex between 46.III and MAO-B simulated by docking 
is not correct. Indeed, if 47.III had to bind to MAO-B in a similar way than 46.III, this would 
imply loss of a hydrogen bond interaction with a conserved water molecule by replacement of 
the NH (H bond donor) of 46.III by a N-methyl group in 47.III. Consequently, one would 
expect a decrease in activity for 47.III, unless extra stabilization of the methylated compound 
within the hydrophobic cage formed by Tyr398, Tyr435 and FAD is able to compensate the 
loss of stabilization by loss of hydrogen bond interaction. An alternative explanation of the 
increased activity of 47.III could be displacement of the conserved water molecule that would 
lead to a beneficial entropic effect. This hypothesis could not be tested by classical modeling 
approaches. Therefore, efforts in trying to obtain a crystal structure of MAO-B in complex 
with 46.III and/or 47.III should be pursued. 
 
 
2. CONCLUSION 
 
In order to identify new potential MAO-A and –B inhibitors including an indole core, a series 
of indole analogues from the department of Pharmacy (Prof. Masereel, FUNDP, Belgium), 
was evaluated by a luminescent test on hMAO-A and –B. First, the results confirm that 
680C91 (40.III) is inactive on MAO-A and –B in agreement with the literature. Secondly, 
compound 41.III which is substituted in the N-1 position with a methyl group compared to 
680C91 (40.III) is the most potent of this series on MAO-A although moderate with a Ki 
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value of 1.15 µM. The MAO-B inhibition results bring to light that the substitution at C-5 of 
the indole core by a lipophilic group (44-47.III) allows to appreciably increase the inhibition 
of MAO-B. The introduction of a benzyloxy group (46.III) instead of a vinyl pyridin group 
(44-45.III) increases both the inhibitory potency and the selectivity on MAO-B. Surprisingly, 
the 1-methyl-5-benzyloxyindole derivative (47.III, Ki value of 0.12 µM) displays a significant 
increase in the selectivity and inhibitory potency on MAO-B compared to compound 5-
benzyloxyindole (46.III, Ki value of 2.91 µM). With the aim of trying to understand the 
crucial role played by the methyl group in the N-1 position, a comparative study of packing 
from crystallography structures of compounds 46.III and 47.III and molecular docking 
studies were performed. The X-ray structures of compounds 46.III and 47.III show that the 
NH and N-methyl groups are implicated in hydrogen bonds and π-hydrogen bonds 
respectively. Docking simulations of 5-benzyloxyindole (46.III) compared to 2f.III (Ki = 0.22 
µM) into the active site of hMAO-B suggest that the β-carboline and indole cores incorporate 
into the substrate cavity. The stability of both compounds differs mainly by the π-π interaction 
with the Gln206 side chain, and the stabilization of the lateral chain in the entrance cavity. 
Indeed, reduction to two cycles of the central aromatic linker leads to the loss of the π-π 
interaction between the amide group of the Gln206 side chain and 46.III. The reduction of the 
cycle and hydrogen bond prevents the benzyloxy group to extend in the entrance cavity 
compared to the -carboline derivative for which the cyclohexyl chain points to a 
hydrophobic pocket of the entrance cavity where it is stabilized. The beneficial effect of 
methyl group on the activity on MAO-B is difficult to rationalize since NH group of 
corresponding compound 46.III is supposed to be implicated in a hydrogen bond with a 
conserved water molecule. Definite explanation of the enhanced activity of 47.III versus 
46.III could benefit from crystal structures of those inhibitors with MAO-B. In the same time, 
it would be interesting to confirm the competitive-type inhibition of MAO-B by compounds 
46-47.III from the Lineweaver–Burk plots, such as performed previously for 30a.III on 
MAO-B. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
GENERAL CONCLUSIONS AND PERSPECTIVES 
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The last generation of reversible and selective MAOIs has shown a great promise in a broad 
range of treatments against pathologies including depression, anxiety disorders, Parkinson’s 
and Alzheimer’s diseases. Due to their selective and reversible inhibition of MAO, this new 
generation of MAOIs displays a safer profile compared to the former irreversible MAOIs, 
particularly with regard to the cheese-effect and drug interaction. Most current MAOIs lead to 
side effects by a lack of affinity and selectivity towards one of the isoforms. Furthermore, the 
recent crystal structures of hMAO-A and –B in complex with inhibitors opened the way 
towards the discovery by structure-based drug design of new, more selective and potent 
inhibitors. The main objective of this work was therefore the design of new, more potent, 
reversible and selective MAO-A and –B inhibitors derived from β-carbolines, indoles and 5H-
indeno[1,2-c]pyridazin-5-ones. 
In order to design new and more potent MAO-A inhibitors related to harmine (3.I, Figure 
1.IV), a series of 7-alkyloxy-β-carboline analogues (2a-5.III) has been synthesized.  
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Figure 1.IV. Chemical structures of -carboline (3.I, 2e-2f.III, 2o.III, 3.III, 5.III, 8-9.III and 
46.I), 5H-indeno[1,2-c]pyridazin-5-one (30a.III) and indole (46-47.III) derivatives. 
3.I           2e.III                2f.III 
2o.III           3.III                5.III 
8.III           9.III                46.I 
30a.III           46.III                     47.III               
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The MAO inhibitory potencies show that the replacement of the methoxy group of harmine 
(3.I) by a lipophilic group increases the inhibition for MAO-A (e.g., 2e.III, Ki hMAO-A = 3.6 
nM, is the most active of this series, Figure 1.IV). Docking simulations into the active site of 
hMAO-A show that compound 2e.III incorporates into the active site with harmine-like 
interactions (Figure 2.IV). The lateral chain points to the lipophilic pocket where it is 
stabilized in agreement with an enhanced inhibitory potency towards MAO-A. Interestingly, 
the compound 2o.III (Ki hMAO-A = 255.7 nM, Figure 1.IV) containing an ethylmorpholine 
group, although less active compared to 2e.III, is a potent and selective inhibitor of MAO-A, 
and displays a higher solubility in buffer (pH 7.4) (totally soluble at >500 µM) compared to 
2e.III (<3 µM). Therefore, efforts in trying to obtain a crystal structure of hMAO-A in 
complex with 2o.III could be pursued.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.IV. Binding mode of compound 2e.III in the active site of hMAO-A (2Z5X.pdb). 
Only amino acids directly implicated in the active site are displayed and labeled in cyan. 
Compound 2e.III and FAD are in green and yellow respectively. The water molecules are 
displayed as red spheres. The hydrogen bonds discussed in the text are depicted as dashed 
blue lines. 
 
All the synthesized compounds are selective of MAO-A but some of them show also a 
moderate MAO-B inhibition (e.g., 2f.III, Ki hMAO-B = 221.6 nM, Figure 1.IV) when 
compared to harmine (3.I). Docking simulations for compound 2f.III performed in hMAO-B 
show that the β-carboline core incorporates into the substrate cavity (Figure 3.IV). A shift is 
observed for the β-carboline core orientation in MAO-B compared to MAO-A induced by the 
Tyr326 side chain in MAO-B which produces a restriction that is less pronounced in hMAO-
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A where Ile335 occupies that position. In contrast to Gln215 in MAO-A, π-π interaction of the 
-carboline core with the equivalent amide group of the Gln206 in MAO-B is less favorable. 
In addition, the -carboline core is stabilized by two hydrogen bonds with water molecules in 
MAO-A compared to only one hydrogen bond in MAO-B which may explain the selectivity 
of the β-carboline derivatives towards MAO-A compared to MAO-B. Interestingly, the 
cyclohexyl chain of compound 2f.III points to a lipophilic pocket in the entrance cavity where 
it is stabilized in agreement with an enhanced inhibitory potency towards MAO-B compared 
to harmine (3.I).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.IV. Binding mode of compound 2f.III in the active site of hMAO-A and –B. Only 
amino acids directly implicated in the active site are displayed and labeled in cyan (MAO-A) 
and in green (MAO-B). Compound 2f.III is in green (MAO-A) and magenta (MAO-B). FAD 
is in yellow. The water molecules involved in MAO-B are displayed as red spheres. The 
hydrogen bond discussed in the text is depicted as a dashed blue line. 
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indeno[1,2-c]pyridazin-5-one derivatives substituted both in the 3 and 8-positions by 
lipophilic groups has been synthesized (22m.I, 28a-b.III and 30a-b.III). Compounds display 
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is the most active and selective within this series, and displays a competitive-type inhibition 
with a Ki on MAO-B of 0.11 µM. Replacement of the methyl moiety in the 3-position by a 
lipophilic group like a meta-CF3-phenyl group abolishes the inhibitory potency on MAO-B. 
So, the substitution of the 5H-indeno[1,2-c]pyridazin-5-one core in the 3-position 
dramatically influences the MAO-inhibiting properties of these compounds. Docking 
simulations of compound 30a.III in hMAO-B suggest that the 5H-indeno[1,2-c]pyridazin-5-
one core incorporates into the substrate cavity with the meta-chlorobenzyloxy side chain 
extending towards a hydrophobic pocket of the entrance cavity space (Figure 4.IV).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.IV. Binding mode of compound 30a.III in the active site of hMAO-B (2V5Z.pdb). 
Only amino acids directly implicated in the active site are displayed and labeled (in green). 
Compound 30a.III and FAD are in cyan and yellow respectively. The water molecules in the 
active site are displayed as red spheres.  
 
Besides β-carbolines and 5H-indeno[1,2-c]pyridazin-5-ones, we were also interested in the 
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hMAO-A and –B. The MAO-B inhibition results bring to light that the substitution in the 5-
position of the indole core by a lipophilic group allows to increase appreciably the inhibition 
of MAO-B. The introduction of a benzyloxy group (46.III, Figure 1.IV, Ki hMAO-B = 2.91 
µM) instead of a vinyl pyridin group increases both the inhibitory potency and the selectivity 
on MAO-B. Surprisingly, the 1-methyl-5-benzyloxyindole derivative (47.III, Figure 1.IV, Ki 
hMAO-B = 0.12 µM) displays a significant increase in the selectivity and inhibitory potency 
on MAO-B compared to compound 46.III. Docking simulations of 46.III (Figure 5.IV) 
compared to 2f.III (Ki hMAO-B = 221.6 nM, Figure 3.IV) into the active site of hMAO-B 
suggest that the β-carboline and indole cores incorporate into the substrate cavity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.IV. Binding mode of 46.III in the active site of hMAO-B (2V5Z.pdb). Only amino 
acids directly implicated in the active site are displayed and labeled (in green). Compound 
46.III is in gray. FAD is in yellow. The water molecules involved in MAO-B are displayed as 
red spheres. The hydrogen bond discussed in the text is depicted as a dashed blue line. 
 
The stability of both compounds differs mainly by the π-π interaction with the Gln206 side 
chain and the stabilization of the lateral chain in the entrance cavity. Indeed, the reduction to 
two cycles of the central aromatic linker leads to the loss of the π-π interaction between the 
amide group of the Gln206 side chain and 46.III. The reduction of the cycle and hydrogen 
bond prevents the benzyloxy group to extend in the entrance cavity compared to the -
carboline derivative 2f.III for which the cyclohexyl chain points to a hydrophobic pocket of 
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the entrance cavity where it is stabilized. The beneficial effect of the methyl group on the 
activity on MAO-B is difficult to rationalize since the NH group of corresponding compound 
46.III is supposed to be implicated in a hydrogen bond with a conserved water molecule. 
Definite explanation of the enhanced activity of 47.III versus 46.III could benefit from 
crystal structures of those inhibitors with MAO-B. 
 
Secondly, the involvement through a same metabolic pathway (the serotonergic pathways) for 
MAO-A and IDO, and the similarity in the structural properties of MAO and LSD1 led us to 
the investigation of the -carboline and 5H-indeno[1,2-c]pyridazine-5-one derivatives as 
potential inhibitors of IDO and LSD1.  
The IDO inhibitory potency of β-carbolines and 5H-indeno[1,2-c]pyridazin-5-ones revealed 
that, at 25 µM, the synthesized compounds display no inhibition of IDO. Thus, they are 
selective of MAO. However, 3-butyl--carboline (46.I) is known as inhibitor of IDO (Ki 
hIDO = 3.3 µM, Figure 1.IV). Molecular docking studies of 3-butyl--carboline suggest that 
the β-carboline core is stabilized in the pocket A of IDO by Van der Waals interactions, 
complexation with the heme iron and a hydrogen bond (Figure 6.IV, top). Interestingly, the 
butyl side chain points to the pocket B of IDO lined with hydrophobic residues. This binding 
mode evidences that the substitutions in the 1, 2, 7 and 9-positions are not tolerated because 
of steric clashes within the active site of the enzyme. So, these substitutions lead to a new 
orientation of β-carboline scaffold which is not stabilized into the active site in agreement 
with weak obtained inhibition percentages. From results of synthesized β-carbolines, docking 
studies of 3-butyl-β-carboline (46.I) and the pharmacophore model developed on IDO by 
Rohrig et al, we were interested in the synthesis of two new 3-substituted-β-carbolines (N-
ethyl-3-methylamino-β-carboline (8.III) and 3-methylamino-β-carboline (9.III), Figure 1.IV) 
potentially more potent compared to 3-butyl-β-carboline (46.I). These new derivatives should 
incorporate in the active site of IDO with 3-butyl-β-carboline-like interactions but the side 
chain would display also a positive charge at physiological pH which might establish a 
coulomb interaction with the 7-propionate of the heme present in the pocket B, in agreement 
with docking studies performed (Figure 6.IV, bottom). The synthesis of compounds 8.III and 
9.III was performed in two and four steps, respectively from the ethyl β-carboline-3-
carboxylate (10.III) intermediate in modest yields (22-38% yield). Surprisingly, first results 
on 8.III revealed that it displays no inhibition on IDO at 100 µM. Although it was impossible 
to test the compound 9.III due to a lack of availability of this latter, the absence of inhibition 
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observed for 8.III tends to show that the introduction of a positive charge is not tolerated. The 
result of 8.III must be yet confirmed again but this inactivity maybe explained by a more 
hydrophobic character of the pocket B. So, from the result of 8.III and the pharmacophore 
model developed on IDO by Rohrig et al [126], it can be also interesting to explore the 
possibility to synthesize of new 3-substituted-β-carbolines with a negatively charged group 
such as a carboxylate that can form a salt bridge with Arg231.  
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.IV. Simulated binding mode of 3-butyl--carboline (46.I, top) and N-ethyl-3-
methylamino-β-carboline (8.III, bottom) in the active site of hIDO (2D0T.pdb). Only amino 
acids directly implicated in the active site are displayed and labeled.  
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The LSD1 inhibitory potency of β-carbolines shows that, at 25 µM, the synthesized -
carbolines are weak inhibitors of LSD1 and consequently, are selective of MAO-A. However, 
the introduction of lipophilic and bulky groups allows to increase the inhibitory potency of -
carboline scaffold on LSD1 compared to harmine (3.I, inactive at 50 µM). Furthermore, to 
date, no small, potent and non-irreversible inhibitor of LSD1 is known. Although the -
carboline analogues display moderate activities on LSD1, compound 3.III (IC50 = 31.5 µM, 
Figure 1.IV) could be an interesting scaffold for the design of new more potent and selective 
inhibitors of LSD1. In perspective, it would be interesting to overexpress directly the enzyme 
in the laboratory to monitor the activity of the enzyme in the LSD1 inhibitor screening assay. 
The 5H-indeno[1,2-c]pyridazine-5-ones could be then evaluated on LSD1. The purification of 
the enzyme could be performed and thus, efforts in trying to obtain a crystal structure of 
LSD1 in complex with analogues of compound 3.III could be pursued.  
 
 
NEW PERSPECTIVES 
 
A large number of cancer cells such as glioblastomas (brain cancers), brain metastases, 
melanomas, pancreatic cancers, lung cancers of the NSCLC-type (non-small-cell lung 
cancer), refractory prostate cancers and breast cancers are naturally resistant to apoptosis and 
cannot be treated by the many known drugs and chemotherapeutics. Development of new 
compounds having cytotoxic and/or cytostatic effects in tumour and cancer cells which are 
resistant to apoptosis is of considerable importance. Harmine (3.I) and certain of its 
derivatives exhibit anti-tumour and anti-cancer properties [210-214]. However, previous 
reports demonstrated that harmine and its derivatives caused remarkable acute neurotoxicity 
characterized by tremble, twitch, and jumping in experimental mice model [215]. By 
structural analogy, the novel synthesized β-carboline analogues were assessed for their anti-
tumour and anti-cancer activity by the team of Professor Kiss (ULB, Brussels, Belgium). The 
anti-proliferative effects of the present compounds were evaluated by means of the 
colorimetric MTT assay in several human cancer cell-lines including a) U373, T98G and 
Hs683 glioblastoma cells, and b) OE21 and OE33 oesophageal cancer cells. It was 
unexpectedly found that the compounds had important cytostatic and/or anti-cancer effects. 
Whereas the compounds showed mean anti-proliferative effect on glioma cell lines in the low 
micromolar range, the highly effective compound 5.III (Figure 1.IV) displayed mean anti-
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proliferative effect on the glioma cell lines in the submicromolar range (0.7 µM compared to 
harmine (3.I, 28 µM)). Even more promisingly, it was found that the present compound 
exerted its effect via a non-apoptosis-related mechanism, which makes it particularly good 
candidate as anti-proliferative drugs for treating apoptosis-resistant tumours and cancers, and 
for reducing or overcoming problems linked to known anti-cancer drugs, such as acquisition 
of resistance, non-specific cytotoxicity, etc.    
The promising result leads to the synthesis of novel tri-substituted β-carboline 5.III 
analogues, which was performed in the department of Pharmacy (Prof. Masereel, FUNDP, 
Belgium). The new compounds displayed mean anti-proliferative effects on the glioma cell 
lines in the same range compared to 5.III. Thus, a patent including the results was deposited « 
Beta-carbolines derivatives useful in the treatment of proliferative disorders » 
(PCT/EP2010/059083 and US/61/358,609). 
 
 
Harmine (3.I) is a high affinity inhibitor of the dual specificity tyrosine phosphorylation 
regulated kinase 1A (DYRK1A) protein. The DYRK1A gene is located within the Down 
Syndrome Critical Region (DSCR) on chromosome 21 [216]. DYRK1A is a dual-specificity 
protein kinase that autophosphorylates a conserved tyrosine residue (Tyr321) in the activation 
loop but phosphorylates exogenous substrates only at serine or threonine residues [217]. 
DYRK1A is implicated in the neuronal development and thus depicts a target of first 
importance in certain tumoral pathologies of neurological origin [217-218]. In addition to its 
function in neuronal development, recent evidence has also implicated DYRK1A in the 
pathology of neurodegenerative disorders such as Alzheimer’s disease, dementia with Lewy 
bodies and Parkinson’s disease [216-217]. Harmine (3.I) is a potent and specific inhibitor of 
DYRK1A both in vitro and in cultured cells [217]. In vitro, harmine inhibits DYRK1A 
substrate phosphorylation (IC50 = 33 nM) more potently than it inhibits tyrosine 
autophosphorylation (IC50 = 1.9 µM). Importantly, harmine inhibits the phosphorylation of a 
specific substrate by DYRK1A in cultured cells with a potency similar to that observed in 
vitro (IC50 = 48 nM), without negative effects on the viability of the cells [217].  
Consequently, it would be interesting to design by a rational approach, new DYRK1A 
inhibitors derived from β-carbolines and to characterize  their binding mode with the active 
site following a classical strategy including theoretical (molecular modeling) and 
experimental (synthesis, biological evaluation and crystal assays) approaches to establish 
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structure-activity relationships. As a starting point, we could study the ability of our -
carbolines to inhibit DYRK1A compared to harmine (3.I).  
 
 
Previously, it has been proposed that the use of a molecule which both would be a MAO-B 
inhibitor and an acetyl- and butyrylcholinesterase (AChE and BChE) inhibitor is expected to 
have therapeutic benefit for the treatment of Alzheimer’s disease (AD) [219]. Moreover, a 
series of varied 6-hydroxylated and 6-methoxylated harman and norharman derivatives, 
including the corresponding quaternary N-methyl-carbolinium salts were tested in vitro for 
their ability to inhibit AChE and BChE, respectively [67]. Particularly the carbolinium salts 
(quaternary -carboline, i.e., 2.IV, IC50 AChE = 0.8 µM; IC50 BChE = 1.2 µM, Figure 7.IV), 
which can be formed by intracerebral methylation out of the tertiary--carboline prodrugs, 
show inhibitory activity levels reaching those of the reference drugs (galantamine (IC50 AChE 
= 0.6 µM; IC50 BChE = 8.4 µM), physostigmine (IC50 AChE = 0.5 µM; IC50 BChE = 1.2 µM) 
and rivastigmine (IC50 AChE = 48 µM; IC50 BChE = 54 µM).  
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Figure 7.IV. Chemical structures of -carboline derivatives (1-3.IV). 
 
The activity increase between this class of quaternary compounds with tertiary compounds 
could be well explained by the resemblance of quaternary compounds to the natural substrate 
acetylcholine. Interestingly, there was also no prominent difference in inhibitory activity for 
6-methoxylated (2.IV, IC50 AChE = 0.8 µM; IC50 BChE = 1.2 µM) compared to 6-
hydroxylated compounds (3.IV, IC50 AChE = 1.0 µM; IC50 BChE = 1.6 µM, Figure 7.IV). 
Quaternary harmanium salts showed increased inhibitory activity for 2.IV compared to 1.IV 
(IC50 AChE = 2.2 µM; IC50 BChE = 17.5 µM, Figure 7.IV). 
In contrast to the tertiary compounds, which can penetrate the blood–brain barrier, the 
quaternary compounds show strong levels of inhibitory activity. Therefore tertiary compounds 
might act as pro-drugs for the quaternary -carbolines that are formed in vivo in the brain, 
representing a novel and target-specific approach for the therapy of AD. So, by structural 
1.IV            2.IV              3.IV 
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analogy, it would be interesting to study the ability of our -carbolines including the 
corresponding quaternary N-methyl-carbolinium salts to inhibit AChE and BChE. 
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MATERIALS AND METHODS 
 
 
 
 
 
 
 
 
 
 
 
163 
 
1. CHEMISTRY 
 
1.1 Analytical techniques 
 
X-Ray Diffraction: XRD 
The compounds studied by X-ray crystallography were synthesized in the Bioorganic 
chemistry laboratory (Prof. Vincent, FUNDP, Belgium). All crystals were obtained by slow 
evaporation from an appropriate solution (see experimental details in the section 1.5) at room 
temperature. X-ray intensities were collected at room temperature on a Gemini Ultra R system 
(4-circle kappa platform, Ruby CCD detector) using Mo K radiation ( = 0.71073 Å) or Cu 
K radiation ( = 1.54178 Å). The structures were solved by direct-methods using Sir92 
[220] and refined by full matrix least squares on F
2
 using the program Shelxl97 [221]. All 
non-hydrogen atoms were treated anisotropically while a riding model was applied for the 
hydrogens. The molecular geometry analysis and ORTEP representations were carried out by 
PLATON [222]. For the trifluoromethyl groups which present large thermal displacements, a 
disordered model with the trifluoromethyl group distributed over two sites has been defined. 
The disordered model was constrained to have chemically reasonable geometry, whereas 
restraints on the anisotropic displacement parameters were used for trifluoromethyl group.  
 
Nuclear Magnetic Resonance: NMR 
1
H, 
13
C and 
19
F NMR spectra were obtained from a JEOL JNM EX 400 spectrometer (400 
MHz for 
1
H, 100 MHz for 
13
C and 376 MHz for 
19
F). Chemical shifts are reported in ppm 
from tetramethylsilane (TMS, singulet, δ = 0.0 ppm) for 1H NMR and from the solvent 
(CDCl3, DMSO-d6, CD3OD) for 
13
C NMR as internal standard.
 
NMR spectra are treated with 
the DELTA software. The coupling constants (J) are reported in Hertz. The following 
abbreviations are used: s, singlet; d, doublet; t, triplet; q, quadruplet; m, multiplet; dd, doublet 
of doublet; dt, doublet of triplet; Cq, quaternary carbon.  
 
Mass Spectrometry: MS 
Mass spectra were recorded on an Agilent 1100 series LC/MSD Trap spectrometer equipped 
with a C18-3,5 µm column (ZORBAX SB C18, 100 x 3 mm) and an electron spray ionization 
(ESI) source which was used in positive ion mode (MS+). The pressure of the atomizer was 
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40 psi with a flow of nitrogen of 8 L.min
-1
. The voltage of the capillary was 3.5 kV. The 
scanning MS was performed between 300 and 2200 m/z.  
HPLC method: By analysis, 10 µL of the studied samples are injected at a concentration of 20 
g.mL-1 in acetonitrile. Compounds were separated by means of a gradient (flow of 0.5 
mL.min
-1
) which begins with a mixture of water/acetic acid (0.1%) of 95% and 5% of 
acetonitrile. In 5 min, the percentage of acetonitrile reaches 95% during 3 min and comes 
down again in 5% in 10 seconds during 5 min. Compounds are detected at 254 and 360 nm. 
 
Elemental analyses 
Elemental analyses (C, H, N) were performed on a Thermo Finnigan Flash EA 1112 
elemental analyzer. 
 
Melting point 
Melting points were determined with a Totolli-Buchi melting point B-545 apparatus.  
 
Thin-Layer Chromatography (TLC) 
Analytical thin-layer chromatography (TLC) was performed on Merck silica gel 60 F254 
plates. Compounds were visualized by UV illumination at 254 nm. 
 
Reverse Phase High Performance Liquid Chromatography: RP-HPLC (analytical 
chromatography) 
To study the purity of synthesized -carboline derivatives (2a.III-5.III), RP-HPLC analyses 
were performed on a Varian 940-LC apparatus equipped with a C18-10 µm column 
(OmniSpher C18, 250 x 4.6 mm) and a Varian 380-LC detector. By analysis, 10 µL of the 
studied samples in methanol are injected. Compounds were analyzed during 8 min by means 
of an isocratic elution of 20% in water and 80% in methanol (flow of 1.0 mL.min
-1
). 
Compounds are detected at 254 nm. 
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1.2 Purification techniques 
 
Column chromatography 
Column chromatographies were performed on Merck silica gel 60 (40–63 µm). 
Chromatography eluents are expressed in terms of volume fractions (v/v). 
 
Reverse Phase High Performance Liquid Chromatography: RP-HPLC (Semi-
preparative chromatography) 
To purify the synthesized N-ethyl-3-methylamino-β-carboline (8.III), RP-HPLC analyses 
were performed on a Waters 2487 Dual  Absorbance Detector equipped with a C18-10 µm 
column (OmniSpher C18, 250 x 21.4 mm). By analysis, 2.5 mL of the crude product (100 
mg) in methanol (0.1% trifluoroacetic acid (TFA)) are injected. Compound was separated by 
means of a gradient (flow of 10 mL.min
-1
) which begins with a mixture water/TFA (0.1%) of 
85% and 15% of a methanol/TFA (0.1%) solution during 10 min. In 5 min, the percentage of 
methanol/TFA (0.1%) reaches 30% during 15 min. In 10 min, the percentage of 
methanol/TFA (0.1%) reaches 50% during 10 min. Finally, in 5 min, the percentage of 
methanol/TFA (0.1%) reaches 98% during 5 min. Compounds are detected at 254 nm. 
 
 
1.3 Solvents and reagents 
 
Anhydrous solvents are distilled under argon atmosphere. The dry solvents are 
obtained by the standard procedures described below; 
 
-  Tetrahydrofurane (THF) is distilled on sodium and benzophenone. 
-  Dichloromethane (DCM) is distilled on calcium hydride (CaH2). 
-  Dimethylformamide (DMF) is keeped on molecular sieve 4 Å. 
-  Diethyl ether is distilled on sodium and benzophenone. 
 
All reagents were purchased from Sigma–Aldrich, Acros Organics and Fluorochem Co. 
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1.4 Synthesis 
 
Notes. For the synthesis of compounds 2e.III and 25a.III, 4,4,4-trifluoro-1-butanol is first 
transformed to 1-tosyl-4,4,4-trifluorobutane [7]. To a solution of 4,4,4-trifluoro-1-butanol 
(2.000 g, 15.61 mmol) in 20 mL of anhydrous dichloromethane, 2.360 g of triethylamine 
(23.32 mmol), 2.976 g of p-toluenesulfonyl chloride (15.61 mmol) and 0.010 g of 4-
(dimethylamino)pyridine (0.08 mmol) are added. The mixture is stirred for 4 h under argon 
atmosphere. The crude is washed twice with water (10 mL) and once with hydrochloric acid 
(HCl 10%, 10 mL). The organic layer is concentrated under reduced pressure and the crude 
product was used without further purification for the following steps. 
Yield: 83% 
Physical and spectral characteristics: 
 
 Chemical Formula  C11H13F3O3S  
S
O
O
O
F3C  
 
 M.W. (g/mol)  282.28 
 Aspect Colorless liquid 
 TLC (DCM/EtOH: 8/2)  Rf = 0.92 
 
1
H NMR (400 MHz, CDCl3) (ppm): 1.89-1.93 (m, 2H, CF3-CH2-CH2), 2.10-2.20 
(m, 2H, CF3-CH2), 2.45 (s, 3H, Ph-CH3), 4.08 (t, J = 6.1 Hz, 2H, SO3-CH2), 7.35 (d, J = 8.5 
Hz, 2H, ArH), 7.78 (d, J = 8.2 Hz, 2H, ArH). 
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1.4.1. Synthesis of -carbolines 
 
a) Synthesis of harmol hydrobromide dihydrate (1.III) 
Hydrobromic acid 47% aqueous (100 mL) was added to a solution of harmine (5.000 g, 23.35 
mmol) in glacial acetic acid (100 mL). The solution was heated to reflux for 15 h and then 
allowed to cool to room temperature. The mixture was diluted in water (1000 mL), 
concentrated under reduced pressure and was used without further purification for the 
following steps. The molecular structure of compound 1.III was determined by X-ray 
crystallographic analysis (details are reported in section 1.5). 
Yield: 100% 
Physical and spectral characteristics: 
 
 Chemical Formula  C12H15BrN2O3  
N
H
N
HO HBr.2H2O
 
 
 M.W. (g/mol)  315.16 
 Aspect White solid 
 TLC (DCM/EtOH: 8/2)  Rf = 0.35 
 
1
H NMR (400 MHz, DMSO-d6) (ppm): 2.92 (s, 3H, CH3), 6.88 (dd, J6-5 = 8.7 Hz, 
J6-8 = 2.1 Hz, 1H, H-6), 6.99 (d, J8-6 = 2.1 Hz, 1H, H-8), 8.23 (d, J5-6 = 8.7 Hz, 1H, H-5), 8.33  
(d, J3-4 = 6.4 Hz, 1H, H-3), 8.37  (d, J4-3 = 6.2 Hz, 1H, H-4), 10.43 (s, 1H, O-H), 12.45 (s, 1H, 
N-H). 
13
C NMR (100 MHz, DMSO-d6)  (ppm): 16.30 (CH3), 96.95 (C-8), 113.18 (Cq), 
113.31 (C-6), 114.04 (C-4), 125.10 (C-5), 128.96 (C-3), 132.79 (Cq), 133.93 (Cq), 136.78 
(Cq), 146.13 (Cq), 161.75 (Cq).  
MS: [M + H]
+ 
199.1 m/z 
Mp: 247.9°C 
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b) General procedure for the synthesis of 7-alkoxy-1-methyl-β-carbolines (2a-o.III) 
The 7-alkoxy-1-methyl-β-carbolines (2a-o.III) were synthesized according to a previously 
reported procedure [193]. The appropriate alkyl halide (by portion) or 1-tosyl-4,4,4-
trifluorobutane (for compound 2e.III) and cesium carbonate were added to harmol (1.III) 
dissolved in anhydrous dimethylformamide (DMF). Then, the reaction mixture was stirred at 
room temperature or heated for several hours. At the end of the reaction, the mixture was 
cooled and diluted with dichloromethane, washed once with water and three times with brine. 
The organic layer was dried over MgSO4 and concentrated. The crude product was purified by 
liquid chromatography.    
 
7-(Allyloxy)-1-methyl-β-carboline (2a.III) 
The title compound was prepared from a solution of harmol (0.250 g, 0.80 mmol), cesium 
carbonate (0.804 g, 2.47 mmol) and 3-bromo-1-propene (0.119 g, 0.98 mmol) in 5 mL of 
DMF. The reaction mixture was stirred at room temperature for 24 h. The crude product was 
purified by column chromatography (dichloromethane/ethanol 95: 5% v/v). 
Yield: 75% 
Physical and spectral characteristics:  
 
 Chemical Formula   C15H14N2O  
N
H
NO
 
 
 M.W. (g/mol)  238.28 
 Aspect   White solid 
 TLC (DCM/EtOH: 8/2)   Rf = 0.63 
 
1
H NMR (400 MHz, CDCl3) (ppm): 2.79 (s, 3H, CH3), 4.63 (dt, J = 1.4 Hz, J = 5.3 
Hz, 2H, O-CH2), 5.30-5.34 (m, 1H, O-CH2CH=CH2), 5.43-5.48 (m, 1H, O-CH2CH=CH2), 
6.05-6.15 (m, 1H, O-CH2CH), 6.92 (dd, J6-5 = 8.7 Hz, J6-8 = 2.3 Hz, 1H, H-6), 6.97 (d, J8-6 = 
2.1 Hz, 1H, H-8), 7.71 (d, J4-3 = 5.5 Hz, 1H, H-4), 7.96 (d, J5-6 = 8.7 Hz, 1H, H-5), 8.31 (d,    
J3-4= 5.5 Hz, 1H, H-3), 8.39 (s, 1H, N-H). 
13
C NMR (100 MHz, CDCl3)  (ppm): 20.23 (CH3), 69.31 (O-CH2), 95.93 (C-8), 
110.34 (C-6), 112.36 (C-4), 116.05 (Cq), 118.05 (O-CH2CH=CH2), 122.79 (C-5), 128.77 (Cq), 
133.14 (O-CH2CH), 134.72 (Cq), 138.81 (C-3), 141.00 (Cq), 141.72 (Cq), 159.87 (Cq). 
MS: [M + H]
+ 
239.1 m/z 
Mp: 173.9°C 
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Anal. calcd for C15H14N2O+½H2O: C, 72.85%; H, 6.11%; N, 11.33%  
Found: C, 73.76%; H, 5.82%; N, 11.14% 
Purity by HPLC: 99% 
 
 
7-(Isobutyloxy)-1-methyl-β-carboline (2b.III) 
The title compound was prepared from a solution of harmol (0.307 g, 0.98 mmol), cesium 
carbonate (1.764 g, 5.41 mmol) and 1-bromo-2-methylpropane (0.283 g, 2.06 mmol) in 6 mL 
of DMF. The reaction mixture was heated at 60°C for 24 h. The crude product was purified 
by column chromatography (dichloromethane/ethanol 95: 5% v/v). 
Yield: 87% 
Physical and spectral characteristics: 
 
 Chemical Formula   C16H18N2O  
N
H
NO
 
 
 M.W. (g/mol)  254.33 
 Aspect   White solid 
 TLC (DCM/EtOH: 8/2)   Rf = 0.65 
 
1
H NMR (400 MHz, CDCl3) (ppm): 1.02 (d, J = 6.9 Hz, 6H, CH-(CH3)2), 2.05-2.15 
(m, 1H, CH-(CH3)2), 2.78 (s, 3H, CH3), 3.74 (d, J = 6.4 Hz, 2H, O-CH2), 6.88-6.90 (m, 2H, 
H-8 + H-6), 7.74 (d, J4-3 = 5.3 Hz, 1H, H-4), 7.95 (d, J5-6 = 9.4 Hz, 1H, H-5), 8.34 (d, J3-4 = 5.3 
Hz, 1H, H-3), 10.05 (s, 1H, N-H).  
13
C NMR (100 MHz, CDCl3)  (ppm): 19.39 (CH-(CH3)2), 20.25 (CH3), 28.40 (CH-
(CH3)2), 74.87 (O-CH2), 95.51 (C-8), 110.26 (C-6), 112.37 (C-4), 115.65 (Cq), 122.65 (C-5), 
128.86 (Cq), 134.93 (Cq), 138.47 (C-3), 141.09 (Cq), 142.15 (Cq), 160.58 (Cq). 
MS: [M + H]
+
 255.1 m/z  
Mp: 202.9°C 
Anal. calcd for C16H18N2O: C, 75.56%; H, 7.13%; N, 11.01%  
Found: C, 75.54%; H, 7.19%; N, 10.75%  
Purity by HPLC: 98% 
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7-(2-Methoxyethoxy)-1-methyl-β-carboline (2c.III) 
The title compound was prepared from a solution of harmol (0.258 g, 0.82 mmol), cesium 
carbonate (1.135 g, 3.48 mmol) and 2-chloroethyl methyl ether (0.140 g, 1.48 mmol) in 5 mL 
of DMF. The reaction mixture was heated at 60°C for 24 h. The crude product was purified 
by column chromatography (dichloromethane/ethanol 95: 5% v/v). 
Yield: 70% 
Physical and spectral characteristics: 
 
 Chemical Formula  C15H16N2O2  
N
H
NO
O
 
 
 M.W. (g/mol)  256.30 
 Aspect  Brown solid 
 TLC (DCM/EtOH: 8/2)   Rf = 0.55 
 
1
H NMR (400 MHz, CDCl3)  (ppm): 2.82 (s, 3H, CH3), 3.45 (s, 3H, O-CH3), 3.76 (t, 
J = 4.6 Hz , 2H, CH2), 4.15 (t, J = 4.6 Hz , 2H, CH2), 6.91 (dd, J6-8 = 1.8 Hz, J6-5 = 8.7 Hz, 1H, 
H-6), 7.00 (d, J8-6 = 1.4 Hz, 1H, H-8), 7.73 (d, J4-3 = 5.5 Hz, 1H, H-4), 7.93 (d, J5-6 = 8.7 Hz, 
1H, H-5), 8.26 (d, J3-4 = 5.3 Hz, 1H, H-3), 9.78 (s, 1H, N-H). 
13
C NMR (100 MHz, CDCl3)  (ppm): 19.66 (CH3), 59.34 (O-CH3), 67.72 (-CH2-), 
71.06 (-CH2-), 95.75 (C-8), 110.68 (C-6), 112.54 (C-4), 115.72 (Cq), 122.80 (C-5), 129.32 
(Cq), 134.88 (Cq), 137.00 (C-3), 140.56 (Cq), 142.59 (Cq), 160.37 (Cq). 
MS: [M + H ]
+
 257.1 m/z  
Mp: 175.8°C 
Anal. calcd for C15H16N2O2+½H2O: C, 67.91%; H, 6.46%; N, 10.56%  
Found: C, 67.85%; H, 6.31%; N, 10.48%   
Purity by HPLC: 99% 
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7-(2-Hydroxyethyloxy)-1-methyl-β-carboline (2d.III) 
The title compound was prepared from a solution of harmol (0.845 g, 2.69 mmol), cesium 
carbonate (3.070 g, 9.42 mmol) and 2-chloroethanol (0.600 g, 7.46 mmol) in 8 mL of DMF. 
The reaction mixture was refluxed for 15 h. The crude product was purified by column 
chromatography (toluene/ethanol 80: 20% v/v). 
Yield: 58% 
Physical and spectral characteristics: 
 
 Chemical Formula   C14H14N2O2  
N
H
N
O
HO
 
 
 M.W. (g/mol)   242.27 
 Aspect   Brown solid 
 TLC (DCM/EtOH: 8/2)   Rf = 0.33 
 
1
H NMR (400 MHz, DMSO-d6)  (ppm): 2.68 (s, 3H, CH3), 3.75 (dt, J = 4.6 Hz, J = 
5.1 Hz, 2H, CH2-OH), 4.06 (t, J = 4.6 Hz, 2H, O-CH2), 4.89 (t, J = 5.1 Hz, 1H, CH2-OH), 
6.81 (dd, J6-5 = 8.7 Hz, J6-8 = 2.1 Hz, 1H, H-6), 6.97 (d, J8-6 = 2.1 Hz, 1H, H-8), 7.77 (d, J4-3= 
5.3 Hz, 1H, H-4), 8.01 (d, J5-6 = 8.7 Hz, 1H, H-5), 8.11 (d, J3-4= 5.3 Hz, 1H, H-3), 11.37 (s, 
1H, N-H).  
13
C NMR (100 MHz, DMSO-d6)  (ppm): 18.16 (CH3), 60.06 (CH2-OH), 70.58 (O-
CH2), 95.62 (C-8), 112.01 (C-6), 113.78 (C-4), 114.64 (Cq), 124.42 (C-5), 130.81 (Cq), 
132.81 (C-3), 134.56 (Cq), 139.32 (Cq), 144.57 (Cq), 161.69 (Cq).  
MS: [M + H]
+
 243.0 m/z  
Mp: 264.4°C 
Anal. calcd for C14H14N2O2: C, 69.41%; H, 5.82%; N, 11.56% 
Found: C, 68.70%; H, 5.59%; N, 10.77%   
Purity by HPLC: 97% 
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7-(4,4,4-Trifluorobutoxy)-1-methyl-β-carboline (2e.III) 
The title compound was prepared from a solution of harmol (0.100 g, 0.32 mmol), cesium 
carbonate (0.330 g, 1.01 mmol) and 1-tosyl-4,4,4-trifluorobutane (0.150 g, 0.53 mmol) in 7 
mL of DMF. The reaction mixture was heated at 90°C for 7 h. The crude product was purified 
by column chromatography (dichloromethane/ethanol 90: 10% v/v). 
Yield: 72% 
Physical and spectral characteristics: 
 
 Chemical Formula   C16H15F3N2O  
N
H
NO
F3C
 
 
 M.W. (g/mol)   308.30 
 Aspect   White solid 
 TLC (DCM/EtOH: 8/2)  Rf = 0.67 
   
1
H NMR (400 MHz, DMSO-d6)  (ppm): 1.94-2.01 (m, 2H, CF3-CH2-CH2), 2.39-
2.52 (m, 2H, CF3-CH2, overlap with DMSO), 2.68 (s, 3H, CH3), 4.12 (t, J = 6.2 Hz, 2H, O-
CH2), 6.82 (dd, J6-5 = 8.7 Hz, J6-8 = 2.1 Hz, 1H, H-6), 6.97 (d, J8-6 = 2.1 Hz, 1H, H-8), 7.77 (d, 
J4-3 = 5.3 Hz, 1H, H-4), 8.02 (d, J5-6 = 8.7 Hz, 1H, H-5), 8.11 (d, J3-4= 5.3 Hz, 1H, H-3), 11.38 
(s, 1H, N-H).   
13
C NMR (100 MHz, DMSO-d6)  (ppm): 20.88 (CH3), 22.25 (d, J = 2.9 Hz, CF3-
CH2-CH2), 30.13 (q, J = 27.8 Hz, CF3-CH2), 66.55 (O-CH2), 95.88 (C-8), 109.85 (C-6), 
112.49 (C-4), 115.56 (Cq), 123.21 (C-5), 127.69 (Cq), 135.06 (Cq), 138.29 (C-3), 141.83 (Cq), 
142.36 (Cq), 159.59 (Cq). 
19
F NMR (376 MHz, DMSO-d6)  (ppm): -64.67 (t, J = 11.5 Hz). 
MS: [M + H]
+
 309.1 m/z  
Mp: 284.3°C 
Anal. calcd for C16H15F3N2O: C, 62.33%; H, 4.90%; N, 9.09%  
Found: C, 62.68%; H, 4.75%; N, 9.09% 
Purity by HPLC: 98% 
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7-(Cyclohexylmethoxy)-1-methyl-β-carboline (2f.III) 
The title compound was prepared from a solution of harmol (0.200 g, 0.64 mmol), cesium 
carbonate (0.911 g, 2.80 mmol) and (bromomethyl)cyclohexane (0.286 g, 1.61 mmol) in 5 mL 
of DMF. The reaction mixture was stirred at room temperature for 30 h. The crude product 
was purified by column chromatography (dichloromethane/ethanol 95: 5% v/v).  
Yield: 85% 
Physical and spectral characteristics: 
 
 Chemical Formula  C19H22N2O  
N
H
NO
 
 
 M.W. (g/mol)  294.39 
 Aspect  White solid 
 TLC (DCM/EtOH: 8/2)  Rf = 0.65 
 
1
H NMR (400 MHz, CDCl3)  (ppm): 1.03-1.37 (m, 5H, CH (cyclohexyl)), 1.70-1.92 
(m, 6H, CH (cyclohexyl)), 2.79 (s, 3H, CH3), 3.84 (d, J = 6.2 Hz, 2H, O-CH2), 6.89 (dd, J6-8  
= 2.1 Hz, J6-5 = 8.7 Hz , 1H, H-6), 6.93 (d, J8-6 = 2.1 Hz, 1H, H-8), 7.70 (d, J4-3 = 5.3 Hz, 1H, 
H-4), 7.94 (d, J5-6 = 8.7 Hz, 1H, H-5), 8.19 (s, 1H, N-H), 8.31 (d, J3-4 = 5.5 Hz, 1H, H-3). 
13
C NMR (100 MHz, CDCl3)  (ppm): 20.36 (CH3), 25.91 (CH (cyclohexyl)), 
26.61(CH (cyclohexyl)), 30.04 (CH (cyclohexyl)), 37.79 (CH (cyclohexyl)), 73.99 (O-CH2), 
95.44 (C-8), 110.29 (C-6), 112.27 (C-4), 115.72 (Cq), 122.68 (C-5), 128.73 (Cq), 134.63 (Cq), 
139.12 (C-3), 140.98 (Cq), 141.67 (Cq), 160.61 (Cq). 
MS: [M + H]
+
 295.2 m/z  
Mp: 231.8°C 
Anal. calcd for C19H22N2O: C, 77.52%; H, 7.53%; N, 9.52%   
Found: C, 76.59%; H, 7.03%; N, 8.87%   
Purity by HPLC: 97% 
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7-(Benzyloxy)-1-methyl-β-carboline (2g.III) 
The title compound was prepared from a solution of harmol (0.500 g, 1.59 mmol), cesium 
carbonate (1.410 g, 4.33 mmol) and 1-bromomethylbenzene (0.432 g, 2.53 mmol) in 10 mL 
of DMF. The reaction mixture was stirred at room temperature for 5 h. The crude product was 
purified by column chromatography (dichloromethane/ethanol 95: 5% v/v).  
Yield:   70% 
Physical and spectral characteristics: 
 
 Chemical Formula   C19H16N2O  
N
H
NO
 
 
 M.W. (g/mol)  288.34 
 Aspect  White solid 
 TLC (DCM/EtOH: 8/2)  Rf = 0.69 
 
1
H NMR (400 MHz, CDCl3) (ppm): 2.78 (s, 3H, CH3), 5.17 (s, 2H, O-CH2), 6.98 
(dd, J6-5 = 8.7 Hz, J6-8 = 2.3 Hz, 1H, H-6), 7.01 (d, J8-6 = 2.1 Hz, 1H, H-8), 7.32-7.47 (m, 5H, 
ArH), 7.71 (d, J4-3 = 5.5 Hz, 1H, H-4), 7.97 (d, J5-6 = 8.5 Hz, 1H, H-5), 8.28 (s, 1H, N-H), 8.32 
(d, J3-4 = 5.3 Hz, 1H, H-3). 
13
C NMR (100 MHz, CDCl3)  (ppm): 20.31 (CH3), 70.50 (O-CH2), 96.11 (C-8), 
110.39 (C-6), 112.34 (C-4), 116.16 (Cq), 122.82 (C-5), 127.56 (C-ArH), 128.18 (C-ArH), 
128.64 (Cq), 128.77 (C-ArH), 134.74 (Cq), 136.84 (Cq), 139.06 (C-3), 141.12 (Cq), 141.60 
(Cq), 159.96 (Cq). 
MS: [M + H]
+
 289.1 m/z  
Mp: 212.3°C 
Anal. calcd for C19H16N2O: C, 79.14%; H, 5.59%; N, 9.72%   
Found: C, 78.99%; H, 5.60%; N, 9.60%   
Purity by HPLC: 99% 
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7-(Phenethoxy)-1-methyl-β-carboline (2h.III) 
The title compound was prepared from a solution of harmol (0.280 g, 0.89 mmol), cesium 
carbonate (3.010 g, 9.24 mmol) and (2-chloroethyl)benzene (0.363 g, 2.58 mmol) in 5 mL of 
DMF. The reaction mixture was refluxed for 30 h. The crude product was purified by column 
chromatography (dichloromethane/ethanol 95: 5% v/v). 
Yield: 72% 
Physical and spectral characteristics: 
 
 Chemical Formula  C20H18N2O  
N
H
NO
 
 
 M.W. (g/mol)  302.37 
 Aspect  White solid 
 TLC (DCM/EtOH: 8/2)  Rf = 0.67 
 
1
H NMR (400 MHz, CDCl3) (ppm): 2.78 (s, 3H, CH3), 3.14 (t, J = 7.1 Hz, 2H, O-
CH2-CH2), 4.24 (t, J = 7.1 Hz, 2H, O-CH2), 6.89 (dd, 1H, J6-5 = 8.7 Hz, J6-8 = 2.3 Hz, H-6), 
6.93 (d, J8-6 = 2.1 Hz, 1H, H-8), 7.22-7.34 (m, 5H, ArH), 7.71 (d, J4-3 = 5.3 Hz, 1H, H-4), 7.94 
(d, J5-6 = 8.5 Hz, 1H, H-5), 8.30 (d, J3-4 = 5.5 Hz, 1H, H-3), 8.89 (s, 1H, N-H). 
13
C NMR (100 MHz, CDCl3)  (ppm): 20.16 (CH3), 35.85 (CH2), 69.16 (O-CH2), 
95.64 (C-8), 110.27 (C-6), 112.37 (C-4), 115.89 (Cq), 122.78 (C-5), 126.68 (C-ArH), 128.63 
(C-ArH), 128.84 (Cq), 129.12 (C-ArH), 134.80 (Cq), 138.20 (Cq), 138.52 (C-3), 140.98 (Cq), 
141.94 (Cq), 160.12 (Cq). 
MS: [M + H]
+
 303.1 m/z  
Mp: 139.7°C 
Anal. calcd for C20H18N2O: C, 79.44%; H, 6.00%; N, 9.26%  
Found: C, 78.33%; H, 5.94%; N, 8.88%   
Purity by HPLC: 99% 
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7-(Pyridin-2-ylmethoxy)-1-methyl-β-carboline (2i.III) 
The title compound was prepared from a solution of harmol (0.362 g, 1.15 mmol), cesium 
carbonate (1.771 g, 5.44 mmol) and 2-(bromomethyl)pyridine hydrobromide (0.363 g, 1.43 
mmol) in 7 mL of DMF. The reaction mixture was stirred at room temperature for 24 h. The 
crude product was purified by column chromatography (dichloromethane/ethanol 90: 10% 
v/v). 
Yield: 90% 
Physical and spectral characteristics: 
 
 Chemical Formula   C18H15N3O  
N
H
NO
N
 
 
 M.W. (g/mol)  289.33 
 Aspect  White solid 
 TLC (DCM/EtOH: 8/2)   Rf = 0.56 
 
1
H NMR (400 MHz, CDCl3)  (ppm): 2.76 (s, 3H, CH3), 5.29 (s, 2H, O-CH2), 6.97-
7.00 (m, 2H, H-6 + H-8), 7.23 (dd, J = 5.5 Hz, J = 7.1 Hz, 1H, ArH), 7.55 (d, J = 8.0 Hz, 1H, 
ArH), 7.69-7.73 (m, 2H, H-4 + ArH), 7.97 (d, J5-6 = 9.2 Hz, 1H, H-5), 8.31 (d, J3-4 = 5.5 Hz, 
1H, H-3), 8.59 (d, J = 4.8 Hz, 1H, ArH), 8.94 (s, 1H, N-H). 
13
C NMR (100 MHz, CDCl3)  (ppm): 20.33 (CH3), 71.01 (O-CH2), 96.01 (C-8), 
110.36 (C-6), 112.36 (C-4), 116.26 (Cq), 121.56 (C-ArH), 122.87 (C-ArH), 122.90 (C-5), 
128.58 (Cq), 134.88 (Cq), 137.09 (C-ArH), 138.83 (C-3), 141.24 (Cq), 141.74 (Cq), 149.29 (C-
ArH), 157.12 (Cq), 159.46 (Cq). 
MS: [M + H]
+
 290.1 m/z  
Mp: 187.5°C 
Anal. calcd for C18H15N3O: C, 74.72%; H, 5.23%; N, 14.52%   
Found: C, 74.23%; H, 5.23%; N, 14.22%   
Purity by HPLC: 99% 
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7-(Pyridin-3-ylmethoxy)-1-methyl-β-carboline (2j.III) 
The title compound was prepared from a solution of harmol (0.355 g, 1.13 mmol), cesium 
carbonate (1.550 g, 4.76 mmol) and 3-(bromomethyl)pyridine hydrobromide (0.342 g, 1.35 
mmol) in 7 mL of DMF. The reaction mixture was stirred at room temperature for 24 h. The 
crude product was purified by column chromatography (dichloromethane/ethanol 90: 10% 
v/v). 
Yield: 91% 
Physical and spectral characteristics: 
 
 Chemical Formula   C18H15N3O  
N
H
NO
N
 
 
 M.W. (g/mol)  289.33 
 Aspect  Brown solid 
 TLC (DCM/EtOH: 8/2)   Rf = 0.44 
 
1
H NMR (400 MHz, CDCl3)  (ppm): 2.78 (s, 3H, CH3), 5.15 (s, 2H, O-CH2), 6.96 
(dd, J6-5 = 8.7 Hz, J6-8 = 2.1 Hz, 1H, H-6), 6.99 (d, J8-6 = 2.1 Hz, 1H, H-8), 7.33 (dd, J = 4.8 
Hz, J = 7.8 Hz, 1H, ArH), 7.73 (d, 1H, J4-3 = 5.5 Hz, 1H, H-4), 7.80 (dt, J = 1.8 Hz, J = 8.0 Hz, 
1H, ArH), 7.99 (d, J5-6 = 8.7 Hz, 1H, H-5), 8.32 (d, J3-4 = 5.3 Hz, 1H, H-3), 8.59 (dd, J = 1.4 
Hz, J = 4.6 Hz, 1H, ArH), 8.71 (d, J = 1.6 Hz, 1H, ArH), 9.22 (s, 1H, N-H). 
13
C NMR (100 MHz, CDCl3)  (ppm): 20.29 (CH3), 68.00 (O-CH2), 96.25 (C-8), 
110.08 (C-6), 112.41 (C-4), 116.47 (Cq), 122.96 (C-5), 123.74 (C-ArH), 128.61 (Cq), 132.53 
(Cq), 134.96 (Cq), 135.49 (C-ArH), 138.78 (C-3), 141.28 (Cq), 141.81 (Cq), 149.02 (C-ArH), 
149.56 (C-ArH), 159.47 (Cq). 
MS: [M + H]
+
 290.1 m/z  
Mp: 226.6°C 
Anal. calcd for C18H15N3O+½H2O: C, 72.47%; H, 5.41%; N, 14.08%   
Found: C, 72.66%; H, 5.32%; N, 14.01%   
Purity by HPLC: 99% 
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7-(Pyridin-4-ylmethoxy)-1-methyl-β-carboline (2k.III) 
The title compound was prepared from a solution of harmol (0.355 g, 1.13 mmol), cesium 
carbonate (1.695 g, 5.20 mmol) and 4-(bromomethyl)pyridine hydrobromide (0.378 g, 1.49 
mmol) in 7 mL of DMF. The reaction mixture was stirred at room temperature for 24 h. The 
crude product was purified by column chromatography (dichloromethane/ethanol 90: 10% 
v/v). 
Yield: 62% 
Physical and spectral characteristics: 
 
 Chemical Formula   C18H15N3O  
N
H
NON
 
 
 M.W. (g/mol)  289.33 
 Aspect  Brown solid 
 TLC (DCM/EtOH: 8/2)   Rf = 0.39 
   
1
H NMR (400 MHz, CDCl3) (ppm): 2.77 (s, 3H, CH3), 5.20 (s, 2H, O-CH2), 6.95-
6.99 (m, 2H, H-6 + H-8), 7.39 (d, J = 5.5 Hz, 2H, ArH), 7.72 (d, J4-3 = 5.3 Hz, 1H, H-4), 8.00 
(d, J5-6 = 9.2 Hz, 1H, H-5), 8.32 (d, J3-4 = 5.5 Hz, 1H, H-3), 8.48 (s, 1H, N-H), 8.62 (d, J = 5.7 
Hz, 2H, ArH).  
13
C NMR (100 MHz, CDCl3)  (ppm): 20.34 (CH3), 68.65 (O-CH2), 96.21 (C-8), 
110.05 (C-6), 112.39 (C-4), 116.60 (Cq), 121.58 (C-ArH), 123.04 (C-5), 128.49 (Cq), 134.82 
(Cq), 139.16 (C-3), 141.28 (Cq), 141.51 (Cq), 146.19 (Cq), 150.14 (C-ArH), 159.24 (Cq). 
MS: [M + H]
+
 290.1 m/z  
Mp: 232.5°C 
Anal. calcd for C18H15N3O+½H2O: C, 72.47%; H, 5.41%; N, 14.08%   
Found: C, 72.05%; H, 5.34%; N, 14.11%  
Purity by HPLC: 99% 
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7-(Naphthalen-2-ylmethoxy)-1-methyl-β-carboline (2l.III) 
The title compound was prepared from a solution of harmol (0.500 g, 1.59 mmol), cesium 
carbonate (1.555 g, 4.77 mmol) and 2-(bromomethyl)naphthalene (0.540 g, 2.44 mmol)  in 10 
mL of DMF. The reaction mixture was stirred at room temperature for 6 h. The crude product 
was purified by column chromatography (dichloromethane/ethanol 95: 5% v/v). 
Yield: 82% 
Physical and spectral characteristics: 
 
 Chemical Formula  C23H18N2O  
N
H
NO
 
 
 M.W. (g/mol)   338.40 
 Aspect  White solid 
 TLC (DCM/EtOH: 8/2)  Rf = 0.70 
 
1
H NMR (400 MHz, DMSO-d6) (ppm): 2.67 (s, 3H, CH3), 5.38 (s, 2H, O-CH2), 
6.94 (dd, J6-8  = 2.1 Hz, J6-5 = 8.5 Hz , 1H, H-6), 7.09 (d, J8-6 = 2.3 Hz, 1H, H-8), 7.47-7.53 (m, 
2H, ArH), 7.61 (dd, J = 1.6 Hz, J = 8.5 Hz, 1H, ArH), 7.77 (d, J4-3 = 5.3 Hz, 1H, H-4), 7.89-
7.95 (m, 3H, ArH), 8.01 (s, 1H, ArH), 8.04 (d, J5-6 = 8.7 Hz, 1H, H-5), 8.11 (d, J3-4 = 5.3 Hz, 
1H, H-3), 11.38 (s, 1H, N-H). 
13
C NMR (100 MHz, DMSO-d6)  (ppm): 20.86 (CH3), 70.19 (O-CH2), 96.49 (C-8), 
110.24 (C-6), 112.49 (C-4), 115.61 (Cq), 123.22 (C-5), 126.18 (C-ArH), 126.68 (C-ArH), 
126.72 (C-ArH), 126.90 (C-ArH), 127.67 (Cq), 128.17 (C-ArH), 128.33 (C-ArH), 128.66 (C-
ArH), 133.09 (Cq), 133.35 (Cq), 135.10 (Cq), 135.33 (Cq), 138.29 (C-3), 141.85 (Cq), 142.30 
(Cq), 159.60 (Cq).   
MS: [M + H]
+
 339.2 m/z  
Mp: 238.6°C 
Anal. calcd for C23H18N2O: C, 81.63%; H, 5.36%; N, 8.28%  
Found: C, 81.50%; H, 5.29%; N, 7.99%   
Purity by HPLC: 99% 
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7-(N,N-dimethylaminoethyloxy)-1-methyl-β-carboline (2m.III)  
The title compound was prepared from a solution of harmol (0.440 g, 1.40 mmol), cesium 
carbonate (2.060 g, 6.32 mmol) and 2-chloro-N,N-dimethylethylamine hydrochloride (0.330 
g, 2.29 mmol) in 10 mL of DMF. The reaction mixture was heated at 110°C for 7 h. The 
crude product was purified by column chromatography 
(dichloromethane/ethanol/triethylamine 78: 20: 2% v/v/v). Finally, the final product is diluted 
with dichloromethane (10 mL), washed once with water (5 mL) to eliminate the 
triethylammonium salt. The organic layer was dried over MgSO4 and concentrated.  
Yield: 44% 
Physical and spectral characteristics: 
 
 Chemical Formula  C16H19N3O   
N
H
NO
N
 
 
 M.W. (g/mol)  269.34 
 Aspect  Brown solid 
 TLC (DCM/EtOH/NEt3:  
8/2/0.2)   
Rf = 0.26  
 
1
H NMR (400 MHz, CDCl3) (ppm): 2.35 (s, 6H, 2CH3), 2.77 (t, J = 5.7 Hz, 2H, O-
CH2-CH2), 2.78 (s, 3H, CH3), 4.12 (t, J = 5.7 Hz, 2H, O-CH2), 6.90 (dd, J6-5 = 8.5 Hz, J6-8 = 
2.1 Hz, 1H, H-6), 6.94 (d, J8-6 = 2.1 Hz, 1H, H-8), 7.71 (d, J4-3= 5.5 Hz, 1H, H-4), 7.94 (d, J5-6 
= 8.7 Hz, 1H, H-5), 8.31 (d, J3-4= 5.3 Hz, 1H, H-3), 8.94 (s, 1H, N-H).
 
13
C NMR (100 MHz, CDCl3)  (ppm): 20.34 (CH3), 46.06 (2CH3), 58.39 (O-CH2-
CH2), 66.43 (O-CH2), 95.65 (C-8), 110.11 (C-6), 112.34 (C-4), 115.96 (Cq), 122.69 (C-5), 
128.69 (Cq), 134.87 (Cq), 138.79 (C-3), 141.16 (Cq), 141.85 (Cq), 160.05 (Cq). 
MS: [M + H]
+
 270.1 m/z  
Mp: 218.3°C 
Anal. calcd for C16H19N3O+½H2O: C, 69.04%; H, 7.24%; N, 15.10%  
Found: C, 68.95%; H, 6.79%; N, 14.50%   
Purity by HPLC: 99% 
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7-(N,N-dimethylaminopropyloxy)-1-methyl-β-carboline (2n.III)  
The title compound was prepared from a solution of harmol (0.400 g, 1.27 mmol), cesium 
carbonate (1.450 g, 4.45 mmol) and 3-chloro-N,N-dimethylpropylamine hydrochloride (0.440 
g, 2.78 mmol) in 10 mL of DMF. The reaction mixture was heated at 110°C for 7 h. The 
crude product was purified by column chromatography 
(dichloromethane/ethanol/triethylamine 78: 20: 2% v/v/v). Finally, the final product is diluted 
with dichloromethane (10 mL), washed once with water (5 mL) to eliminate the 
triethylammonium salt. The organic layer was dried over MgSO4 and concentrated.  
Yield: 52% 
Physical and spectral characteristics: 
 
 Chemical Formula   C17H21N3O   
N
H
N
O
N
 
 
 M.W. (g/mol)  283.37 
 Aspect  Brown solid 
 TLC (DCM/EtOH/NEt3: 
8/2/0.2)  
Rf = 0.22 
 
1
H NMR (400 MHz, CDCl3)  (ppm): 2.00-2.07 (m, 2H, O-CH2-CH2), 2.30 (s, 6H, 
2CH3), 2.53 (t, J = 7.2 Hz, 2H, O-CH2-CH2-CH2), 2.79 (s, 3H, CH3), 4.12 (t, J = 6.4 Hz, 2H, 
O-CH2), 6.89 (dd, J6-5 = 8.6 Hz, J6-8 = 2.1 Hz, 1H, H-6), 6.96 (d, J8-6 = 2.0 Hz, 1H, H-8), 7.70 
(d, J4-3= 5.5 Hz, 1H, H-4), 7.94 (d, J5-6 = 8.7 Hz, 1H, H-5), 8.12 (s, 1H, N-H), 8.31 (d, J3-4 = 
5.3 Hz, 1H, H-3). 
13
C NMR (100 MHz, CDCl3)  (ppm): 20.38 (CH3), 27.59 (O-CH2-CH2), 45.65 
(2CH3), 56.52 (O-CH2-CH2-CH2), 66.54 (O-CH2), 95.54 (C-8), 109.91 (C-6), 112.39 (C-4), 
115.71 (Cq), 122.60 (C-5), 128.76 (Cq), 135.23 (Cq), 138.23 (C-3), 141.32 (Cq), 142.37 (Cq), 
160.17 (Cq). 
MS: [M + H]
+
 284.1 m/z  
Mp: 179.5°C 
Anal. calcd for C17H21N3O+½H2O: C, 69.84%; H, 7.58%; N, 14.37%   
Found: C, 69.82%; H, 7.42%; N, 14.06%   
Purity by HPLC: 98% 
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7-(Ethyloxymorpholine)-1-methyl-β-carboline (2o.III) 
The title compound was prepared from a solution of harmol (0.440 g, 1.40 mmol), cesium 
carbonate (3.000 g, 9.21 mmol) and 4-(2-chloroethyl)morpholine hydrochloride (0.650 g, 3.49 
mmol) in 10 mL of DMF. The reaction mixture was heated at 60°C for 24 h. The crude 
product was purified by column chromatography (dichloromethane/methanol 90: 10% v/v). 
Yield: 38% 
Physical and spectral characteristics: 
 
 Chemical Formula   C18H21N3O2   
N
H
NO
N
O
 
 
 M.W. (g/mol)   311.38 
 Aspect   Brown solid 
 TLC (DCM/EtOH/NEt3: 
8/2/0.2)   
Rf = 0.42 
 
1
H NMR (400 MHz, CDCl3) (ppm): 2.61 (t, J = 4.6 Hz, 4H, CH2 (morpholine)), 
2.79 (s, 3H, CH3), 2.86 (t, J = 5.7 Hz, 2H, O-CH2-CH2), 3.75 (t, J = 4.6 Hz, 4H, CH2 
(morpholine)), 4.20 (t, J = 5.7 Hz, 2H, O-CH2), 6.90 (dd, J6-5 = 8.7 Hz, J6-8 = 2.3 Hz, 1H, H-
6), 6.96 (d, J8-6 = 2.1 Hz, 1H, H-8), 7.70 (d, J4-3= 5.3 Hz, 1H, H-4), 7.95 (d, J5-6 = 8.7 Hz, 1H, 
H-5), 8.31 (d, J3-4= 5.5 Hz, 1H, H-3), 8.40 (s, 1H, N-H). 
13
C NMR (100 MHz, CDCl3)  (ppm): 20.21 (CH3), 54.22 (2 CH2 (morpholine)), 
57.71 (O-CH2-CH2), 66.33 (O-CH2), 67.01 (2 CH2 (morpholine)), 95.73 (C-8), 110.19 (C-6), 
112.33 (C-4), 116.10 (Cq), 122.80 (C-5), 128.71 (Cq), 134.72 (Cq), 138.93 (C-3), 141.03 (Cq), 
141.68 (Cq), 159.96 (Cq). 
MS: [M + H]
+
 312.1 m/z  
Mp: 174.3°C 
Anal. calcd for C18H21N3O2+2H2O: C, 62.23%; H, 7.25%; N, 12.10%   
Found: C, 62,72%; H, 7.22%; N, 11.82%   
Purity by HPLC: 99% 
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c) Synthesis of 2-benzyl-7-benzyloxy-1-methyl-β-carboline (3.III) 
The title compound was prepared from a solution of 2g.III (0.140 g, 0.49 mmol) and benzyl 
bromide (0.831 g, 4.86 mmol) in 15 mL of anhydrous THF. The reaction mixture was heated 
to reflux for 48 h under argon atmosphere. At the end of the reaction, the mixture was cooled 
and THF is evaporated under reduced pressure to give the crude product which is purified by 
column chromatography (dichloromethane/ethanol 95: 5% v/v).    
Yield: 31% 
Physical and spectral characteristics: 
 
 Chemical Formula  C26H23BrN2O  
N
H
NO
Br  
 
 M.W. (g/mol)  459.38 
 Aspect  Yellow solid  
 TLC (DCM/EtOH: 8/2)   Rf = 0.73 
 
1
H NMR (400 MHz, DMSO-d6) (ppm): 2.94 (s, 3H, CH3), 5.30 (s, 2H, O-CH2), 
5.94 (s, 2H, N-CH2), 7.12-7.20 (m, 4H, H-8 + H-6 + 2ArH), 7.30-7.50 (m, 8H, 8ArH), 8.34 
(d, J5-6 = 8.7 Hz, 1H, H-5), 8.55 (d, J4-3 = 6.4 Hz, 1H, H-4), 8.70 (d, J3-4 = 6.4 Hz, 1H, H-3).  
13
C NMR (100 MHz, DMSO-d6)  (ppm): 15.89 (CH3), 59.54 (N-CH2), 70.37 (O-
CH2), 96.07 (C-8), 113.93 (C-6), 114.32 (Cq), 115.21 (C-4), 125.40 (C-5), 127.49 (2C-ArH), 
128.36 (2C-ArH), 128.61 (C-ArH), 128.99 (C-ArH), 129.10 (2C-ArH), 129.70 (2C-ArH), 
132.03 (Cq), 135.19 (C-3), 135.84 (Cq), 136.98 (Cq), 139.71 (Cq), 146.43 (Cq), 162.53 (Cq).  
MS: [M]
+
 379.14 m/z  
Mp: 257.3°C  
Anal. calcd for C26H23BrN2O+½H2O: C, 66.67%; H, 5.16%; N, 5.98%   
Found: C, 66.12%; H, 5.48%; N, 6.00%   
Purity by HPLC: 98% 
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d) Synthesis of 9-benzyl-7-benzyloxy-1-methyl-β-carboline (4.III) 
The benzyl bromide (0.461 g, 2.69 mmol), potassium hydroxide (0.228 g, 4.06 mmol) were 
added to harmol (0.400 g, 1.27 mmol) dissolved in anhydrous in DMF (8 mL). The reaction 
mixture was stirred at room temperature for 4h. The reaction mixture was diluted in 
dichloromethane (40 mL), washed once with water (10 mL) and three times with brine (10 
mL). The organic layer was dried over MgSO4 and concentrated under reduced pressure. The 
crude product was purified by column chromatography (dichloromethane/ethanol 99: 1% v/v).  
Yield: 84% 
Physical and spectral characteristics: 
 
 Chemical Formula  C26H22N2O 
N
N
O
 
 
 M.W. (g/mol)  378.47 
 Aspect  White solid 
 TLC (DCM/EtOH: 8/2)   Rf = 0.70 
 
1
H NMR (400 MHz, DMSO-d6) (ppm): 2.70 (s, 3H, CH3), 5.14 (s, 2H, O-CH2), 
5.84 (s, 2H, N-CH2), 6.88 (d, 2H, 2ArH), 6.94 (dd, J6-5 = 8.7 Hz, J6-8 = 2.1 Hz, 1H, H-6),  
7.17-7.43 (m, 9H, H-8 + 8ArH), 7.89 (d, J4-3 = 5.0 Hz, 1H, H-4), 8.11 (d, J5-6 = 8.7 Hz, 1H, H-
5), 8.14 (d, J3-4 = 5.0 Hz, 1H, H-3).  
13
C NMR (100 MHz, DMSO-d6)  (ppm): 23.21 (CH3), 47.78 (N-CH2), 70.24 (O-
CH2), 95.46 (C-8), 110.44 (C-6), 112.93 (C-4), 114.96 (Cq), 123.11 (C-5), 125.86 (2C-ArH), 
127.63 (C-ArH), 128.41 (C-ArH), 128.48 (2C-ArH), 128.93 (2C-ArH), 129.08 (Cq), 129.34 
(2C-ArH), 135.52 (Cq), 137.38 (Cq), 138.68 (C-3), 139.51 (Cq), 141.35 (Cq), 143.78 (Cq), 
160.25 (Cq).  
MS: [M + H]
+
 379.2 m/z  
Mp: 155.7°C 
Anal. calcd for C26H22N2O: C, 82.51%; H, 5.86%; N, 7.40%   
Found: C, 81.97%; H, 5.89%; N, 7.34%   
Purity by HPLC: 97% 
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e) Synthesis of 2,9-dibenzyl-7-(benzyloxy)-1-methyl-β-carboline (5.III) 
The title compound was prepared and purified according to procedure described for 3.III 
from 4.III (0.070 g, 0.18 mmol) and benzyl bromide (0.320 g, 1.85 mmol).  
Yield: 36% 
Physical and spectral characteristics: 
 
 Chemical Formula  C33H29BrN2O 
N
NO
Br
 
 M.W. (g/mol)  549.50 
 Aspect  White solid 
 TLC (DCM/EtOH: 8/2)   Rf = 0.73 
 
1
H NMR (400 MHz, DMSO-d6) (ppm): 2.81 (s, 3H, CH3), 5.23 (s, 2H, O-CH2), 
5.96 (s, 2H, N-CH2), 5.98 (s, 2H, N-CH2), 6.94 (d, J = 7.1 Hz, 2H, 2ArH), 7.07 (d, J = 7.1 Hz, 
2H, 2ArH), 7.18-7.45 (m, 12H, 11 ArH + H-6), 7.53 (s, 1H, H-8), 8.45 (d, J5-6 = 8.7 Hz, 1H, 
H-5), 8.69 (d, J4-3 = 6.4 Hz, 1H, H-4), 8.82 (d, J3-4 = 6.2 Hz, 1H, H-3). 
13
C NMR (100 MHz, DMSO-d6)  (ppm): 16.57 (CH3), 48.84 (N-CH2), 60.33 (N-
CH2), 70.67 (O-CH2), 95.55 (C-8), 113.39 (Cq), 114.28 (C-6), 115.23 (C-4), 125.44 (C-5), 
125.98 (2C-ArH), 127.13 (2C-ArH), 128.05 (C-ArH), 128.65 (3C-ArH), 128.86 (C-ArH), 
129.01 (2C-ArH), 129.56 (2C-ArH), 129.63 (2C-ArH), 133.99 (Cq), 135.28 (Cq), 135.89 (Cq), 
136.75 (C-3), 136.77 (Cq), 138.10 (Cq), 140.14 (Cq), 148.51 (Cq), 163.38 (Cq). 
MS: [M]
+
 469.3 m/z  
Mp: 261.8°C                                
Anal. calcd for C33H29BrN2O+½H2O: C, 70.97%; H, 5.41%; N, 5.02%   
Found: C, 69.65%; H, 5.28%; N, 4.83%   
Purity by HPLC: 98% 
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f) Synthesis of N-ethyl-3-methylamino-β-carboline (8.III) 
 
N-Ethyl-3-carboxamide-β-carboline (11.III) 
Ethylamine solution (2.0 M in THF, 2.860 g, 63.44 mmol) was added to a solution of ethyl β-
carboline-3-carboxylate (10.III) (0.508 g, 2.11 mmol) in methanol (15 mL). The resulting 
mixture was then stirred under reflux for 72h. After cooling, the solution was concentrated 
under reduced pressure and was used without further purification for the following step.  
Yield: 100% 
Physical and spectral characteristics:  
 
 Chemical Formula   C14H13N3O 
 
N
H
N
N
H
O
 
 
 M.W. (g/mol)  239.27 
 Aspect   Brown solid 
 TLC (DCM/EtOH: 95/5)   Rf = 0.51 
1
H NMR (400 MHz, CDCl3) (ppm): 1.31 (t, J = 7.3 Hz, 3H, NH-CH2-CH3), 3.58 (q, 
J = 7.3 Hz, 2H, NH-CH2-CH3), 7.34 (dd, J6-5 = 7.8 Hz, J6-7 = 6.9 Hz, 1H, H-6), 7.54 (d, J8-7 = 
7.8 Hz, 1H, H-8), 7.56 (dd, J7-6 = 7.3 Hz, J7-8 = 7.8 Hz, 1H, H-7), 8.13 (s, 1H, N-H), 8.19 (d, 
J5-6 = 7.8 Hz, 1H, H-5), 8.72 (s, 1H, N-H), 8.79 (s, 1H, H-4), 8.93 (s, 1H, H-1). 
MS: [M + H]
+ 
240.0 m/z 
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N-Ethyl-3-methylamino-β-carboline (8.III) 
A solution of the amide 11.III (0.157 g, 0.66 mmol) in anhydrous THF (5 mL) was added 
dropwise to a suspension of lithium aluminium hydride (0.125 g, 3.29 mmol) in anhydrous 
THF (2.5 mL) at -50°C. The reaction mixture was then refluxed overnight, chilled once again 
to -50°C and treated with H2O (2 mL) in order to destroy the excess of lithium aluminium 
hydride. The resulting suspension was stirred for 30 min and filtered through celite. The 
filtrate was diluted with Et2O (45 mL), washed twice with water (20 mL) and twice with brine 
(25 mL), and dried over MgSO4. The solvent was removed under reduced pressure to give the 
crude product which is purified by RP-HPLC semi-preparative (see purification techniques in 
the section 1.2). The derivative 8.III is then deprotonated with a NaOH solution (2N, 5 mL) 
and extracted three times with dichloromethane (20 mL). The organic layer was dried over 
MgSO4 and concentrated under reduced pressure. 
Yield: 22% 
Physical and spectral characteristics:  
 
 Chemical Formula   C14H15N3 
N
H
N
N
H
 
 
 M.W. (g/mol)  225.29 
 Aspect   Brown solid 
1
H NMR (400 MHz, CD3OD) (ppm): 1.19 (t, J = 7.3 Hz, 3H, NH-CH2-CH3), 2.78 
(q, J = 7.1 Hz, 2H, NH-CH2-CH3), 4.08 (s, 2H, -CH2-NH-), 7.21-7.28 (m, 1H, H-6), 7.52-7.56 
(m, 2H, H-7 + H-8), 8.11 (s, 1H, H-4), 8.17 (d, J5-6 = 8.0 Hz, 1H, H-5), 8.77 (s, 1H, H-1). 
13
C NMR (100 MHz, CD3OD)  (ppm): 12.81 (NH-CH2-CH3), 43.0 (NH-CH2-CH3), 
53.0 (-CH2-NH-), 111.56 (C-8), 113.71 (C-4), 119.49 (C-6), 120.83 (Cq), 121.93 (C-5), 
128.49 (C-7), 129.75 (Cq), 132.49 (C-1), 135.65 (Cq), 141.80 (Cq), 145.36 (Cq). 
MS: [M + H]
+
 226.1 m/z 
Anal. calcd for C14H15N3+2H2O: C, 64.35%; H, 7.33%; N, 16.08%  
Found: C, 65.79%; H, 7.06%; N, 14.29% 
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g) Synthesis of 3-methylamino-β-carboline (9.III) 
 
3-Hydroxymethyl-β-carboline (13.III) 
A solution of ethyl β-carboline-3-carboxylate (10.III) (0.570 g, 2.37 mmol) in anhydrous 
THF (20 mL) was added dropwise to a suspension of lithium aluminium hydride (0.450 g, 
11.86 mmol) in anhydrous THF (10 mL) at -50°C. The reaction mixture was then stirred at 
room temperature for 24h, chilled once again to -50°C and treated with H2O (8 mL) in order 
to destroy the excess of lithium aluminium hydride. The resulting suspension was stirred for 
30 min and filtered through celite. The aqueous suspension was extracted with 
dichloromethane (40 mL) and washed once with H2O (10 mL). The solution was dried over 
MgSO4, concentrated under reduced pressure and was used without further purification for the 
following steps.  
Yield: 52% 
Physical and spectral characteristics:  
 
 Chemical Formula   C12H10N2O 
 
N
H
N
OH
 
 
 M.W. (g/mol)  198.22 
 Aspect   Yellow solid 
 TLC (DCM/EtOH: 8/2)   Rf = 0.41 
 
1
H NMR (400 MHz, DMSO-d6) (ppm): 4.61 (s, 2H, -CH2), 6.66 (dd, J6-5 = 7.3 Hz, 
J6-7 = 7.1 Hz, 1H, H-6), 7.07 (dd, J7-8 = 8.0 Hz, J7-6 = 7.1 Hz, 1H, H-7), 7.39 (d, J8-7 = 8.2 Hz, 
1H, H-8), 7.78 (s, 1H, H-4), 7.90 (d, J5-6 = 7.8 Hz, 1H, H-5), 8.62 (s, 1H, H-1). 
MS: [M + H]
+ 
199.0 m/z 
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3-Azidomethyl-β-carboline (16.III) 
A) Via 3-chloromethyl-β-carboline (14.III) 
3-Hydroxymethyl-β-carboline (13.III) (0.097 g, 0.49 mmol) was added to an excess of 
thionyl chloride (15 mL) and the mixture was refluxed for 1 h. The excess thionyl chloride 
was then evapored and the crude product was used without further purification for the 
following step. NaN3 (0.035 g, 0.540 mmol) was added to the crude product (0.100 g) 
containing 14.III dissolved in anhydrous DMF (5 mL). The reaction mixture was heated at 
100°C for 1 h and then diluted in Et2O (10 mL), washed twice with water (5 mL) and three 
times with brine (5 mL). The organic layer was dried over MgSO4 and concentrated under 
reduced pressure.  
 
B) Via 3-(trifluoromethanesulfonate)methyl-β-carboline (15.III) 
To a solution of 3-hydroxymethyl-β-carboline (13.III) (0.081 g, 0.41 mmol) in anhydrous 
pyridine (3 mL), trifluoromethanesulfonic anhydride (0.128 g, 0.45 mmol) was added 
dropwise over 15 min, while the mixture was gently stirred at 0°C. The mixture was then 
stirred for 3 h at room temperature. After completion of the reaction, the reaction mixture was 
diluted in chloroform (15 mL), washed twice with water (5 mL). The organic layer was dried 
over MgSO4 and concentrated under reduced pressure. The crude product was used without 
further purification for the following step. NaN3 (0.043 g, 0.66 mmol) was added to the crude 
product (0.200 g) containing 15.III dissolved in anhydrous DMF (5 mL). The reaction 
mixture was heated at 100°C for 1 h and then diluted in Et2O (10 mL), washed twice with 
water (5 mL) and three times with brine (5 mL). The organic layer was dried over MgSO4 and 
concentrated under reduced pressure. 
Yield: 24% (via B) 
Physical and spectral characteristics:  
 
 Chemical Formula   C12H9N5 
 
N
H
N
N3
 
 M.W. (g/mol)  223.23 
 Aspect   Brown solid 
 TLC (DCM/EtOH: 9/1)   Rf = 0.60 
 
1
H NMR (400 MHz, CDCl3) (ppm): 4.66 (s, 2H, CH2-N3), 7.31 (dd, J6-7 = 7.1 Hz, 
J6-5 = 7.6 Hz, 1H, H-6), 7.52 (d, J8-7 = 8.0 Hz, 1H, H-8), 7.56 (dd, J7-8 = 8.0 Hz, J7-6 = 7.1 Hz, 
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1H, H-7), 7.99 (s, 1H, H-4), 8.13 (d, J5-6 = 8.2 Hz, 1H, H-5), 8.78 (s, 1H, NH), 8.88 (s, 1H, H-
1). 
13
C NMR (100 MHz, CDCl3)  (ppm): 56.32 (CH2-N3), 111.80 (C-8), 113.70 (C-4), 
120.49 (C-6), 121.41 (Cq), 121.96 (C-5), 128.96 (C-7), 129.96 (Cq), 133.44 (C-1), 135.39 
(Cq), 140.94 (Cq), 144.90 (Cq). 
MS: [M + H]
+
 224.0 m/z 
Mp: 138-140°C 
 
 
3-Methylamino-β-carboline (9.III) 
Triphenylphosphine (0.025 g, 0.09 mmol) was added to a solution of 16.III (0.021 g, 0.09 
mmol) in THF (3 mL) and water (0.5 mL). The mixture was stirred at room temperature 
overnight. After the solvents were evaporated, the residue was purified by an acid-base 
extraction. 
Yield: 38% (via B) 
Physical and spectral characteristics:  
 
 Chemical Formula   C12H11N3 
 
N
H
N
NH2
 
 
 M.W. (g/mol)  197.24 
 Aspect   Brown solid 
1
H NMR (400 MHz, CD3OD) (ppm): 4.15 (s, 2H, CH2-NH2), 7.22-7.28 (m, 1H, H-
6), 7.52-7.56 (m, 2H, H-7 + H-8), 8.11 (s, 1H, H-4), 8.17 (d, J5-6 = 8.0 Hz, 1H, H-5), 8.78 (s, 
1H, H-1). 
13
C NMR (100 MHz, CD3OD)  (ppm): 44.74 (CH2-NH2), 111.63 (C-8), 113.12 (C-
4), 119.57 (C-6), 120.97 (Cq), 121.40 (C-5), 128.58 (C-7), 128.43 (Cq), 132.81 (C-1), 135.85 
(Cq), 139.99 (Cq), 141.80 (Cq). 
MS: [M + H]
+
 198.0 m/z 
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h) Synthesis of 3-butyl-β-carboline (46.I) 
 
3-Carbaldehyde-β-carboline (18.III) 
To a stirred solution of ethyl β-carboline-3-carboxylate (10.III) (0.107 g, 0.44 mmol) in 
anhydrous dichloromethane (8 mL) was added DIBAL-H solution (1.0 M in hexane, 3.10 mL, 
3.10 mmol) at -50°C. The mixture was stirred at -50°C for 45 min and quenched by sequential 
addition of MeOH (1 mL) and NaOH (0.1 M, 3 mL) at -50°C. Then the mixture was stirred at 
room temperature for an additional 1h. The precipitates were removed through a celite and 
washed with methanol-chloroforme (50/50 v/v). The combined filtrate was washed once with 
brine (2 mL), dried over MgSO4, concentrated under reduced pressure and was used without 
further purification for the following steps.  
Yield: 93% 
Physical and spectral characteristics:  
 
 Chemical Formula   C12H8N2O 
 
N
H
N
O
H
 
 M.W. (g/mol)  196.20 
 Aspect   Brown solid 
 TLC (DCM/EtOH: 9/1)   Rf = 0.19 
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1-Phenylbutan-1-ol (22.III) 
A solution of 1-bromopropane (0.90 mL, 9.91 mmol) in anhydrous diethyl ether (2 mL) was 
added dropwise to a suspension of magnesium (0.240 g, 9.87 mmol) in anhydrous diethyl 
ether (1 mL) at room temperature. The reaction mixture was then stirred at room temperature 
for 30 min. To a stirred solution of benzaldehyde (0.80 mL, 7.87 mmol) in anhydrous diethyl 
ether (2 mL) was added dropwise the n-propylmagnesium bromide solution at -8°C. The 
mixture was stirred at room temperature for 3 h, quenched by addition of sat. NH4Cl (10 mL) 
and extracted with diethyl ether (30 mL). The combined organic phases were washed once 
with brine (10 mL), dried over MgSO4 and concentrated under reduced pressure. 
Yield: 65% 
Physical and spectral characteristics:  
 
 Chemical Formula   C10H14O 
 
OH
 
 M.W. (g/mol)  150.10 
 Aspect   Colorless oil 
 
1
H NMR (400 MHz, CDCl3) (ppm): 0.95 (t, J = 7.3 Hz, 3H, CH3), 1.25-1.47 (m, 
2H, CH2), 1.61-1.81 (m, 2H, CH2), 3.33 (s, 1H, OH), 4.59 (t, J = 6.6 Hz, 1H, CH), 7.26-7.37 
(m, 5H, ArH). 
MS: [M + H]
+
 151.0 m/z 
 
 
 
 
 
 
 
 
 
 
 
 
 
193 
 
1.4.2 Synthesis of 5H-indeno[1,2-c]pyridazin-5-ones 
 
a) Synthesis of 8-(4,4,4-trifluorobutyloxy)-3-(3’-(trifluoromethyl)phenyl)-5H-indeno 
[1,2-c]pyridazin-5-one (28a.III) [74] 
 
5-(4,4,4-Trifluorobutyloxy)-1-indanone (25a.III) 
1-Tosyl-4,4,4-trifluorobutane (3.480 g, 12.33 mmol) was added to a solution of 5-hydroxy-1-
indanone (24.III, 1.660 g, 11.20 mmol) in anhydrous acetonitrile (15 mL) containing 
potassium carbonate (3.380 g, 24.46 mmol). The resulting mixture was stirred for 4 h at 90 °C 
under an argon atmosphere and then cooled to room temperature. After evaporation of the 
solvents, the residue was poured into ethyl acetate (30 mL), washed twice with water (5 mL), 
dried over magnesium sulfate, filtered, and evaporated to dryness. The crude product was 
purified by column chromatography (pentane/ethyl acetate 70: 30% v/v).  
Yield: 96% 
Physical and spectral characteristics: 
 
 Chemical Formula  C13H13F3O2  
O
O
F3C
 
 
 M.W. (g/mol)  258.24 
 Aspect  Brown solid 
 TLC (pentane/AcOEt: 7/3)   Rf = 0.41 
 
1
H NMR (400 MHz, CDCl3) (ppm): 2.06-2.13 (m, 2H, CF3-CH2-CH2), 2.27-2.39 
(m, 2H, CF3-CH2), 2.67 (t, J = 5.7 Hz, 2H, CH2), 3.08 (t, J = 5.7 Hz, 2H, CH2), 4.08 (t, J = 6.0 
Hz, 2H, O-CH2), 6.86-6.90 (m, 2H, H-4 + H-6), 7.67 (d, J7-6 = 9.2 Hz, 1H, H-7). 
19
F NMR (376 MHz, CDCl3)  (ppm): -66.15 (t, J = 11.6 Hz). 
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5-(4,4,4-Trifluorobutyloxy)ninhydrin (26a.III) 
5-(4,4,4-Trifluorobutyloxy)-1-indanone (25a.III, 1.800 g, 6.97 mmol) was added to a 
suspension of selenium dioxide (3.870 g, 34.88 mmol) in anhydrous dioxane (10 mL). The 
suspension was stirred for 3 h to reflux under an argon atmosphere, filtered, and the solvents 
evaporated. The residue was poured into dichloromethane (30 mL) into which the unreacted 
SeO2 precipitated. The SeO2 was filtered off and the filtrate evaporated to dryness. The crude 
product was purified by column chromatography (dichloromethane/ethyl acetate 80: 20% 
v/v). 
Yield: 76% 
Physical and spectral characteristics: 
 
 Chemical Formula  C13H11F3O5  
O
O
O
OH
OH
F3C
 
 
 M.W. (g/mol)  304.22 
 Aspect  Brown solid 
 TLC (DCM/AcOEt: 3/1)   Rf = 0.41 
1
H NMR (400 MHz, CDCl3) (ppm): 2.10-2.22 (m, 2H, CF3-CH2-CH2), 2.28-2.40 
(m, 2H, CF3-CH2), 4.18 (t, J = 5.8 Hz, 2H, O-CH2), 7.31 (d, J4-6 = 2.3 Hz, 1H, H-4), 7.36 (dd, 
J6-4 = 2.3 Hz, J6-7 = 8.5 Hz, 1H, H-6), 7.90 (d, J7-6 = 8.5 Hz, 1H, H-7). 
19
F NMR (376 MHz, CDCl3)  (ppm): -66.13 (t, J = 11.6 Hz). 
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8-(4,4,4-Trifluorobutyloxy)-3-(3’-(trifluoromethyl)phenyl)-5H-indeno[1,2-c]pyridazin-5-
one (28a.III) 
3’-(Trifluoromethyl)acetophenone (0.310 g, 1.65 mmol) was added to a solution of 5-(4,4,4-
trifluorobutyloxy)ninhydrin (26a.III, 0.500 g, 1.64 mmol) in glacial acetic acid (10 mL) 
which was stirred under reflux for 3 h. After cooling, the solution was concentrated (2 mL), 
and hydrazine monohydrate (0.079 g, 2.48 mmol) added. After stirring vigorously overnight 
at room temperature, the solvent was evaporated. The crude product was purified by column 
chromatography (dichloromethane 100% v). 
Yield: 44% 
Physical and spectral characteristics: 
 
 Chemical Formula  C22H14F6N2O2 
NN
O
O
F3C
CF3
 
 
 M.W. (g/mol)  452.35 
 Aspect  Yellow solid 
 TLC (DCM)  Rf = 0.52 
 
1
H NMR (400 MHz, CDCl3) (ppm): 2.13-2.20 (m, 2H, CF3-CH2-CH2), 2.31-2.43 
(m, 2H, CF3-CH2), 4.25 (t, J = 6.1 Hz, 2H, O-CH2), 7.04 (dd, J7-9 = 2.3 Hz, J7-6 = 8.2 Hz, 1H, 
H-7), 7.65 (d, J9-7 = 2.1 Hz, 1H, H-9), 7.69 (t, J5’-6’  = J5’-4’ = 7.8 Hz, 1H, H-5’), 7.80 (d, J4’-5’ = 
8.5 Hz, 1H, H-4’), 7.83 (d, J6-7 = 8.5 Hz, 1H, H-6), 8.00 (s, 1H, H-4), 8.31 (d, J6’-5’ = 7.8 Hz, 
1H, H-6’), 8.42 (s, 1H, H-2’). 
13
C NMR (100 MHz, CDCl3)  (ppm): 22.10 (d, J = 3.8 Hz, CF3-CH2-CH2), 30.69 (q, 
J = 29.7 Hz, CF3-CH2), 67.18 (O-CH2), 107.38 (C-9), 117.27 (C-4), 118.95 (C-7), 123.94 (q, 
J = 272.2 Hz, Cq), 124.14 (q, J = 3.8 Hz, C-2’), 127.32 (q, J = 3.8 Hz, C-4’), 127.61 (C-6), 
128.27 (Cq), 129.83 (C-5’), 130.31 (C-6’), 131.83 (q, J = 33.6 Hz, C-3’), 132.67 (Cq), 136.81 
(Cq), 145.23 (Cq), 159.11 (Cq), 160.71 (Cq), 165.77 (Cq), 188.11 (Cq). 
19
F NMR (376 MHz, CDCl3)  (ppm): -66.12 (t, J = 11.6 Hz), -62.63 (s). 
MS: [M + H]
+
 453.2 m/z  
Mp: 173.1°C 
Anal. calcd for C22H14F6N2O2: C, 58.41%; H, 3.12%; N, 6.19%   
Found: C, 58.47%; H, 3.21%; N, 6.10%   
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b) Synthesis of 8-(benzyloxy)-3-(3’-(trifluoromethyl)phenyl)-5H-indeno[1,2-c]pyridazin-5-
one (28b.III) 
 
5-Benzyloxy-1-indanone (25b.III) 
Benzyl bromide (1.904 g, 11.13 mmol) was added to a solution of 5-hydroxy-1-indanone 
(24.III, 1.500 g, 10.12 mmol) in anhydrous DMF (15 mL) containing potassium carbonate 
(3.077 g, 22.26 mmol) is suspended. The resulting mixture was stirred for 5 h at room 
temperature under an argon atmosphere. The mixture was diluted with ethyl acetate (30 mL), 
washed once with water (10 mL) and three times with brine (10 mL). The organic layer was 
dried over MgSO4 and concentrated. The crude product was purified by liquid 
chromatography (pentane/ethyl acetate 85: 15% v/v).  
Yield: 90% 
Physical and spectral characteristics: 
 
 Chemical Formula  C16H14O2  
O
O  
 
 M.W. (g/mol)  238.28 
 Aspect  Brown solid 
 TLC(pentane/AcOEt: 7/3)   Rf = 0.64  
 
1
H NMR (400 MHz, CDCl3) (ppm): 2.66 (t, J = 5.7 Hz, 2H, CH2), 3.07 (t, J = 5.7 
Hz, 2H, CH2), 5.13 (s, 2H, O-CH2), 6.96-6.98 (m, 2H, H-4 + H-6), 7.33-7.44 (m, 5H, ArH), 
7.69 (d, J7-6 = 8.9 Hz, 1H, H-7). 
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5-Benzyloxyninhydrin (26b.III) 
The title compound was prepared from 5-benzyloxy-1-indanone (25b.III, 1.800 g, 7.56 
mmol) and selenium dioxide (4.193 g, 37.79 mmol) according to the same procedure than that 
described for 26a.III. The crude product was purified by column chromatography 
(dichloromethane/ethyl acetate 90: 10% v/v).  
Yield: 81% 
Physical and spectral characteristics: 
 
 Chemical Formula  C16H12O5  
O
O
O
OH
OH
 
 
 M.W. (g/mol)  284.26 
 Aspect  Brown solid 
 TLC (DCM/AcOEt: 7/3)   Rf = 0.60 
1
H NMR (400 MHz, CDCl3) (ppm): 5.20 (s, 2H, O-CH2), 7.30-7.52 (m, 7H, H-4 + 
H-6 + 5 ArH), 7.93 (d, J7-6 = 8.2 Hz, 1H, H-7). 
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8-(Benzyloxy)-3-(3’-(trifluoromethyl)phenyl)-5H-indeno[1,2-c]pyridazin-5-one (28b.III) 
The title compound was prepared and purified according to procedure described for 28a.III 
from 3’-(trifluoromethyl)acetophenone (0.331 g, 1.76 mmol) and 5-benzyloxyninhydrin 
(26b.III, 0.500 g, 1.76 mmol).  
Yield: 46% 
Physical and spectral characteristics: 
 
 Chemical Formula  C25H15F3N2O2 
NN
O
O
CF3
 
 
 M.W. (g/mol)   432.39 
 Aspect  Yellow solid 
 TLC (DCM)   Rf = 0.56 
 
1
H NMR (400 MHz, CDCl3) (ppm): 5.29 (s, 2H, O-CH2), 7.11 (dd, J7-9 = 2.3 Hz,  
J7-6 = 8.2 Hz, 1H, H-7), 7.36-7.49 (m, 5H, ArH), 7.69 (t, J5’-6’  = J5’-4’ = 7.8 Hz, 1H, H-5’), 7.75 
(d, J9-7 = 2.3 Hz, 1H, H-9), 7.79 (d, J4’-5’ = 8.5 Hz, 1H, H-4’), 7.82 (d, J6-7 = 8.5 Hz, 1H, H-6), 
8.00 (s, 1H, H-4), 8.31 (d, J6’-5’ = 8.0 Hz, 1H, H-6’), 8.42 (s, 1H, H-2’). 
13
C NMR (100 MHz, CDCl3)  (ppm): 71.01 (O-CH2), 107.92 (C-9), 117.20 (C-4), 
119.39 (C-7), 123.94 (q, J = 273.2 Hz, Cq), 124.13 (q, J = 3.8 Hz, C-2’), 127.29 (q, J = 3.8 
Hz, C-4’), 127.59 (C-6), 127.72 (2C-ArH), 128.17 (Cq), 128.69 (C-ArH), 128.96 (2C-ArH), 
129.81 (C-5’), 130.29 (C-6’), 131.83 (q, J = 32.6 Hz, C-3’), 132.72 (Cq), 135.43 (Cq), 136.83 
(Cq), 145.15 (Cq), 159.08 (Cq), 160.77 (Cq), 165.98 (Cq), 188.16 (Cq).  
19
F NMR (376 MHz, CDCl3)  (ppm): -62.63 (s). 
MS: [M + H]
+
 433.2 m/z  
Mp: 209.3°C 
Anal. calcd for C25H15F3N2O2: C, 69.44%; H, 3.50%; N, 6.48%.   
Found: C, 69.76%; H, 3.62%; N, 6.37%. 
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c) Synthesis of 8-(methoxy)-3-(3’-(trifluoromethyl)phenyl)-5H-indeno[1,2-c]pyridazin-5-one 
(22m.I) [74] 
 
5-Methoxyninhydrin (26c.III) 
The title compound was prepared from 5-(methoxy)-1-indanone (25c.III, 1.000 g, 6.17 mmol) 
and selenium dioxide (3.420 g, 30.82 mmol) according to the same procedure than that 
described for 26a.III. The crude product was purified by column chromatography 
(dichloromethane/ethyl acetate 70: 30% v/v). 
Yield: 73% 
Physical and spectral characteristics: 
 
 Chemical Formula   C10H8O5  
O
O
O
OH
OH
 
 
 M.W. (g/mol)  208.17 
 Aspect  Brown solid 
 TLC (DCM/AcOEt: 7/3)  Rf = 0.45 
1
H NMR (400 MHz, CDCl3) (ppm): 3.99 (s, 3H, O-CH3), 7.40 (d, J4-6 = 2.3 Hz, 1H, 
H-4), 7.44 (dd, J6-4 = 2.3 Hz, J6-7 = 8.5 Hz, 1H, H-6), 7.99 (d, J7-6 = 8.2 Hz, 1H, H-7). 
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8-(Methoxy)-3-(3’-(trifluoromethyl)phenyl)-5H-indeno[1,2-c]pyridazin-5-one (22m.I) 
The title compound was prepared and purified according to procedure described for 28a.III 
from 3’-(trifluoromethyl)acetophenone (0.452 g, 2.40 mmol) and 5-methoxyninhydrin (31c, 
0.500 g, 2.40 mmol).  
Yield: 39% 
Physical and spectral characteristics: 
 
 Chemical Formula  C19H11F3N2O2 NN
O
O
CF3
 
 
 M.W. (g/mol)  356.30 
 Aspect  Yellow solid 
 TLC (pentane/AcOEt 7/3)  Rf = 0.48 
 
1
H NMR (400 MHz, CDCl3) (ppm): 4.01 (s, 3H, O-CH3), 7.03 (dd, J7-9 = 2.3 Hz,  
J7-6 = 8.5 Hz, 1H, H-7), 7.66 (d, J9-7 = 2.1 Hz, 1H, H-9), 7.68 (t, J5’-6’  = J5’-4’ = 7.8 Hz, 1H, H-
5’), 7.78 (d, J4’-5’ = 7.6 Hz, 1H, H-4’), 7.80 (d, J6-7 = 8.5 Hz, 1H, H-6), 7.98 (s, 1H, H-4), 8.31 
(d, J6’-5’ = 7.8 Hz, 1H, H-6’), 8.41 (s, 1H, H-2’). 
13
C NMR (100 MHz, CDCl3)  (ppm): 56.35 (O-CH3), 107.06 (C-9), 117.20 (C-4), 
118.65 (C-7), 123.95 (q, J = 272.2 Hz, Cq), 124.11 (q, J = 3.8 Hz, C-2’), 127.28 (q, J = 3.8 
Hz, C-4’), 127.54 (C-6), 128.00 (Cq), 129.81 (C-5’), 130.30 (C-6’), 131.80 (q, J = 32.6 Hz, C-
3’), 132.75 (Cq), 136.83 (Cq), 145.16 (Cq), 159.09 (Cq), 160.77 (Cq), 166.91 (Cq), 188.15 (Cq).  
19
F NMR (376 MHz, CDCl3)  (ppm): -62.63 (s). 
MS: [M + H]
+
 357.2 m/z  
Mp: 216.3°C 
Anal. calcd for C19H11F3N2O2: C, 64.05%; H, 3.11%; N, 7.86%. 
Found: C, 64.19%; H, 3.21 %; N, 7.73%. 
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d) Synthesis of 3-methyl-8-meta-chlorobenzyloxy-5H-indeno[1,2-c]pyridazin-5-one (30a.III, 
performed by Fabrice Camus, Biological Structural Chemistry Laboratory, FUNDP, Belgium) 
 
Silver oxide (2.320 g, 10.01 mmol) was added at room temperature to a solution of 3-methyl-
8-ol-5H-indeno[1,2-c]pyridazin-5-one (29.III) (0.500 g, 2.36 mmol) and 1-(bromomethyl)-3-
chlorobenzene (2.050 g, 9.98 mmol) in anhydrous DMF (10 mL). The mixture was stirred for 
4 h. The crude suspension was then filtered and washed with ethyl acetate (30 mL). The 
filtrate was evaporated and the crude product was purified by column chromatography (ethyl 
acetate 100%). 
Yield: 15% 
Physical and spectral characteristics: 
 
 Chemical Formula  C19H13ClN2O2 
NN
O
O
Cl
 
 
 M.W. (g/mol)  336.77 
 Aspect  Yellow solid 
 TLC (DCM/AcOEt: 3/1)  Rf = 0.32 
 
1
H NMR (400 MHz, CDCl3) (ppm): 2.78 (s, 3H, CH3), 5.22 (s, 2H, O-CH2), 7.05 
(dd, J7-9 = 2.3 Hz, J7-6 = 8.5 Hz, 1H, H-7), 7.31-7.35 (m, 3H, ArH), 7.40 (s, 1H, H-4), 7.46 (s, 
1H, ArH), 7.67 (d, J9-7 = 2.3 Hz, 1H, H-9), 7.77 (d, J6-7 = 8.5 Hz, 1H, H-6). 
13
C NMR (100 MHz, CDCl3)  (ppm): 23.05 (CH3), 69.97 (O-CH2), 107.36 (C-9), 
119.04 (C-7), 120.23 (C-4), 125.54 (C-ArH), 127.32 (C-6), 127.59 (C-ArH), 128.21 (Cq), 
128.74 (C-ArH), 130.19 (C-ArH), 131.89 (Cq), 134.86 (Cq), 137.58 (Cq), 145.71 (Cq), 159.70 
(Cq), 161.52 (Cq), 165.42 (Cq), 188.75 (Cq). 
MS: [M + H]
+
 337.0 m/z  
Mp: 145°C 
Anal. calcd for C19H13ClN2O2: C, 67.76%; H, 3.89%; N, 8.32%. 
Found: C, 66.90%; H, 3.96%; N, 7.86%. 
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e) Synthesis of 3-methyl-8-meta-methylbenzyloxy-5H-indeno[1,2-c]pyridazin-5-one (30b.III, 
performed by Fabrice Camus, Biological Structural Chemistry Laboratory, FUNDP, Belgium) 
 
The title compound was prepared and purified according to procedure described for 30a.III 
from 3-methyl-8-ol-5H-indeno[1,2-c]pyridazin-5-one (29.III) (0.500 g, 2.36 mmol), silver 
oxide (2.320 g, 10.01 mmol) and 1-(bromomethyl)-3-methylbenzene (2.320 g, 12.54 mmol).  
Yield: 6% 
Physical and spectral characteristics: 
 
 Chemical Formula  C20H16N2O2 
NN
O
O
 
 
 M.W. (g/mol) 316.35 
 Aspect  Yellow solid 
 TLC (DCM/AcOEt: 3/1)   Rf = 0.42 
 
1
H NMR (400 MHz, CDCl3) (ppm): 2.39 (s, 3H, CH3), 2.78 (s, 3H, CH3), 5.21 (s, 
2H, O-CH2), 7.06 (dd, J7-9 = 2.3 Hz, J7-6 = 8.5 Hz, 1H, H-7), 7.17-7.32 (m, 4H, ArH), 7.40 (s, 
1H, H-4), 7.69 (d, J9-7 = 2.3 Hz, 1H, H-9), 7.76 (d, J6-7 = 8.5 Hz, 1H, H-6). 
13
C NMR (100 MHz, CDCl3)  (ppm): 21.52 (CH3), 23.05 (CH3), 71.01 (O-CH2), 
107.46 (C-9), 119.07 (C-7), 120.17 (C-4), 124.80 (C-ArH), 127.27 (C-6), 127.96 (Cq), 128.42 
(C-ArH), 128.80 (C-ArH), 129.39 (C-ArH), 131.97 (Cq), 135.40 (Cq), 138.65 (Cq), 145.64 
(Cq), 159.80 (Cq), 161.49 (Cq), 165.86 (Cq), 188.75 (Cq). 
MS: [M + H]
+
 317.1 m/z  
Mp: 146°C 
Anal. calcd for C20H16N2O2: C, 75.93%; H, 5.10%; N, 8.86%. 
Found: C, 75.05%; H, 4.97%; N, 8.44%. 
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1.5 Experimental details for the compounds studied by X-ray 
crystallography 
 
 1.III  2e.III  2f.III 
Crystal data    
Chemical Formula C12H15BrN2O3 C16H15F3N2O C19H22N2O 
Formula weight 315.16 308.30 294.21 
Crystal system Orthorhombic Trigonal Trigonal 
Space group Pnma   ,   , 
a (Å) 13.320(3) 25.400(2) 25.698(2) 
b (Å) 6.679(3) 25.400(2) 25.698(2) 
c (Å) 13.895(4) 12.703(1) 13.360(1) 
α (°) 90.00 90.00 90.00 
 (°) 90.00 90.00 90.00 
γ (°) 90.00 120.00 120.00 
V (Å³) 1236.2(7) 7097.5(10) 7640.8(9) 
Z 4 18 18 
µ (mm
-1
) 3.316 0.106 0.072 
Dcalc (g.cm
-3
) 1.591 1.298 1.152 
F(000) 596 2880 2844 
Crystal Size (mm) 0.13 x 0.17 x 
0.40 
0.14 x 0.20 x 
0.30 
0.10 x 0.10 x  
0.30 
 
Data collection 
   
Temperature (K) 293 293 293 
Radiation (Å) Mo Kα  
0.71073 Å 
Mo Kα  
0.71073 Å 
Mo Kα  
0.71073 Å 
 Min-Max (°) 3.3, 32.6   3.3, 28.0   3.2, 32.7   
No. of measured reflections 6084 9332 11109 
No. of independent reflections 2236 3321 5628 
Rint 0.0227 0.0273 0.0423 
No. of observed reflections (I>2(I)) 1220 1639 1666 
 
Refinement 
   
Refinement on F² F² F² 
No. of reflections used in refinement 2236 3321 5628 
No. of parameters used 104 208 206 
R[F²>2 (F²)] 0.0302 0.0617 0.0642 
wR[F²] 0.0757 0.1810 0.2066 
S 0.814 0.978 0.785 
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 2g.III 3.III 4.III 
 
Crystal data 
   
Chemical Formula C19H16N2O C26H23BrN2O C26H22N2O 
Formula weight 288.34 459.37 378.46 
Crystal system Trigonal Monoclinic Triclinic 
Space group   , P21/c P-1 
a (Å) 25.588(2) 10.189(1) 5.410(1) 
b (Å) 25.588(2) 29.543(1) 9.667(2) 
c (Å) 12.844(1) 14.822(1) 19.125(3) 
α (°) 90.00 90.00 87.44(1) 
 (°) 90.00 103.08(2) 88.83(1) 
γ (°) 120.00 90.00 87.34(1)   
V (Å³) 7282.9(10) 4345.6(4) 998.0(3) 
Z 18 8 2 
µ (mm
-1
) 0.074 1.912   0.077 
Dcalc (g.cm
-3
) 1.183   1.404 1.259   
F(000) 2736 1888 400 
Crystal Size (mm) 0.15 x 0.20 x  
0.30   
0.10 x 0.18 x  
0.25   
0.09 x 0.14 x  
0.38     
 
Data collection 
   
Temperature (K) 293 293 293 
Radiation (Å) Mo Kα  
0.71073 Å 
Mo Kα  
0.71073 Å 
Mo Kα  
0.71073 Å 
 Min-Max (°) 3.2, 32.5   3.4, 28.0     2.9, 27.9   
No. of measured reflections 10872 26126 10380 
No. of independent reflections 5366 9093 4128 
Rint 0.0311 0.0772 0.0567 
No. of observed reflections (I>2(I)) 1239 2591 2009 
 
Refinement 
   
Refinement on F² F² F² 
No. of reflections used in refinement 5366 9093 4128 
No. of parameters used 182 526 262 
R[F²>2 (F²)] 0.0765 0.0489 0.0532 
wR[F²] 0.3128 0.1519 0.1386 
S 0.779 0.584 0.881 
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 5.III  28a.III 28b.III 
 
Crystal data 
   
Chemical Formula C33H29BrN2O C22H14F6N2O2 C25H15F3N2O2 
Formula weight 549.49 452.35 432.39 
Crystal system Monoclinic Monoclinic Monoclinic 
Space group P21/c  C2C CC 
a (Å) 10.073(3) 9.765(1) 6.365(1) 
b (Å) 12.673(6) 14.631(1) 40.848(3) 
c (Å) 22.987(1)   27.968(4) 7.600(1) 
α (°) 90.00 90.00 90.00 
 (°) 110.10(4) 96.96(1) 94.96(1) 
γ (°) 90.00 90.00 90.00 
V (Å³) 2755.8(2) 3966.5(8) 1968.6(4) 
Z 4 8 4 
µ (mm
-1
) 1.520 0.136   0.113 
Dcalc (g.cm
-3
) 1.324 1.515 1.459   
F(000) 1136 1840 888 
Crystal Size (mm) 0.06 x 0.07 x  
0.30     
0.06 x 0.19 x  
0.40     
0.02 x 0.25 x  
0.40 
 
Data collection 
   
Temperature (K) 293 293 293 
Radiation (Å) Mo Kα  
0.71073 Å 
Mo Kα  
0.71073 Å 
Mo Kα  
0.71073 Å 
 Min-Max (°) 3.2, 28.0   3.0, 30.6   3.3, 30.7 
No. of measured reflections 19358 12585 12165 
No. of independent reflections 5849 5461 2869 
Rint 0.0892 0.0549 0.0351 
No. of observed reflections (I>2(I)) 2080 1690 1570 
 
Refinement 
   
Refinement on F² F² F² 
No. of reflections used in refinement 5849 5461 2869 
No. of parameters used 335 299 299 
R[F²>2 (F²)] 0.0474 0.0611 0.0627 
wR[F²] 0.1024 0.1768 0.1708 
S 0.769 0.854 0.964 
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 30a.III 46.III 47.III 
 
Crystal data 
   
Chemical Formula C19H13ClN2O2 C15H13NO C16H15NO 
Formula weight 336.76 223.27 237.29 
Crystal system Orthorhombic Hexagonal Monoclinic 
Space group P212121   , P21 
a (Å) 4.021(1) 26.670(2) 6.509(2) 
b (Å) 9.681(2) 26.670(2) 7.918(3) 
c (Å) 39.832(5)    9.696(1) 12.348(5) 
α (°) 90.00 90.00 90.00 
 (°) 90.00 90.00 93.85(4) 
γ (°) 90.00 120.00 90.00 
V (Å³) 1550.6(5) 5972.5(7) 635.0(4) 
Z 4 6 2 
µ (mm
-1
) 0.260 0.077 0.606 
Dcalc (g.cm
-3
) 1.443 1.171 1.241 
F(000) 696 2220 252 
Crystal Size (mm) 0.10 x 0.15 x  
0.30   
0.07 x 0.08 x  
0.50      
0.01 x 0.15 x  
0.45   
 
Data collection 
   
Temperature (K) 293 293 293 
Radiation (Å) Mo Kα  
0.71073 Å 
Mo Kα  
0.71073 Å 
Cu Kα 
1.54178 Å 
 Min-Max (°) 3.3, 32.5     3.8, 32.5     3.6, 67.7   
No. of measured reflections 7090 9690 2966 
No. of independent reflections 4895 4295 1695 
Rint 0.0370 0.0415 0.0192 
No. of observed reflections (I>2(I)) 2797 1065 1603 
 
Refinement 
   
Refinement on F² F² F² 
No. of reflections used in refinement 4895 4295 1695 
No. of parameters used 218 209 164 
R[F²>2 (F²)] 0.0841 0.0972 0.0354 
wR[F²] 0.2093 0.3660 0.1103 
S 1.115 0.840 1.159 
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2. MOLECULAR MODELING 
 
The structures of ligands are built and geometry minimized at physiological pH using the 
CHARMm force field implemented in Discovery studio
®
 2.5 (Accelrys Software Inc., San 
Diego, USA) software. Docking of ligands in the active site of the hMAO-A, hMAO-B and 
hIDO structures obtained through X-ray crystallography (2Z5X [3], 2V5Z [4] and 2D0T 
[144], respectively), was carried out using GOLD (version 3.2) software (Cambridge 
Crystallographic Data Centre, Cambridge, U.K.).  
The interaction sphere in the docking was centered on the N5 atom of the flavin (FAD) in the 
catalytic site of the protein (MAO-A and –B) and delimited by a 20Å radius. Seven water 
molecules which occupy the space between harmine (3.I) and FAD were conserved from X-
ray crystallography (2Z5X.pdb) into the MAO-A model. Into the MAO-B model, three 
conserved water molecules have been identified, which are buried in the vicinity of FAD and 
proved to be important for docking simulation of MAO-B selective ligand [73]. So these 
water molecules are kept inside the binding site as an integral part of the protein structure 
during the whole computational procedure.  
The interaction sphere in the docking was centered on the heme in the catalytic site of IDO 
and delimited by a 7Å radius. In addition to PIM (37.I), there are two molecules of CHES 
bound at the entrance of the binding site which were removed for docking studies. A total of 
twenty-five docking solutions were generated using GOLD (version 3.2) software. For the 25 
genetic algorithm (GA) runs performed, a total of 100 000 genetic operations were carried out 
on five islands, each containing 100 individuals. The niche size was set to 2, and the value for 
the selection pressure was set to 1.1. Genetic operator weights for crossover, mutation, and 
migration were set to 95, 95 and 10, respectively. The scoring function used to rank the 
docking was Goldscore. The binding mode of ligands on hMAO-A, –B and hIDO was 
selected from Goldscore and/or as a plausible solution in agreement with literature. 
 
 
3. MOLECULAR ELECTROSTATIC POTENTIAL 
 
The starting geometry for compound 30a.III was obtained from X-ray crystallography. The 
geometry of the system was first optimized at the PBE1PBE level using the 6-311G** basis 
sets. Secondly, using the Gaussian09 program, a first cube file is generated for the total 
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electron density and then a second cube file is produced for the electrostatic potential. 
Mapping of the MEP onto the molecular surface was performed with Gaussview 5.0.8.  
 
 
4. ENZYMATIC ASSAYS  
 
4.1 MAO-A and –B  
 
Inhibition of hMAO-A and –B was evaluated according to a published two steps methodology 
[194]. The MAO enzymes were produced from insect cells infected with recombinant 
baculovirus containing complementary DNA inserts for hMAO-A and –B (Sigma–Aldrich, 
M7316 and M7441, respectively). The recombinant MAO enzymes were provided under 
microsomes at a protein concentration of 5 mg.mL
-1
. 
The MAO-Glo
TM 
two-step bioluminescent assay from Promega Corporation was performed in 
96-wells plates at 37°C. Recombinant MAO enzyme (25.0 µL, final concentration of 0.5 
U.mg
-1
) were first incubated with the test compound (12.5 µL) for 2.5 min. Then, the 
substrate (12.5 µL, final concentration of 120 µM and 15 µM for MAO-A and –B, 
respectively) was added to the mixture. Finally, after 1 h of reaction, 50.0 µL of luciferin 
detection reaction (LDR) was added to the wells. The luminescent signal was measured 20 
min after the addition of the LDR with a 96-wells luminometer Fluoroskan FL (Thermo 
Fisher Scientific). Test compounds were assessed in triplicate for each concentration on 
hMAO-A and –B. IC50 and Ki values of the most active compounds were evaluated. DMSO 
(12.5% final concentration) was used as cosolvant to dissolve the test compounds in buffer 
(100 mM Hepes (pH 7.5) and 5% glycerol). Inhibition percentages at each concentration were 
calculated as follows: I (%) = 100 x {1 – (luminescent signal with test compound/luminescent 
signal without test compound)}. The inhibition percentages were plotted against the 
logarithms of the compound molar concentrations. The IC50 values were calculated from 
normalized sigmoidal dose-response non-linear regression curves using the GraphPad Prism 
5.01 software and were expressed as mean ± SD from triplicate experiments. Ki values were 
determined from the IC50 values using the Cheng–Prusoff equation: Ki = IC50/(1 + [S]/Km) 
[192]. The aminopropylether analogue of methyl ester luciferin exhibited Km values of 116.1 
µM and 14.6 µM for MAO-A and MAO-B, respectively. Ki values were expressed as mean 
with 95% confidence intervals in brackets. Lineweaver-Burk plots on MAO-B by 30a.III 
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were obtained from incubations at four substrate concentrations (5, 15, 50 and 75 µM), 
without or with three different inhibitor concentrations (2, 5 and 15 µM). The inverse values 
of the reaction velocities were then represented as a function of the inverse value of substrate 
concentration. Ki value was calculated from the x-axis intercept (y = 0) using the equation 
1/[S] = -1/(Km . (1 + [I]/Ki)) where Km was obtained in the absence of inhibitor I [223]. 
 
 
4.2 IDO 
 
The IDO inhibition assay was performed as described by Takikawa et al [198] with some 
modifications. It is based on the conversion of L-tryptophan to N-formylkynurenine, followed 
by hydrolysis to produce kynurenine. The measurement of IDO activity in this method relies 
on quantifying the amount of kynurenine produced in the assay through an indirect mean. It 
relies on absorption of the imine (Schiff base) produced by the reaction of the aromatic amino 
group of kynurenine with para-dimethylaminobenzaldehyde (p-DMAB) at 490 nm. The 
measurements are carried out in 96-wells plates at 37°C.  
Plasmid was obtained from Van Den Eynde’s team of the UCL university (Woluwe-Saint-
Lambert, Belgium). The recombinant plasmid, phIDO, encodes a histidine tag at the N-
terminus of IDO. Escherichia coli strain BL21 (DE3) (Invitrogen) was used for 
overexpression of IDO and transformed with the phIDO plasmid. The enzyme was purified by 
IMAC using Ni
2+
 as a ligand and an IMAC Hitrap column (GE Healthcare).  
Briefly, the reaction mixture (200.0 μL) contains a premix solution (100.0 µL of a solution 
containing ascorbic acid (20 mM) and methylene blue (17 μM) in potassium phosphate buffer 
(50 mM, pH 6.5)), potassium phosphate buffer (60.0 µL, 50 mM, pH 6.5), L-tryptophan (10.0 
µL, 2 mM), hIDO (20.0 µL, 50 µg.mL
-1
) and the inhibitor dissolved in DMSO (10.0 µL, 25 
µM final concentration). 
The reaction was initiated by the addition of the substrate to the premix mixture maintained at 
37°C. After 10 min, the reaction was stopped by addition of 30% (w/v) trichloroacetic acid 
(40.0 μL). To convert N-formylkynurenine to kynurenine, the reaction was incubated at 37°C 
for 30 min. Lastly, 100.0 μL of reaction mixture were transferred to 100.0 µL of a solution of 
p-DMAB 2% in a 96-wells plate to form a yellow schiff base. So, the absorption of the Schiff 
base is detected at λ = 490 nm with a 96-wells microplate absorbance reader (BIO-RAD). Test 
compounds were assessed in triplicate for each concentration on hIDO. The inhibitory 
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percentage was calculated for each compound as follows: I (%) = 100 x {1 – (absorbance 
signal with test compound/absorbance signal without test compound)}. The data were 
expressed as mean ± SD from triplicate experiments.  
 
 
4.3 LSD1 
 
The LSD1 inhibition assay was performed as described by Cayman’s LSD1 inhibitor 
screening assay (Cayman) with some modifications. The assay is based on the multistep 
enzymatic reaction in which LSD1 first produces H2O2 during the demethylation of the 
substrate peptide. In the presence of horseradish peroxidase (HRP), H2O2 reacts with ADHP 
(10-acetyl-3,7-dihydroxyphenoxazine) to produce the highly fluorescent compound resorufin. 
The measurement of LSD1 activity is quantified by the amount of resorufin produced which 
is detected by fluorescence (λex 535 nm; λem 595 nm). The measurements are carried out in a 
black 96-wells plate at 37°C.  
Briefly, the reaction mixture (200.0 μL) contains a buffer solution (105.0 µL, 50 mM Hepes, 
pH 7.5), HRP (20.0 µL), ADHP (10.0 µL), recombinant hLSD1 (20.0 µL), LSD1 peptide 
(20.0 µL, 1 mM) and the test compound dissolved in DMSO (25.0 μL, final DMSO 
percentage of 12.5%).  
The reaction was initiated by the addition of the substrate peptide at 37 °C. After stirring, the 
fluorescent signal of resorufin was detected for 30 min at 37°C by measuring emited 
fluorescence (λex 535 nm; λem 595 nm) with a 96-wells Beckman Coulter DTX 880 
Multimode Detector. Test compounds were assessed in triplicate for each concentration on 
hLSD1. IC50 value of the most active compound was evaluated. Inhibition percentages at each 
concentration were calculated as follows: I (%) = 100 x {1 – (fluorescent signal with test 
compound/fluorescent signal without test compound)}. The inhibition percentages were 
plotted against the logarithms of the compound molar concentrations. The IC50 value was 
calculated from normalized sigmoidal dose-response non-linear regression curve using the 
GraphPad Prism 5.01 software and was expressed as mean ± SD from triplicate experiments.  
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